<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>Biomarker</th>
      <th>Gene</th>
      <th>Alteration type</th>
      <th>Alteration</th>
      <th>Targeting</th>
      <th>Drug status</th>
      <th>Drug family</th>
      <th>Drug</th>
      <th>Association</th>
      <th>Evidence level</th>
      <th>Assay type</th>
      <th>Source</th>
      <th>Curator</th>
      <th>Curation date</th>
      <th>Primary Tumor type</th>
      <th>Metastatic Tumor Type</th>
      <th>TCGI included</th>
      <th>Comments</th>
      <th>Drug full name</th>
      <th>Primary Tumor type full name</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td>EZH2 (A692V,Y646C,Y646F,Y646H,Y646N,Y646S,A682G)</td>
      <td>EZH2</td>
      <td>MUT</td>
      <td>EZH2:A692V,Y646C,Y646F,Y646H,Y646N,Y646S,A682G</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EZH2 inhibitor</td>
      <td>Tazemetostat</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma;PMID:33035457</td>
      <td>SDemajo;RShadrina</td>
      <td>29.04.2022</td>
      <td>FL</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FDA granted accelerated approval to tazemetostat for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.</td>
      <td>Tazemetostat (EZH2 inhibitor)</td>
      <td>Follicular lymphoma</td>
    </tr>
    <tr>
      <th>1</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;Chemotherapy</td>
      <td>Neratinib;Capecitabine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945</td>
      <td>SDemajo;RShadrina</td>
      <td>13.05.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Neratinib (ERBB2 inhibitor) + Capecitabine (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>2</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;ERBB2 inhibitor;Chemotherapy</td>
      <td>Pertuzumab;Trastuzumab;Docetaxel</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:23801166</td>
      <td>SDemajo;RShadrina</td>
      <td>13.05.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Pertuzumab (ERBB2 inhibitor)+ Trastuzumab (ERBB2 inhibitor) + Docetaxel (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>3</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;ERBB2 inhibitor;Chemotherapy</td>
      <td>Pertuzumab;Trastuzumab;Docetaxel</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:23801166</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Pertuzumab (ERBB2 inhibitor) + Trastuzumab (ERBB2 inhibitor) + Docetaxel (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>4</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;Hormone therapy</td>
      <td>Lapatinib;Letrozole</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA;PMID:19786658</td>
      <td>SDemajo;RShadrina</td>
      <td>13.05.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Lapatinib (ERBB2 inhibitor) + Letrozole (Hormone therapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>5</th>
      <td>ERBB2 expression -</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:norm</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Estrogen receptor antagonist;CDK4/6 inhibitor</td>
      <td>Fulvestrant;Palbociclib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:27407089</td>
      <td>SDemajo;RShadrina</td>
      <td>21.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>1</td>
      <td>Drug combination indicated for Hormone Receptor (HR)-Positive breast cancer</td>
      <td>Fulvestrant (Estrogen receptor antagonist) + Palbociclib (CDK4/6 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>6</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor</td>
      <td>Margetuximab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer</td>
      <td>SDemajo;RShadrina</td>
      <td>21.04.2023</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>1</td>
      <td>In combination with chemotherapy</td>
      <td>Margetuximab (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>7</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor</td>
      <td>Margetuximab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>1</td>
      <td>In combination with chemotherapy</td>
      <td>Margetuximab (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>8</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;ERBB2 inhibitor;Chemotherapy</td>
      <td>Tucatinib;Trastuzumab;Capecitabine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569</td>
      <td>SDemajo;RShadrina</td>
      <td>21.04.2024</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>1</td>
      <td>Drug combination. Indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.</td>
      <td>Tucatinib (ERBB2 inhibitor) + Trastuzumab (ERBB2 inhibitor) + Capecitabine (chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>9</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Talazoparib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guideline Breast cancer 2022;PMID: 30110579</td>
      <td>SDemajo;RShadrina</td>
      <td>22.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Patients with Germline BRCA1 Mutation</td>
      <td>Talazoparib (PARP inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>10</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Talazoparib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guideline Breast cancer 2022;PMID: 30110579</td>
      <td>SDemajo;RShadrina</td>
      <td>22.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Patients with Germline BRCA2 Mutation</td>
      <td>Talazoparib (PARP inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>11</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PI3K inhibitor; Estrogen receptor antagonist</td>
      <td>Alpelisib;Fulvestrant</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guideline Breast cancer 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>22.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Indicated for For HR-positive/HER2-negative breast cancer; Preferred second- or subsequent-line therapy; Specific mutations FDA-approved C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R</td>
      <td>Alpelisib (PI3K inhibitor) + Fulvestrant (Estrogen receptor antagonist)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>12</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>TRK Kinase Inhibitor</td>
      <td>Larotrectinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guideline Breast cancer 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>22.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Larotrectinib and entrectinib are indicated for the treatment of solid tumors that have an NTRK gene fusion without a known acquired resistance mutation and have no satisfactory alternative treatments or that have progressed following treatment.</td>
      <td>Larotrectinib (TRK Kinase Inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>13</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Entrectinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guideline Breast cancer 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>22.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Larotrectinib and entrectinib are indicated for the treatment of solid tumors that have an NTRK gene fusion without a known acquired resistance mutation and have no satisfactory alternative treatments or that have progressed following treatment.</td>
      <td>Entrectinib (Pan-TK inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>14</th>
      <td>CD274 (PD-L1) +</td>
      <td>CD274</td>
      <td>EXPR</td>
      <td>CD274:norm</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PD-1 blocking antibody</td>
      <td>Pembrolizumab</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guideline Breast cancer 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>22.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>CD274 is commonly known as PD-L1. FDA granted regular approval to pembrolizumab in combination with chemotherapy for patients with locally recurrent unresectable or metastatic TNBC (Triple Negative Breast Cancer) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) as determined by an FDA approved test.</td>
      <td>Pembrolizumab (PD-1-blocking antibody)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>15</th>
      <td>FLT3-ITD</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3::consequence::inframe_variant:572-630</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Midostaurin</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114</td>
      <td>SDemajo;RShadrina</td>
      <td>27.04.2022</td>
      <td>AML</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug and chemoterphy (high dose quemotherapy) should be used in combination</td>
      <td>Midostaurin (Pan-TK inhibitor)</td>
      <td>Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <th>16</th>
      <td>FLT3 (D835,I836)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:D835.,I836.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Gilteritinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA: https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation</td>
      <td>SDemajo;RShadrina</td>
      <td>27.04.2022</td>
      <td>AML</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Bibliography: https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation AND PMID: 31665578</td>
      <td>Gilteritinib (Kinase inhibitor )</td>
      <td>Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <th>17</th>
      <td>FLT3-ITD</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3::consequence::inframe_variant:572-630</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Gilteritinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578</td>
      <td>SDemajo;RShadrina</td>
      <td>27.04.2022</td>
      <td>AML</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Gilteritinib (Kinase inhibitor )</td>
      <td>Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <th>18</th>
      <td>FLT3 (D835,I836)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:D835.,I836.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Midostaurin</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114</td>
      <td>SDemajo;RShadrina</td>
      <td>27.04.2022</td>
      <td>AML</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug and chemoterphy (high dose quemotherapy) should be used in combination</td>
      <td>Midostaurin (Pan-TK inhibitor)</td>
      <td>Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <th>19</th>
      <td>ABL1 (T315I,V299L,G250E,F317L)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I,V299L,G250E,F317L</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 3rd gen</td>
      <td>Bosutinib</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN</td>
      <td>SDemajo;RShadrina</td>
      <td>19.04.2022</td>
      <td>ALL;CML</td>
      <td>NaN</td>
      <td>1</td>
      <td>NaN</td>
      <td>Bosutinib (BCR-ABL inhibitor 3rd gen)</td>
      <td>Acute lymphoblastic leukemia; Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>20</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Asciminib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia</td>
      <td>SDemajo;RShadrina</td>
      <td>26.04.2022</td>
      <td>CML</td>
      <td>NaN</td>
      <td>1</td>
      <td>Bibliography: https://ash.confex.com/ash/2020/webprogram/Paper143816.html ||| FDA indication: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)</td>
      <td>Asciminib (Kinase inhibitor)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>21</th>
      <td>BCR-ABL1</td>
      <td>ABL1</td>
      <td>FUS</td>
      <td>ABL1__BCR</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Asciminib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>SDemajo;RShadrina</td>
      <td>26.04.2022</td>
      <td>CML</td>
      <td>NaN</td>
      <td>1</td>
      <td>Bibliography: PMID:  34407542 ||| FDA indication: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).</td>
      <td>Asciminib (Kinase inhibitor)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>22</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN Guideline ALL 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>19.04.2022</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>1</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>23</th>
      <td>ABL1 (E255V,Y253H,F359V)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:E255V,Y253H,F359V</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN Guidelines Chronic Myeloid Leukemia 2022; PMID:34407543</td>
      <td>SDemajo;RShadrina</td>
      <td>7.04.2022</td>
      <td>CML</td>
      <td>NaN</td>
      <td>1</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>24</th>
      <td>MYD88 (L265P)</td>
      <td>MYD88</td>
      <td>MUT</td>
      <td>MYD88:L265P</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Zanubrutinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia</td>
      <td>SDemajo;RShadrina</td>
      <td>29.04.2022</td>
      <td>WM</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Zanubrutinib may be also used in pateints with MYD88 wild type: PMID: 33284944</td>
      <td>Zanubrutinib (Kinase inhibitor)</td>
      <td>Waldenström macroglobulinemia</td>
    </tr>
    <tr>
      <th>25</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Tyrosine kinase inhibitor</td>
      <td>Pralsetinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)</td>
      <td>SDemajo;RShadrina</td>
      <td>29.04.2022</td>
      <td>THM</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pralsetinib (Tyrosine kinase inhibitor)</td>
      <td>Medullary thyroid cancer</td>
    </tr>
    <tr>
      <th>26</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>RET kinase inhibitor</td>
      <td>Selpercatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)</td>
      <td>SDemajo;RShadrina</td>
      <td>29.04.2022</td>
      <td>THM</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Selpercatinib (RET kinase inhibitor)</td>
      <td>Medullary thyroid cancer</td>
    </tr>
    <tr>
      <th>27</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27825636</td>
      <td>SDemajo;RShadrina</td>
      <td>29.04.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Cabozantinib (Kinase inhibitor )</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>28</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MEK inhibitor;BRAF inhibitor</td>
      <td>Trametinib;Dabrafenib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid</td>
      <td>SDemajo;RShadrina</td>
      <td>8.04.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>1</td>
      <td>Drug combination dabrafenib plus trametinib is a preferred treatment option for patients with BRAF p.V600E mutations (NCCN).</td>
      <td>Trametinib (MEK inhibitor) + Dabrafenib (BRAF inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>29</th>
      <td>EGFR (S786I,G719., L861Q)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:S786I,G719.,L861Q</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN Non-Small Cell Lung Cancer guidlines 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>8.04.2023</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Osimertinib (EGFR inhibitor 3d gen)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>30</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Entrectinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines Gastric Cancer 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>25.04.2022</td>
      <td>ST</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Second-Line or Subsequent Therapy Useful in Certain Circumstances</td>
      <td>Entrectinib (Pan-TK inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>31</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>TRK Kinase Inhibitor</td>
      <td>Larotrectinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines Gastric Cancer 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>25.04.2022</td>
      <td>ST</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Second-Line or Subsequent Therapy Useful in Certain Circumstances</td>
      <td>Larotrectinib (TRK Kinase Inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>32</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Niraparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273</td>
      <td>SDemajo;RShadrina</td>
      <td>21.04.2022</td>
      <td>OV</td>
      <td>NaN</td>
      <td>1</td>
      <td>NaN</td>
      <td>Niraparib (PARP inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>33</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Niraparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273</td>
      <td>SDemajo;RShadrina</td>
      <td>21.04.2022</td>
      <td>OV</td>
      <td>NaN</td>
      <td>1</td>
      <td>NaN</td>
      <td>Niraparib (PARP inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>34</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor;VEGF mAb inhibitor</td>
      <td>Olaparib;Bevacizumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary</td>
      <td>SDemajo;RShadrina</td>
      <td>25.04.2022</td>
      <td>OV</td>
      <td>NaN</td>
      <td>1</td>
      <td>First-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.</td>
      <td>Olaparib (PARP inhibitor) + Bevacizumab (VEGF mAb inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>35</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor;VEGF mAb inhibitor</td>
      <td>Olaparib;Bevacizumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary</td>
      <td>SDemajo;RShadrina</td>
      <td>25.04.2022</td>
      <td>OV</td>
      <td>NaN</td>
      <td>1</td>
      <td>First-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.</td>
      <td>Olaparib (PARP inhibitor) + Bevacizumab (VEGF mAb inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>36</th>
      <td>ALK oncogenic mutation</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Lorlatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf</td>
      <td>SDemajo;RShadrina</td>
      <td>13.04.2022</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>1</td>
      <td>Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.</td>
      <td>Lorlatinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>37</th>
      <td>EGFR (L858R,S768I,L861Q,G719.)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,S768I,L861Q,G719.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor</td>
      <td>Dacomitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>NCCN Non-Small Cell Lung Cancer guidlines 2022;FDA:https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0</td>
      <td>SDemajo;RShadrina</td>
      <td>13.04.2020</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>1</td>
      <td>NaN</td>
      <td>Dacomitinib (EGFR inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>38</th>
      <td>VHL oncogenic mutation</td>
      <td>VHL</td>
      <td>MUT</td>
      <td>VHL:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Hypoxia-inducible factor inhibitor</td>
      <td>Belzutifan</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease</td>
      <td>SDemajo;RShadrina</td>
      <td>25.04.2022</td>
      <td>R</td>
      <td>R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Belzutifan (hypoxia-inducible factor inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>39</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>Resistant</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:26980062</td>
      <td>SDemajo;RShadrina</td>
      <td>14.04.2020</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>40</th>
      <td>FGFR2 fusion</td>
      <td>FGFR2</td>
      <td>FUS</td>
      <td>FGFR2__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>FGFR inhibitor</td>
      <td>Erdafitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>For patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy</td>
      <td>Erdafitinib (FGFR inhibitor)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>41</th>
      <td>ATM oncogenic mutation</td>
      <td>ATM</td>
      <td>MUT</td>
      <td>ATM:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>42</th>
      <td>BARD1 oncogenic mutation</td>
      <td>BARD1</td>
      <td>MUT</td>
      <td>BARD1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>43</th>
      <td>BRIP1 oncogenic mutation</td>
      <td>BRIP1</td>
      <td>MUT</td>
      <td>BRIP1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>44</th>
      <td>CDK12 oncogenic mutation</td>
      <td>CDK12</td>
      <td>MUT</td>
      <td>CDK12:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>45</th>
      <td>CHEK1 oncogenic mutation</td>
      <td>CHEK1</td>
      <td>MUT</td>
      <td>CHEK1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>46</th>
      <td>FANCL oncogenic mutation</td>
      <td>FANCL</td>
      <td>MUT</td>
      <td>FANCL:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>47</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Rucaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>1</td>
      <td>For BRCA-mutated metastatic castration-resistant prostate cancer</td>
      <td>Rucaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>48</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Rucaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>1</td>
      <td>For BRCA-mutated metastatic castration-resistant prostate cancer</td>
      <td>Rucaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>49</th>
      <td>FGFR3 fusion</td>
      <td>FGFR3</td>
      <td>FUS</td>
      <td>FGFR3__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>FGFR inhibitor</td>
      <td>Erdafitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>For patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy</td>
      <td>Erdafitinib (FGFR inhibitor)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>50</th>
      <td>FGFR3 (G370C,R248C,S249C,Y373C)</td>
      <td>FGFR3</td>
      <td>MUT</td>
      <td>FGFR3:G370C,R248C,S249C,Y373C</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>FGFR inhibitor</td>
      <td>Erdafitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094</td>
      <td>SDemajo;RShadrina</td>
      <td>2.05.2022</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Erdafitinib (FGFR inhibitor)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>51</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor;EGFR mAb inhibitor</td>
      <td>Encorafenib;Cetuximab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309</td>
      <td>SDemajo;RShadrina</td>
      <td>4.05.2022</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Encorafenib (BRAF inhibitor) + Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>52</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PD-1 blocking antibody;ERBB2 mAb inhibitor</td>
      <td>Pembrolizumab;Trastuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120</td>
      <td>SDemajo;RShadrina</td>
      <td>4.05.2022</td>
      <td>ST;GEJA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma</td>
      <td>Pembrolizumab (PD-1 blocking antibody) + Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Stomach;Gastroesophageal junction adenocarcinoma</td>
    </tr>
    <tr>
      <th>53</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PD-1 blocking antibody;ERBB2 mAb inhibitor</td>
      <td>Pembrolizumab;Trastuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120</td>
      <td>SDemajo;RShadrina</td>
      <td>4.05.2022</td>
      <td>ST;GEJA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma</td>
      <td>Pembrolizumab (PD-1 blocking antibody) + Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Stomach;Gastroesophageal junction adenocarcinoma</td>
    </tr>
    <tr>
      <th>54</th>
      <td>KRAS wildtype</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS::wildtype:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID: 31268481</td>
      <td>SDemajo;RShadrina</td>
      <td>04.05.2022</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>1</td>
      <td>Drug alone or in combination with chemotherapy (fluorouracil-leucovorin)</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal cancer</td>
    </tr>
    <tr>
      <th>55</th>
      <td>KRAS wildtype</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS::wildtype:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID: 19339720</td>
      <td>SDemajo;RShadrina</td>
      <td>04.05.2022</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>1</td>
      <td>Drug alone or in combination with chemotherapy</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>56</th>
      <td>KIT (Y823D,N822,C809G,D820,A829P,D816,T670I)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:Y823D,N822.,C809G,D820.,A829P,D816,T670I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Ripretinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor;PMID:32511981</td>
      <td>SDemajo;RShadrina</td>
      <td>05.05.2022</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Approved for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.</td>
      <td>Ripretinib (Kinase inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>57</th>
      <td>EGFR exon 20 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:762-823</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor</td>
      <td>Mobocertinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20</td>
      <td>SDemajo;RShadrina</td>
      <td>18.05.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Approved for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.</td>
      <td>Mobocertinib (EGFR inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>58</th>
      <td>EGFR exon 20 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:762-823</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Amivantamab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer</td>
      <td>SDemajo;RShadrina</td>
      <td>18.05.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Approved for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.</td>
      <td>Amivantamab (EGFR mAb inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>59</th>
      <td>FGFR2 fusion</td>
      <td>FGFR2</td>
      <td>FUS</td>
      <td>FGFR2__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>FGFR kinase inhibitor</td>
      <td>Infigratinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma</td>
      <td>SDemajo;RShadrina</td>
      <td>18.05.2022</td>
      <td>CH</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test</td>
      <td>Infigratinib (FGFR kinase inhibitor)</td>
      <td>Cholangiocarcinoma</td>
    </tr>
    <tr>
      <th>60</th>
      <td>FGFR2 fusion</td>
      <td>FGFR2</td>
      <td>FUS</td>
      <td>FGFR2__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>FGFR kinase inhibitor</td>
      <td>Pemigatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA;PMID:32203698</td>
      <td>SDemajo;RShadrina</td>
      <td>18.05.2022</td>
      <td>CH</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf</td>
      <td>Pemigatinib (FGFR kinase inhibitor)</td>
      <td>Cholangiocarcinoma</td>
    </tr>
    <tr>
      <th>61</th>
      <td>IDH1 oncogenic mutation</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:R132</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>IDH1 inhibitor</td>
      <td>Ivosidenib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA;PMID:34554208;PMID:32416072</td>
      <td>SDemajo;RShadrina</td>
      <td>18.05.2022</td>
      <td>CH</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Ivosidenib (IDH1 inhibitor)</td>
      <td>Cholangiocarcinoma</td>
    </tr>
    <tr>
      <th>62</th>
      <td>IDH1 (R132C,R132G,R132H,R132L,R132S)</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:R132C,R132G,R132H,R132L,R132S</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>IDH1 inhibitor</td>
      <td>Ivosidenib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf</td>
      <td>SDemajo;RShadrina</td>
      <td>23.05.2022</td>
      <td>AML</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Ivosidenib (IDH1 inhibitor)</td>
      <td>Acute Myeloid Leukemia</td>
    </tr>
    <tr>
      <th>63</th>
      <td>KRAS (G12C)</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:G12C</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>RAS GTPase family inhibitor</td>
      <td>Sotorasib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc</td>
      <td>SDemajo;RShadrina</td>
      <td>18.05.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Sotorasib (RAS GTPase family inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>64</th>
      <td>PDGFRA exon 18 mutations</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA::consequence::inframe_deletion:814-852,::inframe_insertion:814-852,::missense_variant:814-852</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Avapritinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation</td>
      <td>SDemajo;RShadrina</td>
      <td>23.05.2022</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Avapritinib (Kinase inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>65</th>
      <td>PDGFRA (D842V)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:D842V</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Avapritinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108</td>
      <td>SDemajo;RShadrina</td>
      <td>23.05.2022</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Avapritinib (Kinase inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>66</th>
      <td>MET exon 14 skipping mutations</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET::consequence::skipping_mutation:963-1010</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MET inhibitor</td>
      <td>Tepotinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238</td>
      <td>SDemajo;RShadrina</td>
      <td>23.05.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Tepotinib (MET inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>67</th>
      <td>MET exon 14 skipping mutations</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET::consequence::skipping_mutation:963-1010</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MET inhibitor</td>
      <td>Capmatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer;ASCO 2019 (abstr 9004);ASCO 2019 (abstr 9020)</td>
      <td>SDemajo;RShadrina</td>
      <td>23.05.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Capmatinib (MET inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>68</th>
      <td>ROS1 fusion</td>
      <td>ROS1</td>
      <td>FUS</td>
      <td>ROS1__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Entrectinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA;PMID:28183697;ESMO 2019 (abstr 4178)</td>
      <td>SDemajo;RShadrina</td>
      <td>23.05.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Entrectinib (Pan-TK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>69</th>
      <td>CXCR4</td>
      <td>CXCR4</td>
      <td>MUT</td>
      <td>CXCR4:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Kinase inhibitor</td>
      <td>Ibrutinib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:31267520</td>
      <td>SDemajo;RShadrina</td>
      <td>24.05.2022</td>
      <td>WM</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Ibrutinib (Kinase inhibitor )</td>
      <td>Waldenström macroglobulinemia</td>
    </tr>
    <tr>
      <th>70</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 3rd gen</td>
      <td>Bosutinib</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN Guideline ALL 2022</td>
      <td>SDemajo;RShadrina</td>
      <td>17.06.2022</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Bosutinib (BCR-ABL inhibitor 3rd gen)</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>71</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>TRK Kinase Inhibitor</td>
      <td>Larotrectinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions</td>
      <td>SDemajo;RShadrina</td>
      <td>29.06.2022</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Larotrectinib and entrectinib are indicated for the treatment of solid tumors that have an NTRK gene fusion without a known acquired resistance mutation and have no satisfactory alternative treatments or that have progressed following treatment.</td>
      <td>Larotrectinib (TRK Kinase Inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>72</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Entrectinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc</td>
      <td>SDemajo;RShadrina</td>
      <td>29.06.2022</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Larotrectinib and entrectinib are indicated for the treatment of solid tumors that have an NTRK gene fusion without a known acquired resistance mutation and have no satisfactory alternative treatments or that have progressed following treatment.</td>
      <td>Entrectinib (Pan-TK inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>73</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;Chemotherapy</td>
      <td>Neratinib;Capecitabine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Neratinib (ERBB2 inhibitor) + Capecitabine (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>74</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;Hormone therapy</td>
      <td>Lapatinib;Letrozole</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA;PMID:19786658</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Drug combination</td>
      <td>Lapatinib (ERBB2 inhibitor) + Letrozole (Hormone therapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>75</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;ERBB2 inhibitor;Chemotherapy</td>
      <td>Tucatinib;Trastuzumab;Capecitabine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>1</td>
      <td>Drug combination. Indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.</td>
      <td>Tucatinib (ERBB2 inhibitor) + Trastuzumab (ERBB2 inhibitor) + Capecitabine (chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>76</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Tyrosine kinase inhibitor</td>
      <td>Pralsetinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pralsetinib (Tyrosine kinase inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>77</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>RET kinase inhibitor</td>
      <td>Selpercatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions</td>
      <td>SDemajo;RShadrina</td>
      <td>30.06.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Selpercatinib (RET kinase inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>78</th>
      <td>PALB2 oncogenic mutation</td>
      <td>PALB2</td>
      <td>MUT</td>
      <td>PALB2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>04.07.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>79</th>
      <td>RAD51B oncogenic mutation</td>
      <td>RAD51B</td>
      <td>MUT</td>
      <td>RAD51B:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>04.07.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>80</th>
      <td>RAD51C oncogenic mutation</td>
      <td>RAD51C</td>
      <td>MUT</td>
      <td>RAD51C:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>04.07.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>81</th>
      <td>RAD51D oncogenic mutation</td>
      <td>RAD51D</td>
      <td>MUT</td>
      <td>RAD51D:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>04.07.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>82</th>
      <td>RAD54L oncogenic mutation</td>
      <td>RAD54L</td>
      <td>MUT</td>
      <td>RAD54L:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>SDemajo;RShadrina</td>
      <td>04.07.2022</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>For Metastatic Castration-Resistant Prostate Cancer</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>83</th>
      <td>PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PI3K inhibitor; Estrogen receptor antagonist</td>
      <td>Alpelisib;Fulvestrant</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>FDA;PMID:31091374</td>
      <td>SDemajo;RShadrina</td>
      <td>22.04.2022</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Indicated for For HR-positive/HER2-negative breast cancer; Preferred second- or subsequent-line therapy; Specific mutations FDA-approved C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R</td>
      <td>Alpelisib (PI3K inhibitor) + Fulvestrant (Estrogen receptor antagonist)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>84</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor</td>
      <td>Trastuzumab deruxtecan-nxki</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas</td>
      <td>SDemajo;RShadrina</td>
      <td>12.09.2022</td>
      <td>ST;GEJA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Indicated for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.</td>
      <td>Trastuzumab deruxtecan-nxki (Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)</td>
      <td>Stomach;Gastroesophageal junction adenocarcinoma</td>
    </tr>
    <tr>
      <th>85</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor</td>
      <td>Trastuzumab deruxtecan-nxki</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas</td>
      <td>SDemajo;RShadrina</td>
      <td>12.09.2022</td>
      <td>ST;GEJA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Indicated for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.</td>
      <td>Trastuzumab deruxtecan-nxki (Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)</td>
      <td>Stomach;Gastroesophageal junction adenocarcinoma</td>
    </tr>
    <tr>
      <th>86</th>
      <td>ERBB2 oncogenic mutation</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor</td>
      <td>Trastuzumab deruxtecan-nxki</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung</td>
      <td>SDemajo;RShadrina</td>
      <td>12.09.2022</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Indicated for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.</td>
      <td>Trastuzumab deruxtecan-nxki (Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>87</th>
      <td>AKT1 (Q79K,E17K)</td>
      <td>AKT1</td>
      <td>MUT</td>
      <td>AKT1:Q79K,E17K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24265152</td>
      <td>RDientsmann;DTamborero</td>
      <td>03/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>88</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>VEGFR inhibitor</td>
      <td>Axitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25686603</td>
      <td>DTamborero</td>
      <td>03/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Axitinib (VEGFR inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>89</th>
      <td>ABL1-BCR fusion</td>
      <td>ABL1</td>
      <td>FUS</td>
      <td>ABL1__BCR</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor  3rd gen</td>
      <td>Bosutinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Bosutinib (BCR-ABL inhibitor  3rd gen)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>90</th>
      <td>ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor  3rd gen</td>
      <td>Bosutinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Bosutinib (BCR-ABL inhibitor  3rd gen)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>91</th>
      <td>ARAF oncogenic mutation</td>
      <td>ARAF</td>
      <td>MUT</td>
      <td>ARAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 428)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>92</th>
      <td>ABL1 (V299L)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:V299L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26924578</td>
      <td>DTamborero</td>
      <td>03/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib (Pan-kinase inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>93</th>
      <td>ABL1 (V299L)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:V299L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26924578</td>
      <td>DTamborero</td>
      <td>03/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>94</th>
      <td>ABL1-BCR fusion</td>
      <td>ABL1</td>
      <td>FUS</td>
      <td>ABL1__BCR</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>CML;ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>In patients who are using imatinib or second-generation TKIs first-line, resistance is associated with mutations in 10% to 68% of patients, and 14% to 33% of patients using nilotinib or dasatinib as second line treatment develop BCR-ABL1 mutations. FDA guidline https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000AdminCorres.pdf</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Chronic myeloid leukemia;Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>95</th>
      <td>ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:F359V,F359C,F359I,Y253H,E255K,E255V</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>96</th>
      <td>ARAF oncogenic mutation</td>
      <td>ARAF</td>
      <td>MUT</td>
      <td>ARAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 428)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + MEK inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>97</th>
      <td>ABL1-BCR fusion</td>
      <td>ABL1</td>
      <td>FUS</td>
      <td>ABL1__BCR</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen;BCL2 inhibitor</td>
      <td>Dasatinib;Venetoclax</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27582059</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib + Venetoclax (BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>98</th>
      <td>ABL1 (V299L)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:V299L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MET inhibitor</td>
      <td>Foretinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26924578</td>
      <td>DTamborero</td>
      <td>03/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Foretinib  (MET inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>99</th>
      <td>ABL1-BCR fusion</td>
      <td>ABL1</td>
      <td>FUS</td>
      <td>ABL1__BCR</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>EMA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>CML;ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf; "In patients who are using imatinib or second-generation TKIs first-line, resistance is associated with mutations in 10% to 68% of patients, and 14% to 33% of patients using nilotinib or dasatinib as second line treatment develop BCR-ABL1 mutations. FDA guidline https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000AdminCorres.pdf  "</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Chronic myeloid leukemia;Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>100</th>
      <td>B2M oncogenic mutation</td>
      <td>B2M</td>
      <td>MUT</td>
      <td>B2M:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27433843</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>101</th>
      <td>ABL1-BCR fusion</td>
      <td>ABL1</td>
      <td>FUS</td>
      <td>ABL1__BCR</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>In patients who are using imatinib or second-generation TKIs first-line, resistance is associated with mutations in 10% to 68% of patients, and 14% to 33% of patients using nilotinib or dasatinib as second line treatment develop BCR-ABL1 mutations. FDA guidline https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000AdminCorres.pdf</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>102</th>
      <td>ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315A,F317L,F317V,F317I,F317C,V299L</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>103</th>
      <td>ABL1-BCR fusion</td>
      <td>ABL1</td>
      <td>FUS</td>
      <td>ABL1__BCR</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>CML;ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Chronic myeloid leukemia;Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>104</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>12/15</td>
      <td>CML;ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP: from T315. to T315I, 12/15 label update states the complete aminoacid change</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Chronic myeloid leukemia;Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>105</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>106</th>
      <td>ABL1 (V299L)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:V299L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Vandetanib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26924578</td>
      <td>DTamborero</td>
      <td>03/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vandetanib (Pan-TK inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>107</th>
      <td>AKT1 (E17K)</td>
      <td>AKT1</td>
      <td>MUT</td>
      <td>AKT1:E17K</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>[AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AKT inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>108</th>
      <td>AKT1 (E17K)</td>
      <td>AKT1</td>
      <td>MUT</td>
      <td>AKT1:E17K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[allosteric AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2015 (abstract B109);PMID:28489509</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>allosteric AKT inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>109</th>
      <td>BRAF (V600E,G469A)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E,G469A</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR TK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22773810</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>UPDATE: delete G469A mutation in v16 GDKD?</td>
      <td>EGFR TK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>110</th>
      <td>AKT1 (E17K)</td>
      <td>AKT1</td>
      <td>MUT</td>
      <td>AKT1:E17K</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>[non-allosteric AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2015 (abstract B109);PMID:28489509</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>non-allosteric AKT inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>111</th>
      <td>AKT1 (E17K)</td>
      <td>AKT1</td>
      <td>MUT</td>
      <td>AKT1:E17K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26763254</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>112</th>
      <td>AKT1 (H238Y)</td>
      <td>AKT1</td>
      <td>MUT</td>
      <td>AKT1:H238Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 11010)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>FH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Fibrous histiocytoma</td>
    </tr>
    <tr>
      <th>113</th>
      <td>AKT1 (E17K)</td>
      <td>AKT1</td>
      <td>MUT</td>
      <td>AKT1:E17K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Tensirolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27016228</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tensirolimus (MTOR inhibitor)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>114</th>
      <td>AKT2 amplification</td>
      <td>AKT2</td>
      <td>CNA</td>
      <td>AKT2:amp</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>Allosteric AKT inhibitor</td>
      <td>MK2206</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 373)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MK2206 (Allosteric AKT inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>115</th>
      <td>AKT3 fusion</td>
      <td>AKT3</td>
      <td>FUS</td>
      <td>AKT3__.</td>
      <td>Direct</td>
      <td>Clinical Trials;Clinical Trials</td>
      <td>[ATP competitive AKT inhibitor]</td>
      <td>[AZD5363,GSK2141795]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:22722202</td>
      <td>JAlbanell;ARovira;RDientsmann</td>
      <td>09/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ATP competitive AKT inhibitors (AZD5363,GSK2141795,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>116</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ALK inhibitor;IGF1R inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25173427</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ALK inhibitor + IGF1R inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>117</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ALK inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26301689</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ALK inhibitor + MEK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>118</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ALK inhibitor;SRC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25394791</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ALK inhibitor + SRC inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>119</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ALK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26633560</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ALK inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>120</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23553849</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>121</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[novel ALK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23639470</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>novel ALK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>122</th>
      <td>ALK (F1174L)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:F1174L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[novel ALK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24327273</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>novel ALK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>123</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Alectinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Alectinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>124</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Alectinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>EArriola;CRubio-Perez</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Alectinib (ALK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>125</th>
      <td>CCND1 amplification</td>
      <td>CCND1</td>
      <td>CNA</td>
      <td>CCND1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SMO inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24951114</td>
      <td>DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>MB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SMO inhibitors</td>
      <td>Medulloblastoma</td>
    </tr>
    <tr>
      <th>126</th>
      <td>ALK amplification</td>
      <td>ALK</td>
      <td>CNA</td>
      <td>ALK:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Brigatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9065)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Brigatinib (Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>127</th>
      <td>ALK (E1408V)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:E1408V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Brigatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9065)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Brigatinib (Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>128</th>
      <td>ALK (L1196M)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:L1196M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Brigatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9065)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Brigatinib (Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>129</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Ceritinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>12/16</td>
      <td>NSCLC;LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ceritinib (ALK inhibitor)</td>
      <td>Non-small cell lung;Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>130</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Ceritinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26633560;PMID:26933125;PMID:27742657</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>COREAD;IM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ceritinib (ALK inhibitor)</td>
      <td>Colorectal adenocarcinoma;Inflammatory myofibroblastic</td>
    </tr>
    <tr>
      <th>131</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>ALK inhibitor</td>
      <td>Ceritinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02186821</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>HEMATO</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ceritinib (ALK inhibitor)</td>
      <td>Hematologic malignancies</td>
    </tr>
    <tr>
      <th>132</th>
      <td>ALK inframe insertion (1151T)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK::consequence::inframe_insertion:.1151T.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Ceritinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:24670165</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ceritinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>133</th>
      <td>CTNNB1 oncogenic mutation</td>
      <td>CTNNB1</td>
      <td>MUT</td>
      <td>CTNNB1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Tankyrase inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23539443</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tankyrase inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>134</th>
      <td>ALK (L1196M,S1206Y,G1269A,I1171T)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:L1196M,S1206Y,G1269A,I1171T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Ceritinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:24670165;PMID:24327273</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ceritinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>135</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24491302;NCT02270034</td>
      <td>MMartínez;RDientsmann</td>
      <td>09/15</td>
      <td>LY;GB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lymphoma;Glioblastoma</td>
    </tr>
    <tr>
      <th>136</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC;LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Non-small cell lung;Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>137</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:20979472;PMID:24687827</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>IM;THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Inflammatory myofibroblastic;Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>138</th>
      <td>EGFR inframe deletion (30-336)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:30-336</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 1st gen]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19204207</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gens</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>139</th>
      <td>EGFR exon 20 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:762-823</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 1st gen]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:21764376;PMID:26773740;PMID:26051236</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gens</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>140</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 1st gen]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:16282176;PMID:16278407</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gens</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>141</th>
      <td>EGFR (D761Y)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:D761Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 1st gen]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:19680293</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gens</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>142</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 1st gen]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:19680293</td>
      <td>DTamborero</td>
      <td>01/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gens</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>143</th>
      <td>EGFR inframe deletion (30-336)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:30-336</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 2nd gen]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19204207</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 2nd gens</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>144</th>
      <td>ALK (F856S,A348D)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:F856S,A348D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26032424</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>145</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 2nd gen]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:16282176;PMID:16278407</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 2nd gens</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>146</th>
      <td>ALK (L1198F)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:L1198F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26698910</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>147</th>
      <td>ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:R1275Q,G1128A,I1171N,R1192P,F1245C</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22072639</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>148</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Entrectinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26633560;PMID:26933125</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Entrectinib (Pan-TK inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>149</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK&amp;ROS1 inhibitor</td>
      <td>Lorlatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26951079</td>
      <td>RDientsmann;CRubio-Perez</td>
      <td>07/17</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lorlatinib (ALK&amp;ROS1 inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>150</th>
      <td>ALK fusion</td>
      <td>ALK</td>
      <td>FUS</td>
      <td>ALK__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Brigatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann;CRubio-Perez</td>
      <td>07/17</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Brigatinib (Pan-TK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>151</th>
      <td>ALK (C1156Y)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:C1156Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK&amp;ROS1 inhibitor</td>
      <td>Lorlatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27401242</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lorlatinib (ALK&amp;ROS1 inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>152</th>
      <td>APC oncogenic mutation</td>
      <td>APC</td>
      <td>MUT</td>
      <td>APC:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Tankyrase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22440753;PMID:23539443</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tankyrase inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>153</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 2nd gen]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:22452896</td>
      <td>DTamborero</td>
      <td>01/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 2nd gens</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>154</th>
      <td>EGFR inframe deletion (30-336)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:30-336</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 3rd gen]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19204207</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gens</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>155</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 3rd gen]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:16282176;PMID:16278407</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gens</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>156</th>
      <td>AR amplification</td>
      <td>AR</td>
      <td>CNA</td>
      <td>AR:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AR inhibitor next gen]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23589709;PMID:21859989</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AR inhibitor next gens</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>157</th>
      <td>AR overexpression</td>
      <td>AR</td>
      <td>EXPR</td>
      <td>AR:over</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>[AR inhibitor]</td>
      <td>[Bicalutamide,Enzalutamide,Orterone,4OHtestosterone]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 1003)</td>
      <td>JAlbanell;ARovira</td>
      <td>09/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>158</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22956644</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>159</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22586653;PMID:23348520</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>160</th>
      <td>ERBB3 amplification</td>
      <td>ERBB3</td>
      <td>CNA</td>
      <td>ERBB3:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25520391</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>161</th>
      <td>ESR1-YAP1 fusion</td>
      <td>ESR1</td>
      <td>FUS</td>
      <td>ESR1__YAP1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ESR1 inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24055055</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ESR1 inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>162</th>
      <td>AR overexpression</td>
      <td>AR</td>
      <td>EXPR</td>
      <td>AR:over</td>
      <td>Direct</td>
      <td>Approved</td>
      <td>AR inhibitor</td>
      <td>Enzalutamide</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24882673</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Enzalutamide (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>163</th>
      <td>FBXW7 oncogenic mutation</td>
      <td>FBXW7</td>
      <td>MUT</td>
      <td>FBXW7:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Tubulin inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21368834</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tubulin inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>164</th>
      <td>AR (F877L) + AR (T878A)</td>
      <td>AR;AR</td>
      <td>MUT;MUT</td>
      <td>AR:F877L;AR:T878A</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>AR inhibitor</td>
      <td>Enzalutamide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27196756</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Enzalutamide (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>165</th>
      <td>FBXW7 deletion</td>
      <td>FBXW7</td>
      <td>CNA</td>
      <td>FBXW7:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Tubulin inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21368834</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tubulin inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>166</th>
      <td>FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion</td>
      <td>FGFR2;FGFR2</td>
      <td>MUT;FUS</td>
      <td>FGFR2:N549H,V564F,K659M,L617V,K641R,R565A;FGFR2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28034880;ASCO 2017 (abstr 2500)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Cholangiocarcinoma</td>
    </tr>
    <tr>
      <th>167</th>
      <td>ARAF (S214C)</td>
      <td>ARAF</td>
      <td>MUT</td>
      <td>ARAF:S214C</td>
      <td>Direct:primary target</td>
      <td>FDA approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>http://www.jci.org/articles/view/72763;PMID:24569458</td>
      <td>JAlbanell;ARovira;RDientsmann</td>
      <td>09/15</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>168</th>
      <td>AREG amplification</td>
      <td>AREG</td>
      <td>CNA</td>
      <td>AREG:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19738126;PMID:26341080</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>169</th>
      <td>ARID1A oncogenic mutation</td>
      <td>ARID1A</td>
      <td>MUT</td>
      <td>ARID1A:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ATR inhibitors]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27958275</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ATR inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>170</th>
      <td>ARID1A oncogenic mutation</td>
      <td>ARID1A</td>
      <td>MUT</td>
      <td>ARID1A:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25686104</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>171</th>
      <td>ARID1A oncogenic mutation</td>
      <td>ARID1A</td>
      <td>MUT</td>
      <td>ARID1A:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26069190</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>172</th>
      <td>FGFR3 (V555M)</td>
      <td>FGFR3</td>
      <td>MUT</td>
      <td>FGFR3:V555M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22869148</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>173</th>
      <td>GLI2 amplification</td>
      <td>GLI2</td>
      <td>CNA</td>
      <td>GLI2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SMO inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24951114</td>
      <td>DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>MB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SMO inhibitors</td>
      <td>Medulloblastoma</td>
    </tr>
    <tr>
      <th>174</th>
      <td>ATM oncogenic mutation</td>
      <td>ATM</td>
      <td>MUT</td>
      <td>ATM:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ATR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2015 (abstr A48)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ATR inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>175</th>
      <td>ATM deletion</td>
      <td>ATM</td>
      <td>CNA</td>
      <td>ATM:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ATR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2015 (abstr A48)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ATR inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>176</th>
      <td>ATM oncogenic mutation</td>
      <td>ATM</td>
      <td>MUT</td>
      <td>ATM:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[DNA-PKc inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23761041</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>LY</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>DNA-PKc inhibitors</td>
      <td>Lymphoma</td>
    </tr>
    <tr>
      <th>177</th>
      <td>ATM deletion</td>
      <td>ATM</td>
      <td>CNA</td>
      <td>ATM:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[DNA-PKc inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23761041</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>LY</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>DNA-PKc inhibitors</td>
      <td>Lymphoma</td>
    </tr>
    <tr>
      <th>178</th>
      <td>ATM oncogenic mutation</td>
      <td>ATM</td>
      <td>MUT</td>
      <td>ATM:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 8LBA)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>179</th>
      <td>ATM deletion</td>
      <td>ATM</td>
      <td>CNA</td>
      <td>ATM:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 8LBA)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>180</th>
      <td>ATM biallelic inactivation</td>
      <td>ATM</td>
      <td>BIA</td>
      <td>ATM:.</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>ATR inhibitor</td>
      <td>AZD6738</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>BCL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AZD6738 (ATR inhibitor)</td>
      <td>B cell lymphoma</td>
    </tr>
    <tr>
      <th>181</th>
      <td>ATM oncogenic mutation</td>
      <td>ATM</td>
      <td>MUT</td>
      <td>ATM:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26238431</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>182</th>
      <td>ATM deletion</td>
      <td>ATM</td>
      <td>CNA</td>
      <td>ATM:del</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26238431</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>183</th>
      <td>ATM oncogenic mutation</td>
      <td>ATM</td>
      <td>MUT</td>
      <td>ATM:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 8LBA)</td>
      <td>RDientsmann;RShadrina;SDemajo</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>184</th>
      <td>ATM oncogenic mutation</td>
      <td>ATM</td>
      <td>MUT</td>
      <td>ATM:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Temozolomide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23960094</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Temozolomide (Chemotherapy)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>185</th>
      <td>ATR oncogenic mutation</td>
      <td>ATR</td>
      <td>MUT</td>
      <td>ATR:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:23548269</td>
      <td>CRubio-Perez;ECampo;RDientsmann</td>
      <td>NaN</td>
      <td>OV;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Ovary;Any cancer type</td>
    </tr>
    <tr>
      <th>186</th>
      <td>ATR deletion</td>
      <td>ATR</td>
      <td>CNA</td>
      <td>ATR:del</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:23548269</td>
      <td>CRubio-Perez;ECampo;RDientsmann</td>
      <td>NaN</td>
      <td>OV;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Ovary;Any cancer type</td>
    </tr>
    <tr>
      <th>187</th>
      <td>ATR oncogenic mutation</td>
      <td>ATR</td>
      <td>MUT</td>
      <td>ATR:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Temozolomide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23960094</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Temozolomide (Chemotherapy)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>188</th>
      <td>AURKA amplification</td>
      <td>AURKA</td>
      <td>CNA</td>
      <td>AURKA:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AURK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22302096;PMID:22389870</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PRAD;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AURK inhibitors</td>
      <td>Prostate adenocarcinoma;Any cancer type</td>
    </tr>
    <tr>
      <th>189</th>
      <td>IGF2 amplification</td>
      <td>IGF2</td>
      <td>CNA</td>
      <td>IGF2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25632036</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>190</th>
      <td>BAP1 oncogenic mutation</td>
      <td>BAP1</td>
      <td>MUT</td>
      <td>BAP1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26437366</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>MESO</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Mesothelioma</td>
    </tr>
    <tr>
      <th>191</th>
      <td>BAP1 deletion</td>
      <td>BAP1</td>
      <td>CNA</td>
      <td>BAP1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26437366</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>MESO</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Mesothelioma</td>
    </tr>
    <tr>
      <th>192</th>
      <td>BAP1 oncogenic mutation</td>
      <td>BAP1</td>
      <td>MUT</td>
      <td>BAP1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HDAC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22038994</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HDAC inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>193</th>
      <td>BAP1 deletion</td>
      <td>BAP1</td>
      <td>CNA</td>
      <td>BAP1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HDAC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22038994</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HDAC inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>194</th>
      <td>BAP1 oncogenic mutation</td>
      <td>BAP1</td>
      <td>MUT</td>
      <td>BAP1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22683710</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>R;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Renal;Any cancer type</td>
    </tr>
    <tr>
      <th>195</th>
      <td>BAP1 deletion</td>
      <td>BAP1</td>
      <td>CNA</td>
      <td>BAP1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22683710</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>R;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Renal;Any cancer type</td>
    </tr>
    <tr>
      <th>196</th>
      <td>BCL2 overexpression</td>
      <td>BCL2</td>
      <td>EXPR</td>
      <td>BCL2:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCL2 inhibitor;Proteasome inhibitor</td>
      <td>Venetoclax;Bortezomib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASH 2015 (Blood 2015 126:2975)</td>
      <td>CRubio-Perez</td>
      <td>02/17</td>
      <td>MM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Venetoclax + Bortezomib (BCL2 inhibitor + Proteasome inhibitor)</td>
      <td>Multiple myeloma</td>
    </tr>
    <tr>
      <th>197</th>
      <td>BCL2 amplification</td>
      <td>BCL2</td>
      <td>CNA</td>
      <td>BCL2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BCL2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22649144</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LY</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BCL2 inhibitors</td>
      <td>Lymphoma</td>
    </tr>
    <tr>
      <th>198</th>
      <td>BCL6 overexpression</td>
      <td>BCL6</td>
      <td>EXPR</td>
      <td>BCL6:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>HSP90 inhibitor</td>
      <td>Onalespib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02572453</td>
      <td>CRubio-Perez</td>
      <td>02/17</td>
      <td>LY</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Onalespib (HSP90 inhibitor)</td>
      <td>Lymphoma</td>
    </tr>
    <tr>
      <th>199</th>
      <td>BCOR oncogenic mutation</td>
      <td>BCOR</td>
      <td>MUT</td>
      <td>BCOR:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>PKCb inhibitor</td>
      <td>Enzastaurin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Enzastaurin (PKCb inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>200</th>
      <td>JAK1 oncogenic mutation</td>
      <td>JAK1</td>
      <td>MUT</td>
      <td>JAK1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27903500</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>201</th>
      <td>JAK1 oncogenic mutation</td>
      <td>JAK1</td>
      <td>MUT</td>
      <td>JAK1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27433843</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>202</th>
      <td>JAK2 oncogenic mutation</td>
      <td>JAK2</td>
      <td>MUT</td>
      <td>JAK2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27433843</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>203</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;CDK2/4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22997239</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + CDK2/4 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>204</th>
      <td>BRAF (V600)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28363909</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>205</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22351686</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + HSP90 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>206</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr 9029)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + MEK inhibitors</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>207</th>
      <td>BRAF fusion</td>
      <td>BRAF</td>
      <td>FUS</td>
      <td>BRAF__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9072)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + MEK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>208</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22389471;PMID:21156289</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + PI3K pathway inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>209</th>
      <td>BRAF (L597R)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:L597R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23715574</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>210</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22038996;PMID:22586120</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>211</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22608338</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>212</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 4119)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>213</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23614898;PMID:22997239</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>214</th>
      <td>BRAF (G469A)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:G469A</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2508)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>215</th>
      <td>BRAF (L485W)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:L485W</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2508)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Billiary tract</td>
    </tr>
    <tr>
      <th>216</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2508)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>217</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22241789</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>218</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19018267</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>219</th>
      <td>BRAF inframe deletion (L485),inframe deletion (P490)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-RAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26732095</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-RAF inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>220</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-RAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-RAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>221</th>
      <td>BRAF fusion</td>
      <td>BRAF</td>
      <td>FUS</td>
      <td>BRAF__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[Trametinib]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24727320;PMID:24345920;PMID:20526349</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD;CM;PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors (Trametinib,etc)</td>
      <td>Lung adenocarcinoma;Cutaneous melanoma;Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>222</th>
      <td>BRAF (K601R,L597R,V600R)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:K601R,L597R,V600R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[Trametinib]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23248257;PMID:22805292;PMID:23248257</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors (Trametinib,etc)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>223</th>
      <td>KRAS (G13D)</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:G13D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>No Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:27114605</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>224</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>LUAD;TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Lung adenocarcinoma;Thyroid</td>
    </tr>
    <tr>
      <th>225</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN</td>
      <td>CRubio-Perez</td>
      <td>06/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>226</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>227</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23470635;PMID:22608338</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>228</th>
      <td>BRAF (V600R)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23237741</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>229</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor;MEK inhibitor</td>
      <td>Dabrafenib;Trametinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26392102;ASCO 2015 (abstr 8006)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>230</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor;MEK inhibitor</td>
      <td>Dabrafenib;Trametinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27048246</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>NEU</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)</td>
      <td>Neuroendocrine</td>
    </tr>
    <tr>
      <th>231</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor;MEK inhibitor</td>
      <td>Dabrafenib;Trametinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:27283860</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>232</th>
      <td>BRAF (V600E,V600K)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E,V600K</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor;MEK inhibitor</td>
      <td>Dabrafenib;Trametinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>233</th>
      <td>BRAF (G466V)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:G466V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22649091</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>234</th>
      <td>BRAF (Y472C)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:Y472C</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22649091</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>235</th>
      <td>BRAF (V600)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor</td>
      <td>Irinotecan;Vemurafenib;Cetuximab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27729313</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Irinotecan + Vemurafenib + Cetuximab (TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>236</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26802155</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>237</th>
      <td>BRAF (V600)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600.</td>
      <td>Indirect</td>
      <td>Approved; Approved;Clinical Trials</td>
      <td>EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor</td>
      <td>Panitumumab;Dabrafenib;BYL719</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 11LBA)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab + Dabrafenib + BYL719 (EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>238</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>Indirect</td>
      <td>Approved; Approved;Clinical Trials</td>
      <td>EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor</td>
      <td>Panitumumab;Dabrafenib;Trametinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>239</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>PLX4720</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMC3638050</td>
      <td>MMartínez</td>
      <td>09/15</td>
      <td>MA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PLX4720 (BRAF inhibitor)</td>
      <td>Malignant astrocytoma</td>
    </tr>
    <tr>
      <th>240</th>
      <td>BRAF fusion</td>
      <td>BRAF</td>
      <td>FUS</td>
      <td>BRAF__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26324360</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>241</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01089101</td>
      <td>MMartínez</td>
      <td>09/15</td>
      <td>PG</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Pediatric glioma</td>
    </tr>
    <tr>
      <th>242</th>
      <td>BRAF fusion</td>
      <td>BRAF</td>
      <td>FUS</td>
      <td>BRAF__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:238900088;PMID:20526349;PMID:24727320</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM;LUAD;PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Cutaneous melanoma;Lung adenocarcinoma;Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>243</th>
      <td>BRAF (D594G,G469E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:D594G,G469E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18794803</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>244</th>
      <td>BRAF (V600E,V600K)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E,V600K</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann;SDemajo</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Although trametinib is FDA approved for single-agent use to treat patients with unresectable or metastatic melanoma with BRAF V600E mutation, Trametinib monotherapy is no longer an NCCN-recommended treatment option due to relatively poor efficacy compared with BRAF inhibitor monotherapy and BRAF/MEK inhibitor combination therapy.</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>245</th>
      <td>NRAS (12,13,59,61,117,146)</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.12.,.13.,.59.,.61.,.117.,.146.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>PMID:24024839;PMID:20619739;PMID:23325582</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>246</th>
      <td>KRAS amplification</td>
      <td>KRAS</td>
      <td>CNA</td>
      <td>KRAS:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 428)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>247</th>
      <td>BRAF (V600D,V600K,V600M,V600G,V600R)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600D,V600K,V600M,V600G,V600R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN</td>
      <td>CRubio-Perez</td>
      <td>16/06</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>248</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22743296;PMID:22621641;PMID:23612012</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>LUAD;HCL;MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Lung adenocarcinoma;Hairy-Cell leukemia;Myeloma</td>
    </tr>
    <tr>
      <th>249</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22586120</td>
      <td>MMartínez</td>
      <td>09/15</td>
      <td>MA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Malignant astrocytoma</td>
    </tr>
    <tr>
      <th>250</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>251</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22608338;PMID:20818844;PMID:23489023</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>252</th>
      <td>BRAF (V600E,V600D,V600K,V600M,V600G,V600R)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E,V600D,V600K,V600M,V600G,V600R</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>PMID:26287849</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>NSCLC;HISLC;HISEC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis</td>
    </tr>
    <tr>
      <th>253</th>
      <td>BRAF (V600E,V600K)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E,V600K</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor;MEK inhibitor</td>
      <td>Vemurafenib;Cobimetinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>254</th>
      <td>BRAF (G469A) + EGFR oncogenic mutation</td>
      <td>BRAF;EGFR</td>
      <td>MUT;MUT</td>
      <td>BRAF:G469A;EGFR:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR TK inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22773810</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR TK inhibitor + MEK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>255</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor;Chemotherapy]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22307137;ASCO 2012 (abstr 1009)</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitor + Chemotherapys</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>256</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>257</th>
      <td>BRCA1 deletion</td>
      <td>BRCA1</td>
      <td>CNA</td>
      <td>BRCA1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22392482</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>258</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[WEE1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25964244</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>WEE1 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>259</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[Olaparib]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:20609467;PMID:25366685</td>
      <td>RDientsmann;JAlbanell</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors (Olaparib,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>260</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:26510020;PMID: 32343890</td>
      <td>RDientsmann;RShadrina;SDemajo</td>
      <td>06/22</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>261</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>262</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Platinum Agent</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25847936</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Platinum Agent (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>263</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Platinum Agent</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:22406760;PMID:22711857</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Platinum Agent (Chemotherapy)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>264</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Rucaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Rucaparib (PARP inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>265</th>
      <td>BRCA1 oncogenic mutation</td>
      <td>BRCA1</td>
      <td>MUT</td>
      <td>BRCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>PARP inhibitor;Chemotherapy</td>
      <td>Veliparib;Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26801247</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>266</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor;Chemotherapy]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22307137;ASCO 2012 (abstr 1009)</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitor + Chemotherapys</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>267</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26997480</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>268</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>[PARP inhibitor]</td>
      <td>[Olaparib]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:20609467</td>
      <td>JAlbanell;ARovira;RDientsmann</td>
      <td>09/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors (Olaparib,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>269</th>
      <td>BRCA2 deletion</td>
      <td>BRCA2</td>
      <td>CNA</td>
      <td>BRCA2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[Olaparib]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22392482</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors (Olaparib,etc)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>270</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322</td>
      <td>RDientsmann;ARodriguez-Vida;RShadrina;SDemajo</td>
      <td>06/22</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>271</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>272</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Platinum Agent</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25847936</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Platinum Agent (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>273</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Platinum Agent</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:22406760;PMID:22711857</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Platinum Agent (Chemotherapy)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>274</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Platinum Agent</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25719666</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Platinum Agent (Chemotherapy)</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>275</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Rucaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Rucaparib (PARP inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>276</th>
      <td>BRCA2 oncogenic mutation</td>
      <td>BRCA2</td>
      <td>MUT</td>
      <td>BRCA2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>PARP inhibitor;Chemotherapy</td>
      <td>Veliparib;Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26801247</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>277</th>
      <td>KRAS amplification</td>
      <td>KRAS</td>
      <td>CNA</td>
      <td>KRAS:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 428)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitor + MEK inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>278</th>
      <td>BRD4-C15orf55 fusion</td>
      <td>C15orf55</td>
      <td>FUS</td>
      <td>BRD4__C15orf55</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2015 (abstr A49)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>NMC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>NUT midline carcinoma</td>
    </tr>
    <tr>
      <th>279</th>
      <td>CA9 overexpression</td>
      <td>CA9</td>
      <td>EXPR</td>
      <td>CA9:over</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24086736</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>280</th>
      <td>CBL (Y371H,C384R)</td>
      <td>CBL</td>
      <td>MUT</td>
      <td>CBL:Y371H,C384R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23696637</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>281</th>
      <td>CBL (Y371H,C384R)</td>
      <td>CBL</td>
      <td>MUT</td>
      <td>CBL:Y371H,C384R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23696637</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>282</th>
      <td>CCND1 amplification</td>
      <td>CCND1</td>
      <td>CNA</td>
      <td>CCND1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 2528)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>283</th>
      <td>CCND1 amplification</td>
      <td>CCND1</td>
      <td>CNA</td>
      <td>CCND1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>284</th>
      <td>KRAS (12,13)</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.12.,.13.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA guidelines</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>285</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19238210</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitors</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>286</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22614881;PMID:22290393</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>287</th>
      <td>CCND2 amplification</td>
      <td>CCND2</td>
      <td>CNA</td>
      <td>CCND2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>288</th>
      <td>CCND2 amplification</td>
      <td>CCND2</td>
      <td>CNA</td>
      <td>CCND2:amp</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>CDK4/6 inhibitor</td>
      <td>Palbociclib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02154490</td>
      <td>CRubio-Perez;DTamborero</td>
      <td>NaN</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Palbociclib (CDK4/6 inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>289</th>
      <td>CCND3 amplification</td>
      <td>CCND3</td>
      <td>CNA</td>
      <td>CCND3:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>290</th>
      <td>CCNE1 amplification</td>
      <td>CCNE1</td>
      <td>CNA</td>
      <td>CCNE1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK2 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>291</th>
      <td>CD274 (PD-L1) amplification</td>
      <td>CD274</td>
      <td>CNA</td>
      <td>CD274:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27942391</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BCC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Basal cell carcinoma</td>
    </tr>
    <tr>
      <th>292</th>
      <td>CD274 (PD-L1) amplification</td>
      <td>CD274</td>
      <td>CNA</td>
      <td>CD274:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PDL1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25079317</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PDL1 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>293</th>
      <td>CD274 (PD-L1) overexpression</td>
      <td>CD274</td>
      <td>EXPR</td>
      <td>CD274:over</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>PDL1 inhibitor</td>
      <td>Atezolizumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01375842;doi: 10.1093/annonc/mdu337.2</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>CM;R;CANCER</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Atezolizumab (PDL1 inhibitor)</td>
      <td>Cutaneous melanoma;Renal;Any cancer type</td>
    </tr>
    <tr>
      <th>294</th>
      <td>CD274 (PD-L1) overexpression</td>
      <td>CD274</td>
      <td>EXPR</td>
      <td>CD274:over</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>PD1 Ab inhibitor</td>
      <td>Nivolumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25452452</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>R</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nivolumab (PD1 Ab inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>295</th>
      <td>CD274 (PD-L1) overexpression</td>
      <td>CD274</td>
      <td>EXPR</td>
      <td>CD274:over</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>PD1 Ab</td>
      <td>Pembrolizumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01848834</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pembrolizumab (PD1 Ab)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>296</th>
      <td>CD69 undexpression</td>
      <td>CD69</td>
      <td>EXPR</td>
      <td>CD69:under</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Alkylating agent</td>
      <td>Bendamustine</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:26701728</td>
      <td>CRubio-Perez</td>
      <td>01/16</td>
      <td>CLL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Ibrutinib and idelalisib as adjuvants (not added)</td>
      <td>Bendamustine (Alkylating agent)</td>
      <td>Chronic lymphocytic leukemia</td>
    </tr>
    <tr>
      <th>297</th>
      <td>CDH1 oncogenic mutation</td>
      <td>CDH1</td>
      <td>MUT</td>
      <td>CDH1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>AR inhibitor</td>
      <td>Bicalutamide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Bicalutamide (AR inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>298</th>
      <td>CDK12 oncogenic mutation</td>
      <td>CDK12</td>
      <td>MUT</td>
      <td>CDK12:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitors]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24240700;PMID:24554720</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>299</th>
      <td>CDK12 amplification</td>
      <td>CDK12</td>
      <td>CNA</td>
      <td>CDK12:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitors]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24240700;PMID:24554720</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>300</th>
      <td>CDK4 oncogenic mutation</td>
      <td>CDK4</td>
      <td>MUT</td>
      <td>CDK4:.</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>CDK4/6 inhibitor</td>
      <td>LEE011</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102</td>
      <td>CRubio-Perez;DTamborero</td>
      <td>NaN</td>
      <td>LIP;LY;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>LEE011 (CDK4/6 inhibitor)</td>
      <td>Liposarcoma;Lymphoma;Any cancer type</td>
    </tr>
    <tr>
      <th>301</th>
      <td>CDK4 amplification</td>
      <td>CDK4</td>
      <td>CNA</td>
      <td>CDK4:amp</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>CDK4/6 inhibitor</td>
      <td>LEE011</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102</td>
      <td>CRubio-Perez;DTamborero</td>
      <td>NaN</td>
      <td>LIP;LY;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>LEE011 (CDK4/6 inhibitor)</td>
      <td>Liposarcoma;Lymphoma;Any cancer type</td>
    </tr>
    <tr>
      <th>302</th>
      <td>CDK4 amplification + RB1 expression</td>
      <td>CDK4;RB1</td>
      <td>CNA;EXPR</td>
      <td>CDK4:amp;RB1:norm</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23569312</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LIP</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4 inhibitors</td>
      <td>Liposarcoma</td>
    </tr>
    <tr>
      <th>303</th>
      <td>CDK6 amplification</td>
      <td>CDK6</td>
      <td>CNA</td>
      <td>CDK6:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK6 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>304</th>
      <td>CDK6 oncogenic mutation</td>
      <td>CDK6</td>
      <td>MUT</td>
      <td>CDK6:.</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>CDK4/6 inhibitor</td>
      <td>LEE011</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02187783;NCT01237236</td>
      <td>CRubio-Perez;DTamborero</td>
      <td>NaN</td>
      <td>LIP;LY;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>LEE011 (CDK4/6 inhibitor)</td>
      <td>Liposarcoma;Lymphoma;Any cancer type</td>
    </tr>
    <tr>
      <th>305</th>
      <td>CDK6 amplification</td>
      <td>CDK6</td>
      <td>CNA</td>
      <td>CDK6:amp</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>CDK4/6 inhibitor</td>
      <td>LEE011</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02187783;NCT01237236;http://meetinglibrary.asco.org/content/83791-102</td>
      <td>CRubio-Perez;DTamborero</td>
      <td>NaN</td>
      <td>LIP;LY;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>LEE011 (CDK4/6 inhibitor)</td>
      <td>Liposarcoma;Lymphoma;Any cancer type</td>
    </tr>
    <tr>
      <th>306</th>
      <td>CDKN1A oncogenic mutation</td>
      <td>CDKN1A</td>
      <td>MUT</td>
      <td>CDKN1A:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK2/4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22997239</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK2/4 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>307</th>
      <td>CDKN1A deletion</td>
      <td>CDKN1A</td>
      <td>CNA</td>
      <td>CDKN1A:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK2/4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22997239</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK2/4 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>308</th>
      <td>CDKN1B oncogenic mutation</td>
      <td>CDKN1B</td>
      <td>MUT</td>
      <td>CDKN1B:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK2/4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK2/4 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>309</th>
      <td>CDKN1B deletion</td>
      <td>CDKN1B</td>
      <td>CNA</td>
      <td>CDKN1B:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK2/4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK2/4 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>310</th>
      <td>CDKN2A oncogenic mutation</td>
      <td>CDKN2A</td>
      <td>MUT</td>
      <td>CDKN2A:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr 2500)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>311</th>
      <td>CDKN2A oncogenic mutation</td>
      <td>CDKN2A</td>
      <td>MUT</td>
      <td>CDKN2A:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22586120;PMID:22711607</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Glioma;Any cancer type</td>
    </tr>
    <tr>
      <th>312</th>
      <td>CDKN2A deletion</td>
      <td>CDKN2A</td>
      <td>CNA</td>
      <td>CDKN2A:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr 2500)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>313</th>
      <td>CDKN2A deletion</td>
      <td>CDKN2A</td>
      <td>CNA</td>
      <td>CDKN2A:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22586120;PMID:22711607</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Glioma;Any cancer type</td>
    </tr>
    <tr>
      <th>314</th>
      <td>CDKN2A oncogenic mutation</td>
      <td>CDKN2A</td>
      <td>MUT</td>
      <td>CDKN2A:.</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>AURKA-VEGF inhibitor</td>
      <td>Ilorasertib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02478320</td>
      <td>CRubio-Perez;DTamborero</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ilorasertib (AURKA-VEGF inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>315</th>
      <td>CDKN2A deletion</td>
      <td>CDKN2A</td>
      <td>CNA</td>
      <td>CDKN2A:del</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>AURKA-VEGF inhibitor</td>
      <td>Ilorasertib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02478320</td>
      <td>CRubio-Perez;DTamborero</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ilorasertib (AURKA-VEGF inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>316</th>
      <td>CDKN2B oncogenic mutation</td>
      <td>CDKN2B</td>
      <td>MUT</td>
      <td>CDKN2B:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22711607</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Glioma;Any cancer type</td>
    </tr>
    <tr>
      <th>317</th>
      <td>CDKN2B deletion</td>
      <td>CDKN2B</td>
      <td>CNA</td>
      <td>CDKN2B:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22711607</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitors</td>
      <td>Glioma;Any cancer type</td>
    </tr>
    <tr>
      <th>318</th>
      <td>CDKN2C oncogenic mutation</td>
      <td>CDKN2C</td>
      <td>MUT</td>
      <td>CDKN2C:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22997239;PMID:22711607</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK2 inhibitors</td>
      <td>Glioma;Any cancer type</td>
    </tr>
    <tr>
      <th>319</th>
      <td>CDKN2C deletion</td>
      <td>CDKN2C</td>
      <td>CNA</td>
      <td>CDKN2C:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22471707;PMID:22997239;PMID:22711607</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK2 inhibitors</td>
      <td>Glioma;Any cancer type</td>
    </tr>
    <tr>
      <th>320</th>
      <td>CHEK2 oncogenic mutation</td>
      <td>CHEK2</td>
      <td>MUT</td>
      <td>CHEK2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:26510020;AACR 2015 (abstr CT322);FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890</td>
      <td>RDientsmann; RShadrina;SDemajo</td>
      <td>07/22</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>321</th>
      <td>CHEK2 deletion</td>
      <td>CHEK2</td>
      <td>CNA</td>
      <td>CHEK2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2015 (abstr CT322)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>322</th>
      <td>MAP2K1 (P124)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:P124.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25370473</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>323</th>
      <td>MAP2K1 (Q56P,P124S,P124L;C121S)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:Q56P,P124S,P124L,C121S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:19915144;PMID:21383288</td>
      <td>RDientsmann;DTamborero</td>
      <td>03/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>324</th>
      <td>MAP2K1 oncogenic mutation</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26030179</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>325</th>
      <td>MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19915144</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Reference added by carlota</td>
      <td>MEK inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>326</th>
      <td>MAP2K1 (P124L,K57N,C121S)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:P124L,K57N,C121S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:19915144;PMID:23444215;PMID:21383288</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>327</th>
      <td>MAP2K1 (Q56P,P124S,P124L)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:Q56P,P124S,P124L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:19915144</td>
      <td>DTamborero</td>
      <td>03/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>328</th>
      <td>CRLF2 fusion</td>
      <td>CRLF2</td>
      <td>FUS</td>
      <td>CRLF2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22904298</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>329</th>
      <td>CRLF2 fusion</td>
      <td>CRLF2</td>
      <td>FUS</td>
      <td>CRLF2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22955920</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>330</th>
      <td>CSF1R (Y571D)</td>
      <td>CSF1R</td>
      <td>MUT</td>
      <td>CSF1R:Y571D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18971950</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>331</th>
      <td>CSF3R frameshift variant (D771),frameshift variant (S783)</td>
      <td>CSF3R</td>
      <td>MUT</td>
      <td>CSF3R::consequence::frameshift_variant:D771.,::frameshift_variant:S783.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23656643</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ACML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Atypical chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>332</th>
      <td>MAP2K2 (Q60P)</td>
      <td>MAP2K2</td>
      <td>MUT</td>
      <td>MAP2K2:Q60P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24265154</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>333</th>
      <td>CTNNB1 (H36Y,S37C,S37Y,D32V)</td>
      <td>CTNNB1</td>
      <td>MUT</td>
      <td>CTNNB1:H36Y,S37C,S37Y,D32V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;Hormonal therapy</td>
      <td>Everolimus;Letrozole</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25624430</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>334</th>
      <td>CYP17A1 expression</td>
      <td>CYP17A1</td>
      <td>EXPR</td>
      <td>CYP17A1:norm</td>
      <td>Direct</td>
      <td>Approved</td>
      <td>AR inhibitor</td>
      <td>Abiraterone</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22184395</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Abiraterone (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>335</th>
      <td>CYP17A1 expression</td>
      <td>CYP17A1</td>
      <td>EXPR</td>
      <td>CYP17A1:norm</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>AR inhibitor</td>
      <td>Enzalutamide</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24882673</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Enzalutamide (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>336</th>
      <td>MAP2K2 (V35M,L46F,N126D,C125S)</td>
      <td>MAP2K2</td>
      <td>MUT</td>
      <td>MAP2K2:V35M,L46F,N126D,C125S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24265153</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>337</th>
      <td>DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)</td>
      <td>DDR2</td>
      <td>MUT</td>
      <td>DDR2:I638F,L239R,G253C,G774V,L63V,G505S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22328973</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>338</th>
      <td>DDR2 (S768R)</td>
      <td>DDR2</td>
      <td>MUT</td>
      <td>DDR2:S768R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22328973</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>339</th>
      <td>DDR2 (S768R)</td>
      <td>DDR2</td>
      <td>MUT</td>
      <td>DDR2:S768R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22328973</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>340</th>
      <td>DNMT3A oncogenic mutation</td>
      <td>DNMT3A</td>
      <td>MUT</td>
      <td>DNMT3A:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Daunorubicin</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:22417203</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Daunorubicin (Chemotherapy)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>341</th>
      <td>DPYD splice donor variant</td>
      <td>DPYD</td>
      <td>MUT</td>
      <td>DPYD::consequence::splice_donor_variant:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Capecitabine</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Capecitabine (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>342</th>
      <td>DPYD biallelic inactivation</td>
      <td>DPYD</td>
      <td>BIA</td>
      <td>DPYD:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Capecitabine</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Capecitabine (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>343</th>
      <td>DPYD (I560S,D949V)</td>
      <td>DPYD</td>
      <td>MUT</td>
      <td>DPYD:I560S,D949V</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Capecitabine</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Capecitabine (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>344</th>
      <td>DPYD splice donor variant</td>
      <td>DPYD</td>
      <td>MUT</td>
      <td>DPYD::consequence::splice_donor_variant:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Flourouracil</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Flourouracil (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>345</th>
      <td>DPYD biallelic inactivation</td>
      <td>DPYD</td>
      <td>BIA</td>
      <td>DPYD:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Flourouracil</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Flourouracil (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>346</th>
      <td>DPYD (I560S,D949V)</td>
      <td>DPYD</td>
      <td>MUT</td>
      <td>DPYD:I560S,D949V</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Flourouracil</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Flourouracil (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>347</th>
      <td>DPYD splice donor variant</td>
      <td>DPYD</td>
      <td>MUT</td>
      <td>DPYD::consequence::splice_donor_variant:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Tegafur</td>
      <td>Increased Toxicity</td>
      <td>CPIC guidelines</td>
      <td>NaN</td>
      <td>PMID:23988873</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tegafur (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>348</th>
      <td>DPYD biallelic inactivation</td>
      <td>DPYD</td>
      <td>BIA</td>
      <td>DPYD:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Tegafur</td>
      <td>Increased Toxicity</td>
      <td>CPIC guidelines</td>
      <td>NaN</td>
      <td>PMID:23988873</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tegafur (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>349</th>
      <td>DPYD (I560S,D949V)</td>
      <td>DPYD</td>
      <td>MUT</td>
      <td>DPYD:I560S,D949V</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Fluoropyrimidine</td>
      <td>Tegafur</td>
      <td>Increased Toxicity</td>
      <td>CPIC guidelines</td>
      <td>NaN</td>
      <td>PMID:23988873</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tegafur (Fluoropyrimidine)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>350</th>
      <td>MAP2K2 (Q60P)</td>
      <td>MAP2K2</td>
      <td>MUT</td>
      <td>MAP2K2:Q60P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24265154</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>351</th>
      <td>MAP2K2 (V35M,L46F,N126D,C125S)</td>
      <td>MAP2K2</td>
      <td>MUT</td>
      <td>MAP2K2:V35M,L46F,N126D,C125S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24265153</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>352</th>
      <td>MCL1 amplification</td>
      <td>MCL1</td>
      <td>CNA</td>
      <td>MCL1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Tubulin inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21368834</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tubulin inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>353</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 1st gen]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22189054;PMID:23729478</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>NSCLC;COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gens</td>
      <td>Non-small cell lung;Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>354</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23729478</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>355</th>
      <td>MET (D1246V)</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:D1246V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MET inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27694386</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MET inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>356</th>
      <td>MET amplification + EGFR oncogenic mutation</td>
      <td>MET;EGFR</td>
      <td>CNA;MUT</td>
      <td>MET:amp;EGFR:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR TK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 8089)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR TK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>357</th>
      <td>MITF amplification</td>
      <td>MITF</td>
      <td>CNA</td>
      <td>MITF:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24265153</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>358</th>
      <td>MITF amplification</td>
      <td>MITF</td>
      <td>CNA</td>
      <td>MITF:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24265153</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>359</th>
      <td>MYCN amplification</td>
      <td>MYCN</td>
      <td>CNA</td>
      <td>MYCN:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SMO inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24951114</td>
      <td>DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>MB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SMO inhibitors</td>
      <td>Medulloblastoma</td>
    </tr>
    <tr>
      <th>360</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Retinoic Acid]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20655465</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>NB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Retinoic Acids</td>
      <td>Neuroblastoma</td>
    </tr>
    <tr>
      <th>361</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 3rd gen]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gens</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>362</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26763254</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>363</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18794099;PMID:17664472</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>364</th>
      <td>EGFR exon 19 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:729-761</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR TK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:22753918</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR TK inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>365</th>
      <td>EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR TK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:22753918</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR TK inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>366</th>
      <td>EGFR exon 19 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:729-761</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2012 (abstr 4380)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>367</th>
      <td>EGFR exon 20 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:762-823</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 8015)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>368</th>
      <td>EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2012 (abstr 4380)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>369</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2012 (abstr 4380)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>370</th>
      <td>EGFR exon 19 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:729-761</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor (alone or in combination)]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23102728</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor (alone or in combination)s</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>371</th>
      <td>EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor (alone or in combination)]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23102728</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor (alone or in combination)s</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>372</th>
      <td>EGFR (S492R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:S492R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[novel EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25962717</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>novel EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>373</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 3rd gen]</td>
      <td>[Rociletinib,HM61713]</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>NCT02322281</td>
      <td>CRubio-Perez;RDientsmann</td>
      <td>01/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gens (Rociletinib,HM61713,etc)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>374</th>
      <td>EGFR exon 19 deletions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:729-761</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>375</th>
      <td>EGFR exon 19 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:729-761</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:22753918;PMID:25589191</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>376</th>
      <td>EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>377</th>
      <td>EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>378</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Retinoic Acid]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20655465</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>NB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Retinoic Acids</td>
      <td>Neuroblastoma</td>
    </tr>
    <tr>
      <th>379</th>
      <td>EGFR exon 19 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:729-761</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen;EGFR mAb inhibitor</td>
      <td>Afatinib;Cetuximab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2012 (abstr 1289)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib + Cetuximab (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen + EGFR mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>380</th>
      <td>EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen;EGFR mAb inhibitor</td>
      <td>Afatinib;Cetuximab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2012 (abstr 1289)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib + Cetuximab (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen + EGFR mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>381</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen;EGFR mAb inhibitor</td>
      <td>Afatinib;Cetuximab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25074459</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib + Cetuximab (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen + EGFR mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>382</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen;EGFR mAb inhibitor</td>
      <td>Afatinib;Nimotuzumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26667485</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib + Nimotuzumab (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen + EGFR mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>383</th>
      <td>EGFR overexpression</td>
      <td>EGFR</td>
      <td>EXPR</td>
      <td>EGFR:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>384</th>
      <td>EGFR (P546S)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:P546S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23578570</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>385</th>
      <td>EGFR (P753S)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:P753S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor;MTOR inhibitor</td>
      <td>Cetuximab;Sirolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24934779</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor)</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>386</th>
      <td>EGFR-RAD51 fusion</td>
      <td>EGFR</td>
      <td>FUS</td>
      <td>EGFR__RAD51</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27102076</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>387</th>
      <td>EGFR-RAD51 fusion</td>
      <td>EGFR</td>
      <td>FUS</td>
      <td>EGFR__RAD51</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27102076</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>388</th>
      <td>EGFR exon 19 deletions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:729-761</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>exon 19 deletions</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>389</th>
      <td>EGFR exon 19 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:729-761</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22190593</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>390</th>
      <td>EGFR inframe insertion (769-770)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:769-770</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26773740;PMID:23328547</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>391</th>
      <td>EGFR (A289V,R108K,G598V,T263P)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:A289V,R108K,G598V,T263P</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:17177598</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>392</th>
      <td>NRAS (Q61)</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:Q61.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23569304;PMID:24265153</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>393</th>
      <td>EGFR (K757R,E746G)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:K757R,E746G</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26773740</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>394</th>
      <td>EGFR (L858R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>395</th>
      <td>EGFR (L858R,L861,G719,S768I)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,L861.,G719.,S768I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>396</th>
      <td>PDGFRA amplification</td>
      <td>PDGFRA</td>
      <td>CNA</td>
      <td>PDGFRA:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PDGFR inhibitor]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23544171</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PDGFR inhibitors</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>397</th>
      <td>PIK3CA (E545*)</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:E545*</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMC3936420</td>
      <td>DTamborero</td>
      <td>03/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>398</th>
      <td>EGFR exon 19 deletions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:729-761</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>399</th>
      <td>PIK3CA amplification</td>
      <td>PIK3CA</td>
      <td>CNA</td>
      <td>PIK3CA:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24366379</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>400</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9054)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>401</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:24950987</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>402</th>
      <td>EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>403</th>
      <td>EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>404</th>
      <td>PIK3CB (D1067Y)</td>
      <td>PIK3CB</td>
      <td>MUT</td>
      <td>PIK3CB:D1067Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26759240</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>405</th>
      <td>EGFR (E690K)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:E690K</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22885469</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>406</th>
      <td>EGFR exon 19 deletions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:729-761</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02465060</td>
      <td>CRubio-Perez</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Osimertinib (EGFR inhibitor 3rd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>407</th>
      <td>EGFR exon 20 insertions</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_insertion:762-823</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>PMID:26515464</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Insertion exon 20</td>
      <td>Osimertinib (EGFR inhibitor 3rd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>408</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:21163703;PMID:19398573</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>409</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:21163703;PMID:19398573</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>410</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:21788564;PMID:23238879</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>411</th>
      <td>EGFR (L858R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L858R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN Non-Small Cell Lung Cancer 2022;PMID:30659024</td>
      <td>CRubio-Perez;RShadrina;SDemajo</td>
      <td>01/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Osimertinib (EGFR inhibitor 3rd gen)</td>
      <td>Non-Small Cell Lung Cancer</td>
    </tr>
    <tr>
      <th>412</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Osimertinib (EGFR inhibitor 3rd gen)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>413</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:21788564;PMID:23238879</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>414</th>
      <td>PTEN oncogenic mutation + BRAF oncogenic mutation</td>
      <td>PTEN;BRAF</td>
      <td>MUT;MUT</td>
      <td>PTEN:.;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>http://ascopubs.org/doi/abs/10.1200/PO.16.00054</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>415</th>
      <td>EGFR (S492R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:S492R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22270724</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>416</th>
      <td>EGFR inframe deletion (6-273)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:6-273</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>Vaccine</td>
      <td>Rindopepimut</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>NCT01480479</td>
      <td>MMartínez</td>
      <td>09/15</td>
      <td>GB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>he EGFRvIII variant receptor is characterized by a deletion of exons 2–7 of the wild type (Wt) EGFR gene. This results in an in-frame truncation of amino acids (AA) 6 to 273 in the extracellular domain of the full length protein,</td>
      <td>Rindopepimut (Vaccine)</td>
      <td>Glioblastoma</td>
    </tr>
    <tr>
      <th>417</th>
      <td>PTEN deletion + BRAF oncogenic mutation</td>
      <td>PTEN;BRAF</td>
      <td>CNA;MUT</td>
      <td>PTEN:del;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>http://ascopubs.org/doi/abs/10.1200/PO.16.00054</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>418</th>
      <td>EPHA2 (G391R)</td>
      <td>EPHA2</td>
      <td>MUT</td>
      <td>EPHA2:G391R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20360610</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>419</th>
      <td>EPHA2 (G391R)</td>
      <td>EPHA2</td>
      <td>MUT</td>
      <td>EPHA2:G391R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20360610</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>420</th>
      <td>EPHA2 amplification</td>
      <td>EPHA2</td>
      <td>CNA</td>
      <td>EPHA2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18047674;PMID:19010823;PMID:19861960</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>421</th>
      <td>EPHA2 amplification</td>
      <td>EPHA2</td>
      <td>CNA</td>
      <td>EPHA2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18047674;PMID:19010823;PMID:19861960</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>422</th>
      <td>EPHA2 (G391R)</td>
      <td>EPHA2</td>
      <td>MUT</td>
      <td>EPHA2:G391R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20360610</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>423</th>
      <td>EPHA2 (G391R)</td>
      <td>EPHA2</td>
      <td>MUT</td>
      <td>EPHA2:G391R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20360610</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>424</th>
      <td>EPHA3 amplification</td>
      <td>EPHA3</td>
      <td>CNA</td>
      <td>EPHA3:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EPHA3 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25125683</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EPHA3 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>425</th>
      <td>EPHA3 amplification</td>
      <td>EPHA3</td>
      <td>CNA</td>
      <td>EPHA3:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EPHA3 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25125683</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EPHA3 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>426</th>
      <td>PTEN oncogenic mutation + BRAF oncogenic mutation</td>
      <td>PTEN;BRAF</td>
      <td>MUT;MUT</td>
      <td>PTEN:.;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23039341</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>427</th>
      <td>PTEN deletion + BRAF oncogenic mutation</td>
      <td>PTEN;BRAF</td>
      <td>CNA;MUT</td>
      <td>PTEN:del;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23039341</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>428</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERBB2 inhibitor;CDK4/6 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26977878</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor + CDK4/6 inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>429</th>
      <td>ERBB2 proximal exon 20</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:775-881</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERBB2 inhibitor]</td>
      <td>[Afatinib,Lapatinib,Neratinib]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26598547</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERBB2 inhibitors (Afatinib,Lapatinib,Neratinib,etc)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>430</th>
      <td>ERBB2 proximal exon 20</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:775-881</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERBB2 mAb inhibitor]</td>
      <td>[Trastuzumab]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26598547</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitors (Trastuzumab,etc)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>431</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Ado-Trastuzumab Emtansine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>432</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Ado-Trastuzumab Emtansine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>433</th>
      <td>ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:A775YVMA,::inframe_insertion:G776VC</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Ado-Trastuzumab Emtansine</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 8510)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>434</th>
      <td>ERBB2 (V659E,S310F)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:V659E,S310F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Ado-Trastuzumab Emtansine</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 8510)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>435</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>AACR 2014 (abstr CT228)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>436</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:20142587;PMID:22418700;PMID:23632474</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>437</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27044931</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>438</th>
      <td>ERBB2 proximal exon 20</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:775-881</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26598547;ASCO 2017 (abstr 9071)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>439</th>
      <td>ERBB2 (T798I)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:T798I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:28274957</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>440</th>
      <td>ERBB2 oncogenic mutation</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan ERBB inhibitor</td>
      <td>Dacomitinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25899785</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dacomitinib (Pan ERBB inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>441</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor;Chemotherapy</td>
      <td>Lapatinib;Capecitabine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538</td>
      <td>RDientsmann;CRubio-Perez;SDemajo</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>For the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.</td>
      <td>Lapatinib (ERBB2 inhibitor);Capecitabine (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>442</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26022204</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Billiary tract</td>
    </tr>
    <tr>
      <th>443</th>
      <td>ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23220880</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>444</th>
      <td>RAC1 (P29S) + BRAF oncogenic mutation</td>
      <td>RAC1;BRAF</td>
      <td>MUT;MUT</td>
      <td>RAC1:P29S;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25056119</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>445</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 inhibitor;Chemotherapy</td>
      <td>Lapatinib;Capecitabine</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538</td>
      <td>CRubio-Perez;SDemajo</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>For the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.</td>
      <td>Lapatinib (ERBB2 inhibitor);Capecitabine (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>446</th>
      <td>ERBB2 (V659E)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:V659E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23950206</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA;LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma;Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>447</th>
      <td>ERBB2 proximal exon 20</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:775-881</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26598547;ASCO 2017 (abstr 9071)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>448</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor;Chemotherapy</td>
      <td>Lapatinib;Chemotherapy</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25694417;NCT02015169</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib + Chemotherapy (ERBB2 inhibitor + Chemotherapy)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>449</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Allosteric AKT inhibitor;ERBB2 mAb inhibitor</td>
      <td>MK2206;Trastuzumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr 2605);PMID:26104654</td>
      <td>DCasadevall</td>
      <td>NaN</td>
      <td>SOLID</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MK2206 + Trastuzumab (Allosteric AKT inhibitor + ERBB2 mAb inhibitor)</td>
      <td>Solid tumors</td>
    </tr>
    <tr>
      <th>450</th>
      <td>ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_deletion:755-759,::inframe_insertion:.780GSP,::inframe_insertion:.781GSP</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23220880</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>451</th>
      <td>ERBB2 oncogenic mutation</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2014 (abstr LBA39_PR)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>452</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:20142587;PMID:22418700;PMID:23632474</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>453</th>
      <td>ERBB2 (K753E)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:K753E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27697991</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>454</th>
      <td>ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23220880</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>455</th>
      <td>ERBB2 proximal exon 20</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:775-881</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26598547;ASCO 2017 (abstr 9071)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>456</th>
      <td>ERBB2 (L869R)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:L869R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:28274957</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>457</th>
      <td>ERBB2 (S310,L755,V777)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:S310.,L755.,V777.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2017 (abstr CT001)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>458</th>
      <td>ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:P780GSP,::inframe_insertion:.781GSP,::inframe_insertion:A775YVMA,::inframe_insertion:G776YVMA</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2017 (abstr CT001)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>459</th>
      <td>RAC1 (P29S) + BRAF oncogenic mutation</td>
      <td>RAC1;BRAF</td>
      <td>MUT;MUT</td>
      <td>RAC1:P29S;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25056119</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>460</th>
      <td>RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation</td>
      <td>RAF1;BRAF</td>
      <td>MUT;MUT</td>
      <td>RAF1:S257P,G361A,P261P;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23737487</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>461</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Pertuzumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24960402</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pertuzumab (ERBB2 mAb inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>462</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Pertuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann;CRubio-Perez</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pertuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>463</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Pertuzumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26022204</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pertuzumab (ERBB2 mAb inhibitor)</td>
      <td>Billiary tract</td>
    </tr>
    <tr>
      <th>464</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Pertuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pertuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>465</th>
      <td>ERBB2 oncogenic mutation</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Tensirolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2014 (abstr LBA39_PR)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tensirolimus (MTOR inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>466</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez</td>
      <td>04/16</td>
      <td>ST;GEJA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Stomach;Gastroesophageal junction adenocarcinoma</td>
    </tr>
    <tr>
      <th>467</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann;CRubio-Perez</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>In combination with adjuvant chemotherapy</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>468</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26022204</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Billiary tract</td>
    </tr>
    <tr>
      <th>469</th>
      <td>STK11 oncogenic mutation</td>
      <td>STK11</td>
      <td>MUT</td>
      <td>STK11:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23129625;PMID:24045185</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>470</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21380780</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>471</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:20003286;PMID:12525520</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>472</th>
      <td>ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23220880;PMID:22908275</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA;CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma;Any cancer type</td>
    </tr>
    <tr>
      <th>473</th>
      <td>ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22908275</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>474</th>
      <td>ERBB2 (G776L)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:G776L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:16775247</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>475</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>In combination with adjuvant chemotherapy</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>476</th>
      <td>ERBB2 overexpression</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>ST;GEJA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Stomach;Gastroesophageal junction adenocarcinoma</td>
    </tr>
    <tr>
      <th>477</th>
      <td>ERBB2 proximal exon 20</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2::consequence::inframe_insertion:775-881</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26598547;ASCO 2017 (abstr 9071)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>478</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Ado-Trastuzumab Emtansine</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>http://ascopubs.org/doi/full/10.1200/PO.16.00055</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>479</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy</td>
      <td>Trastuzumab;Everolimus;Chemotherapy</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:21107682;PMID:20975068</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab + Everolimus + Chemotherapy (ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>480</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor;HSP90 inhibitor</td>
      <td>Trastuzumab;HSP90 inhibitor</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:21558407</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab + HSP90 inhibitor (ERBB2 mAb inhibitor + HSP90 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>481</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor;ERBB2 inhibitor</td>
      <td>Trastuzumab;Lapatinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 3508);NCT01104571;EBCC10</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>482</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor;ERBB2 inhibitor</td>
      <td>Trastuzumab;Lapatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25294905</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>483</th>
      <td>ERBB2 expression + ESR1 overexpression</td>
      <td>ERBB2;ESR1</td>
      <td>EXPR;EXPR</td>
      <td>ERBB2:norm;ESR1:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>[Hormonal therapy]</td>
      <td>[Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist]</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>JAlbanell;ARovira</td>
      <td>09/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Hormonal therapys (Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>484</th>
      <td>ERBB2 expression + ESR1 overexpression</td>
      <td>ERBB2;ESR1</td>
      <td>EXPR;EXPR</td>
      <td>ERBB2:norm;ESR1:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitor</td>
      <td>Abemaciclib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26658964</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Abemaciclib (CDK4/6 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>485</th>
      <td>ERBB2 expression + ESR1 overexpression</td>
      <td>ERBB2;ESR1</td>
      <td>EXPR;EXPR</td>
      <td>ERBB2:norm;ESR1:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>JAlbanell;ARovira</td>
      <td>09/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>HER2- (not overexpressed and not amplified) and ER+ (&gt;1% positive tumor cells)</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>486</th>
      <td>ERBB2 expression -</td>
      <td>ERBB2</td>
      <td>EXPR</td>
      <td>ERBB2:norm</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>CDK4/6 inhibitor</td>
      <td>Palbociclib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance</td>
      <td>CRubio-Perez;RShadrina;SDemajo</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or fulvestrant in women with disease progression following endocrine therapy.</td>
      <td>Palbociclib (CDK4/6 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>487</th>
      <td>STK11 oncogenic mutation + KRAS oncogenic mutation</td>
      <td>STK11;KRAS</td>
      <td>MUT;MUT</td>
      <td>STK11:.;KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9016)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>488</th>
      <td>ERBB3 (P262H,G284R)</td>
      <td>ERBB3</td>
      <td>MUT</td>
      <td>ERBB3:P262H,G284R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERBB3 mAb inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23680147</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERBB3 mAb inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>489</th>
      <td>ERBB3 (P262H,G284R,Q809R)</td>
      <td>ERBB3</td>
      <td>MUT</td>
      <td>ERBB3:P262H,G284R,Q809R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23680147</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>490</th>
      <td>ERBB3 (G284R,R103G)</td>
      <td>ERBB3</td>
      <td>MUT</td>
      <td>ERBB3:G284R,R103G</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr e15516)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>491</th>
      <td>ERBB3 (G284R,V104M,R103G)</td>
      <td>ERBB3</td>
      <td>MUT</td>
      <td>ERBB3:G284R,V104M,R103G</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27044931</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>492</th>
      <td>ERBB3 (P262H,G284R,Q809R)</td>
      <td>ERBB3</td>
      <td>MUT</td>
      <td>ERBB3:P262H,G284R,Q809R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23680147</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>493</th>
      <td>ERBB3 (P262H,G284R)</td>
      <td>ERBB3</td>
      <td>MUT</td>
      <td>ERBB3:P262H,G284R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Pertuzumab</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23680147</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pertuzumab (ERBB2 mAb inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>494</th>
      <td>ERBB3 (P262H,G284R,Q809R)</td>
      <td>ERBB3</td>
      <td>MUT</td>
      <td>ERBB3:P262H,G284R,Q809R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23680147</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>495</th>
      <td>STK11 deletion + KRAS oncogenic mutation</td>
      <td>STK11;KRAS</td>
      <td>CNA;MUT</td>
      <td>STK11:del;KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9016)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>496</th>
      <td>ERBB4 (E317K,E452K,R544W,R393W,E872K)</td>
      <td>ERBB4</td>
      <td>MUT</td>
      <td>ERBB4:E317K,E452K,R544W,R393W,E872K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19718025</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>497</th>
      <td>ERBB4 fusion</td>
      <td>ERBB4</td>
      <td>FUS</td>
      <td>ERBB4__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor;ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen</td>
      <td>Lapatinib;Afatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24727320</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib + Afatinib (ERBB2 inhibitor + ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>498</th>
      <td>ERCC1 oncogenic mutation</td>
      <td>ERCC1</td>
      <td>MUT</td>
      <td>ERCC1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23934192</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>499</th>
      <td>ERCC1 deletion</td>
      <td>ERCC1</td>
      <td>CNA</td>
      <td>ERCC1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23934192</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>500</th>
      <td>ERCC1 oncogenic mutation</td>
      <td>ERCC1</td>
      <td>MUT</td>
      <td>ERCC1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23275151;PMID:23934192</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>501</th>
      <td>ERCC1 deletion</td>
      <td>ERCC1</td>
      <td>CNA</td>
      <td>ERCC1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23275151;PMID:23934192</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>502</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MDM2 inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23084521;ASCO 2015 (abstr 10564)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LIP</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MDM2 inhibitors</td>
      <td>Liposarcoma</td>
    </tr>
    <tr>
      <th>503</th>
      <td>ERCC2 oncogenic mutation</td>
      <td>ERCC2</td>
      <td>MUT</td>
      <td>ERCC2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25096233</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>504</th>
      <td>ERCC4 oncogenic mutation</td>
      <td>ERCC4</td>
      <td>MUT</td>
      <td>ERCC4:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25634215</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>505</th>
      <td>ERCC6 oncogenic mutation</td>
      <td>ERCC6</td>
      <td>MUT</td>
      <td>ERCC6:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25634215</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>506</th>
      <td>EREG amplification</td>
      <td>EREG</td>
      <td>CNA</td>
      <td>EREG:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19738126;PMID:26341080</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>507</th>
      <td>ZBTB16 undexpression</td>
      <td>ZBTB16</td>
      <td>EXPR</td>
      <td>ZBTB16:under</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[LHRH analogues or antagonist]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16637071</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>PR</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>LHRH analogues or antagonists</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>508</th>
      <td>ESR1 (E380Q,537,538,L536,P535H)</td>
      <td>ESR1</td>
      <td>MUT</td>
      <td>ESR1:E380Q,.537.,.538.,L536.,P535H</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[novel ER degrader]</td>
      <td>[GDC-0810]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>AACR 2015 (abstr CT231)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>novel ER degraders (GDC-0810,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>509</th>
      <td>NTRK1 (G595R,G667C)</td>
      <td>NTRK1</td>
      <td>MUT</td>
      <td>NTRK1:G595R,G667C</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-TK inhibitor]</td>
      <td>[Entrectinib]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26546295</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-TK inhibitors (Entrectinib,etc)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>510</th>
      <td>ESR1 oncogenic mutation</td>
      <td>ESR1</td>
      <td>MUT</td>
      <td>ESR1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Hormonal therapy</td>
      <td>Fluvestrant</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:27269946</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Fluvestrant (Hormonal therapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>511</th>
      <td>ERBB4 (H809G)</td>
      <td>ERBB4</td>
      <td>MUT</td>
      <td>ERBB4:H809G</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERBB2 inhibitor]</td>
      <td>[Lapatinib]</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26530965</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERBB2 inhibitors (Lapatinib,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>512</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>[BCR-ABL inhibitor 2nd gen]</td>
      <td>[Nilotinib,Dasatinib]</td>
      <td>Resistant</td>
      <td>European LeukemiaNet guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>CRubio-Perez</td>
      <td>12/15</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Has to be rechecked</td>
      <td>BCR-ABL inhibitor 2nd gens (Nilotinib,Dasatinib,etc)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>513</th>
      <td>EZH2 (Y641,A677)</td>
      <td>EZH2</td>
      <td>MUT</td>
      <td>EZH2:Y641.,A677.</td>
      <td>Direct</td>
      <td>Pre-clinical</td>
      <td>[EZH2 inhibitor]</td>
      <td>[EPZ-005687,EPZ-6438]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:23023262;PMID:24563539</td>
      <td>RDientsmann;ECampo</td>
      <td>NaN</td>
      <td>LY</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors (EPZ-005687,EPZ-6438,etc)</td>
      <td>Lymphoma</td>
    </tr>
    <tr>
      <th>514</th>
      <td>FANCA oncogenic mutation</td>
      <td>FANCA</td>
      <td>MUT</td>
      <td>FANCA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26510020</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>515</th>
      <td>FANCA deletion</td>
      <td>FANCA</td>
      <td>CNA</td>
      <td>FANCA:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26510020</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>516</th>
      <td>FANCC oncogenic mutation</td>
      <td>FANCC</td>
      <td>MUT</td>
      <td>FANCC:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26238431</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>517</th>
      <td>FANCC deletion</td>
      <td>FANCC</td>
      <td>CNA</td>
      <td>FANCC:del</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26238431</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>518</th>
      <td>FAT1 oncogenic mutation</td>
      <td>FAT1</td>
      <td>MUT</td>
      <td>FAT1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>519</th>
      <td>FBXW7 oncogenic mutation</td>
      <td>FBXW7</td>
      <td>MUT</td>
      <td>FBXW7:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Steroid]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:20861909</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Steroids</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>520</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>CDK4/CDK6 inhibitor</td>
      <td>Abemaciclib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27217383</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Abemaciclib (CDK4/CDK6 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>521</th>
      <td>FBXW7 deletion</td>
      <td>FBXW7</td>
      <td>CNA</td>
      <td>FBXW7:del</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Sirolimus</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:23558291</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sirolimus (MTOR inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>522</th>
      <td>FGF3 amplification</td>
      <td>FGF3</td>
      <td>CNA</td>
      <td>FGF3:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FGFR inhibitor</td>
      <td>Dovitinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23658459</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dovitinib (FGFR inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>523</th>
      <td>FGF3 amplification</td>
      <td>FGF3</td>
      <td>CNA</td>
      <td>FGF3:amp</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>FGFR inhibitor</td>
      <td>Lucitanib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25193991</td>
      <td>JAlbanell;ARovira</td>
      <td>09/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lucitanib (FGFR inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>524</th>
      <td>FGF4 amplification</td>
      <td>FGF4</td>
      <td>CNA</td>
      <td>FGF4:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FGFR inhibitor</td>
      <td>Dovitinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23658459</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dovitinib (FGFR inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>525</th>
      <td>FGF4 amplification</td>
      <td>FGF4</td>
      <td>CNA</td>
      <td>FGF4:amp</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>FGFR inhibitor</td>
      <td>Lucitanib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25193991</td>
      <td>JAlbanell;ARovira</td>
      <td>09/15</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lucitanib (FGFR inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>526</th>
      <td>FGFR1 amplification</td>
      <td>FGFR1</td>
      <td>CNA</td>
      <td>FGFR1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27870574</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>527</th>
      <td>FGFR1 amplification</td>
      <td>FGFR1</td>
      <td>CNA</td>
      <td>FGFR1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2500)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>528</th>
      <td>FGFR1 amplification</td>
      <td>FGFR1</td>
      <td>CNA</td>
      <td>FGFR1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>529</th>
      <td>FGFR1 amplification</td>
      <td>FGFR1</td>
      <td>CNA</td>
      <td>FGFR1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23418312</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>530</th>
      <td>FGFR1 amplification</td>
      <td>FGFR1</td>
      <td>CNA</td>
      <td>FGFR1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[Lucitanib]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25193991</td>
      <td>RDientsmann;JAlbanell</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors (Lucitanib,etc)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>531</th>
      <td>AR amplification</td>
      <td>AR</td>
      <td>CNA</td>
      <td>AR:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>AR inhibitor</td>
      <td>Abiraterone</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26537258</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Abiraterone (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>532</th>
      <td>AR (L702H,T878A)</td>
      <td>AR</td>
      <td>MUT</td>
      <td>AR:L702H,T878A</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>AR inhibitor</td>
      <td>Abiraterone</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26537258</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.</td>
      <td>Abiraterone (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>533</th>
      <td>FGFR2 fusion</td>
      <td>FGFR2</td>
      <td>FUS</td>
      <td>FGFR2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 109)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Billiary tract</td>
    </tr>
    <tr>
      <th>534</th>
      <td>FGFR2 inframe insertion (A266),inframe insertion (S267)</td>
      <td>FGFR2</td>
      <td>MUT</td>
      <td>FGFR2::consequence::inframe_insertion:A266.,::inframe_insertion:S267.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26048680</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>535</th>
      <td>FGFR2 amplification</td>
      <td>FGFR2</td>
      <td>CNA</td>
      <td>FGFR2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 2508)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>536</th>
      <td>FGFR2 amplification</td>
      <td>FGFR2</td>
      <td>CNA</td>
      <td>FGFR2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25193991</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>537</th>
      <td>EGFR overexpression</td>
      <td>EGFR</td>
      <td>EXPR</td>
      <td>EGFR:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Resistant</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA guidelines</td>
      <td>CRubio-Perez;RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>538</th>
      <td>FGFR2 (S252W,N550K)</td>
      <td>FGFR2</td>
      <td>MUT</td>
      <td>FGFR2:S252W,N550K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18552176;PMID:22238366;PMID:23002168</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP: N549K to N500K to have all mutations in same transcript (ENST00000457416)</td>
      <td>FGFR inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>539</th>
      <td>FGFR2 (V565I)</td>
      <td>FGFR2</td>
      <td>MUT</td>
      <td>FGFR2:V565I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 381)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>540</th>
      <td>FGFR2 (W290C,S320C,K660N)</td>
      <td>FGFR2</td>
      <td>MUT</td>
      <td>FGFR2:W290C,S320C,K660N</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23786770;PMID:25035393</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>541</th>
      <td>FGFR2 fusion</td>
      <td>FGFR2</td>
      <td>FUS</td>
      <td>FGFR2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2500)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>542</th>
      <td>ALK (I1171T)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:I1171T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Alectinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25228534</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Alectinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>543</th>
      <td>FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)</td>
      <td>FGFR2</td>
      <td>MUT</td>
      <td>FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23908597</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>544</th>
      <td>FGFR3 fusion</td>
      <td>FGFR3</td>
      <td>FUS</td>
      <td>FGFR3__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26324363</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>545</th>
      <td>FGFR3 oncogenic mutation</td>
      <td>FGFR3</td>
      <td>MUT</td>
      <td>FGFR3:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27870574</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>546</th>
      <td>FGFR3 (K650,Y373C)</td>
      <td>FGFR3</td>
      <td>MUT</td>
      <td>FGFR3:K650.,Y373C</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16091734;PMID:20439987;PMID:22869148</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>547</th>
      <td>FGFR3 (S249C,G691R)</td>
      <td>FGFR3</td>
      <td>MUT</td>
      <td>FGFR3:S249C,G691R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27998968</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>548</th>
      <td>AR (F877L)</td>
      <td>AR</td>
      <td>MUT</td>
      <td>AR:F877L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>AR inhibitor</td>
      <td>Arn-509</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23779130</td>
      <td>RDientsmann;ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>TRUE</td>
      <td>REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge.</td>
      <td>Arn-509 (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>549</th>
      <td>FGFR3 fusion</td>
      <td>FGFR3</td>
      <td>FUS</td>
      <td>FGFR3__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26324363;ASCO 2017 (abstr 2500)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>550</th>
      <td>FGFR3 (K650)</td>
      <td>FGFR3</td>
      <td>MUT</td>
      <td>FGFR3:K650.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Proteasome inhibitor</td>
      <td>Bortezomib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19331127;PMID:21273588</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Bortezomib (Proteasome inhibitor)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>551</th>
      <td>FGFR3-TACC3 fusion</td>
      <td>FGFR3</td>
      <td>FUS</td>
      <td>FGFR3__TACC3</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>NaN</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25294908</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors (,etc)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>552</th>
      <td>FGFR4 (N535,V550)</td>
      <td>FGFR4</td>
      <td>MUT</td>
      <td>FGFR4:N535.,V550.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19809159;PMID:24124571</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>RHBDS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP:changed N535 and V550 from K535 and E550. Reference added by carlota</td>
      <td>FGFR inhibitors</td>
      <td>Rhabdomyosarcoma</td>
    </tr>
    <tr>
      <th>553</th>
      <td>FLCN oncogenic mutation</td>
      <td>FLCN</td>
      <td>MUT</td>
      <td>FLCN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23995526</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>554</th>
      <td>FLCN deletion</td>
      <td>FLCN</td>
      <td>CNA</td>
      <td>FLCN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25295501</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>555</th>
      <td>FLT1 overexpression</td>
      <td>FLT1</td>
      <td>EXPR</td>
      <td>VEGFR1:over</td>
      <td>Direct</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24086736;PMID:21478036</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>556</th>
      <td>FLT1 overexpression</td>
      <td>FLT1</td>
      <td>EXPR</td>
      <td>VEGFR2:over</td>
      <td>Direct</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24086736;PMID:21478036</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>557</th>
      <td>FGFR3 (Y373C)</td>
      <td>FGFR3</td>
      <td>MUT</td>
      <td>FGFR3:Y373C</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Proteasome inhibitor</td>
      <td>Bortezomib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19331127;PMID:21273588</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Bortezomib (Proteasome inhibitor)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>558</th>
      <td>FLT3-ITD</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3::consequence::inframe_variant:572-630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FLT3 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:16857985</td>
      <td>RDientsmann;SDemajo;RShadrina</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>ITD (codified as inframe) in Juxtamembrane domain</td>
      <td>FLT3 inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>559</th>
      <td>FLT3 (F691)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:F691.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[novel FLT3 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25847190</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>novel FLT3 inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>560</th>
      <td>FLT3 (N676)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:N676.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FLT3 inhibitor</td>
      <td>Crenolanib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24619500</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crenolanib (FLT3 inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>561</th>
      <td>FLT3 (D835)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:D835.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Lestaurtinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:16857985</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lestaurtinib (Pan-TK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>562</th>
      <td>FLT3 (D835)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:D835.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Midostaurin</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:20733134</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Midostaurin (Pan-TK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>563</th>
      <td>FLT3 (N676)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:N676.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Midostaurin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24619500</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Midostaurin (Pan-TK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>564</th>
      <td>ABL1 (T315I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:T315I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor  3rd gen</td>
      <td>Bosutinib</td>
      <td>Resistant</td>
      <td>European LeukemiaNet guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>CRubio-Perez</td>
      <td>12/15</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Has to be rechecked</td>
      <td>Bosutinib (BCR-ABL inhibitor  3rd gen)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>565</th>
      <td>FLT3-ITD</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3::consequence::inframe_variant:572-630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Quizartinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASH 2012 (abstr 673);ASH 2012 (abstr 48)</td>
      <td>RDientsmann;SDemajo;RShadrina</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>ITD (codified as inframe) in Juxtamembrane domain</td>
      <td>Quizartinib (Pan-TK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>566</th>
      <td>PTEN biallelic inactivation</td>
      <td>PTEN</td>
      <td>BIA</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>PIK3CA inhibitor</td>
      <td>BYL719</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25409150</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BYL719 (PIK3CA inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>567</th>
      <td>FLT3-ITD</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3::consequence::inframe_variant:572-630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19389879;PMID:22368270</td>
      <td>RDientsmann;SDemajo;RShadrina</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>ITD (codified as inframe) in Juxtamembrane domain</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>568</th>
      <td>FLT3-ITD</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3::consequence::inframe_variant:572-630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor;Chemotherapy</td>
      <td>Sorafenib;Azacytidine</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23613521</td>
      <td>RDientsmann;SDemajo;RShadrina</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>ITD (codified as inframe) in Juxtamembrane domain</td>
      <td>Sorafenib + Azacytidine (Pan-TK inhibitor + Chemotherapy)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>569</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Cediranib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT00326872</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Cediranib (ALK inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>570</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Cediranib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT00326872</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline NCT00326872 (trial results section)</td>
      <td>Cediranib (ALK inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>571</th>
      <td>ALK (G1123S)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:G1123S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Ceritinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26134233</td>
      <td>EArriola</td>
      <td>09/15</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ceritinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>572</th>
      <td>FOXA1 amplification</td>
      <td>FOXA1</td>
      <td>CNA</td>
      <td>FOXA1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BCL2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BCL2 inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>573</th>
      <td>FRS2 amplification</td>
      <td>FRS2</td>
      <td>CNA</td>
      <td>FRS2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23393200</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LIP</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FGFR inhibitors</td>
      <td>Liposarcoma</td>
    </tr>
    <tr>
      <th>574</th>
      <td>G6PD biallelic inactivation</td>
      <td>G6PD</td>
      <td>BIA</td>
      <td>G6PD:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Increased Toxicity (Haemolytic Anemia)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>575</th>
      <td>G6PD (S218F)</td>
      <td>G6PD</td>
      <td>MUT</td>
      <td>G6PD:S218F</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Increased Toxicity (Haemolytic Anemia)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>576</th>
      <td>G6PD (V98M) + G6PD (N156D)</td>
      <td>G6PD;G6PD</td>
      <td>MUT;MUT</td>
      <td>G6PD:V98M;G6PD:N156D</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Dabrafenib</td>
      <td>Increased Toxicity (Haemolytic Anemia)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dabrafenib (BRAF inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>577</th>
      <td>GATA3 oncogenic mutation</td>
      <td>GATA3</td>
      <td>MUT</td>
      <td>GATA3:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Aromatase ihibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24758297</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Aromatase ihibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>578</th>
      <td>ROS1 (S1986Y,S1986F)</td>
      <td>ROS1</td>
      <td>MUT</td>
      <td>ROS1:S1986Y,S1986F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Ceritinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27401242</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ceritinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>579</th>
      <td>GNA11 (Q209L,Q209P)</td>
      <td>GNA11</td>
      <td>MUT</td>
      <td>GNA11:Q209L,Q209P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22733540;PMID:22808163</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>580</th>
      <td>GNA11 (Q209L,Q209P)</td>
      <td>GNA11</td>
      <td>MUT</td>
      <td>GNA11:Q209L,Q209P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr CRA9003)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>581</th>
      <td>GNA11 (Q209L,Q209P)</td>
      <td>GNA11</td>
      <td>MUT</td>
      <td>GNA11:Q209L,Q209P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>HDAC inhibitor</td>
      <td>Vorinostat</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>NCT01587352</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vorinostat (HDAC inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>582</th>
      <td>GNAQ (Q209)</td>
      <td>GNAQ</td>
      <td>MUT</td>
      <td>GNAQ:Q209.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HDAC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>NCT01587352</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HDAC inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>583</th>
      <td>GNAQ (Q209)</td>
      <td>GNAQ</td>
      <td>MUT</td>
      <td>GNAQ:Q209.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22733540;PMID:22808163</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>584</th>
      <td>GNAQ (Q209)</td>
      <td>GNAQ</td>
      <td>MUT</td>
      <td>GNAQ:Q209.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PKC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22653968;PMID:22253748</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PKC inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>585</th>
      <td>GNAQ (Q209)</td>
      <td>GNAQ</td>
      <td>MUT</td>
      <td>GNAQ:Q209.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr CRA9003)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>586</th>
      <td>GNAS (R201)</td>
      <td>GNAS</td>
      <td>MUT</td>
      <td>GNAS:R201.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21835143</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>587</th>
      <td>HDAC2 biallelic inactivation</td>
      <td>HDAC2</td>
      <td>BIA</td>
      <td>HDAC2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>PARP inhibitor</td>
      <td>Olaparib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26510020</td>
      <td>RDientsmann;CRubio-Perez</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Olaparib (PARP inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>588</th>
      <td>HGF overexpression</td>
      <td>HGF</td>
      <td>EXPR</td>
      <td>HGF:over</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Pan-kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Xenograft</td>
      <td>PMID:25534569</td>
      <td>CRubio-Perez;ARodriguez-Vida</td>
      <td>NaN</td>
      <td>UTC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib (Pan-kinase inhibitor)</td>
      <td>Urinary tract carcinoma</td>
    </tr>
    <tr>
      <th>589</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:20619739;PMID:21163703;PMID:23325582</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>590</th>
      <td>HIF1A overexpression</td>
      <td>HIF1A</td>
      <td>EXPR</td>
      <td>HIF1A:over</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24086736</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>591</th>
      <td>HRAS oncogenic mutation</td>
      <td>HRAS</td>
      <td>MUT</td>
      <td>HRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor +/- MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22399013;PMID:22507781</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor +/- MTOR inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>592</th>
      <td>HRAS oncogenic mutation</td>
      <td>HRAS</td>
      <td>MUT</td>
      <td>HRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22345164</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CESC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Cervix squamous cell</td>
    </tr>
    <tr>
      <th>593</th>
      <td>HRAS oncogenic mutation</td>
      <td>HRAS</td>
      <td>MUT</td>
      <td>HRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:15950068</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Cervix</td>
    </tr>
    <tr>
      <th>594</th>
      <td>HRAS oncogenic mutation</td>
      <td>HRAS</td>
      <td>MUT</td>
      <td>HRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Farnesyltransferase inhibitor</td>
      <td>Tipifarnib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02383927</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tipifarnib (Farnesyltransferase inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>595</th>
      <td>HRAS oncogenic mutation</td>
      <td>HRAS</td>
      <td>MUT</td>
      <td>HRAS:.</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>Farnesyltransferase inhibitor</td>
      <td>Tipifarnib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02383927</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tipifarnib (Farnesyltransferase inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>596</th>
      <td>IDH1 oncogenic mutation</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BCL2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25599133</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BCL2 inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>597</th>
      <td>IDH1 oncogenic mutation</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[IDH1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 1LBA)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>IDH1 inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>598</th>
      <td>IDH1 (R132)</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:R132.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:28148839</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>599</th>
      <td>IDH1 oncogenic mutation</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:.</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>IDH1 inhibitor</td>
      <td>AG-120</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02073994;PMID:23558169</td>
      <td>MMartínez;RDientsmann;CRubio-Perez</td>
      <td>09/15</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AG-120 (IDH1 inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>600</th>
      <td>IDH1 oncogenic mutation</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:.</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02428855</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>CH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Cholangiocarcinoma</td>
    </tr>
    <tr>
      <th>601</th>
      <td>IDH1 (R132)</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:R132.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27231123</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Billiary tract</td>
    </tr>
    <tr>
      <th>602</th>
      <td>IDH1 oncogenic mutation</td>
      <td>IDH1</td>
      <td>MUT</td>
      <td>IDH1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCL2 inhibitor</td>
      <td>Venetoclax</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27520294</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>10/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>ITD (codified as inframe) in Juxtamembrane domain</td>
      <td>Venetoclax (BCL2 inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>603</th>
      <td>IDH2 (R140K,R172K)</td>
      <td>IDH2</td>
      <td>MUT</td>
      <td>IDH2:R140K,R172K</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>IDH2 inhibitor</td>
      <td>AG-221</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2014 (abstr CT103)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HEMATO</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AG-221 (IDH2 inhibitor)</td>
      <td>Hematologic malignancies</td>
    </tr>
    <tr>
      <th>604</th>
      <td>IDH2 oncogenic mutation</td>
      <td>IDH2</td>
      <td>MUT</td>
      <td>IDH2:.</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02428855</td>
      <td>CRubio-Perez</td>
      <td>NaN</td>
      <td>CH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Cholangiocarcinoma</td>
    </tr>
    <tr>
      <th>605</th>
      <td>IDH2 (R172)</td>
      <td>IDH2</td>
      <td>MUT</td>
      <td>IDH2:R172.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27231123</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Billiary tract</td>
    </tr>
    <tr>
      <th>606</th>
      <td>IDH2 oncogenic mutation</td>
      <td>IDH2</td>
      <td>MUT</td>
      <td>IDH2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCL2 inhibitor</td>
      <td>Venetoclax</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27520294</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>10/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>ITD (codified as inframe) in Juxtamembrane domain</td>
      <td>Venetoclax (BCL2 inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>607</th>
      <td>EGFR (S464L,G465R,I491M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:S464L,G465R,I491M</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25623215</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>608</th>
      <td>EGFR (S492R,G465R,R451C,K467T)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:S492R,G465R,R451C,K467T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>609</th>
      <td>IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion</td>
      <td>IL7R;SH2B3</td>
      <td>MUT;CNA</td>
      <td>IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22955920</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>610</th>
      <td>IL7R (S185C) + SH2B3 deletion</td>
      <td>IL7R;SH2B3</td>
      <td>MUT;CNA</td>
      <td>IL7R:S185C;SH2B3:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22955920</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>611</th>
      <td>IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion</td>
      <td>IL7R;SH2B3</td>
      <td>MUT;CNA</td>
      <td>IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>JAK inhibitor</td>
      <td>Ruxolitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22897847;PMID:22955920</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ruxolitinib (JAK inhibitor)</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>612</th>
      <td>IL7R (S185C) + SH2B3 deletion</td>
      <td>IL7R;SH2B3</td>
      <td>MUT;CNA</td>
      <td>IL7R:S185C;SH2B3:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>JAK inhibitor</td>
      <td>Ruxolitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22897847;PMID:22955920</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ruxolitinib (JAK inhibitor)</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>613</th>
      <td>INPP4B oncogenic mutation</td>
      <td>INPP4B</td>
      <td>MUT</td>
      <td>INPP4B:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23551093</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>614</th>
      <td>INPP4B deletion</td>
      <td>INPP4B</td>
      <td>CNA</td>
      <td>INPP4B:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23551093</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>615</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26552009</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>616</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22662154</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>617</th>
      <td>JAK1 (S646F;R683)</td>
      <td>JAK1</td>
      <td>MUT</td>
      <td>JAK1:S646F,R683.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>JAK inhibitor</td>
      <td>Ruxolitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22955920;PMID:18805579</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ruxolitinib (JAK inhibitor)</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>618</th>
      <td>JAK2 (V617F)</td>
      <td>JAK2</td>
      <td>MUT</td>
      <td>JAK2:V617F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor (alone or in combination)]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22829971</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitor (alone or in combination)s</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>619</th>
      <td>JAK2 amplification</td>
      <td>JAK2</td>
      <td>CNA</td>
      <td>JAK2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27075627</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>620</th>
      <td>NRAS (12,13,59,61,117,146)</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.12.,.13.,.59.,.61.,.117.,.146.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Resistant</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>621</th>
      <td>JAK2-BRAF fusion</td>
      <td>JAK2</td>
      <td>FUS</td>
      <td>JAK2__BRAF</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>JAK inhibitor</td>
      <td>Ruxolitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22875628;PMID:22899477</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ruxolitinib (JAK inhibitor)</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>622</th>
      <td>JAK2 (V617F)</td>
      <td>JAK2</td>
      <td>MUT</td>
      <td>JAK2:V617F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>JAK inhibitor</td>
      <td>Ruxolitinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22422826</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ruxolitinib (JAK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>623</th>
      <td>JAK2 (V617F)</td>
      <td>JAK2</td>
      <td>MUT</td>
      <td>JAK2:V617F</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>JAK inhibitor</td>
      <td>Ruxolitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MY</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ruxolitinib (JAK inhibitor)</td>
      <td>Myelofibrosis</td>
    </tr>
    <tr>
      <th>624</th>
      <td>JAK3 (A572V,A573V)</td>
      <td>JAK3</td>
      <td>MUT</td>
      <td>JAK3:A572V,A573V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22705984</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LY</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Lymphoma</td>
    </tr>
    <tr>
      <th>625</th>
      <td>JAK3 (R657Q,I87T,Q501H)</td>
      <td>JAK3</td>
      <td>MUT</td>
      <td>JAK3:R657Q,I87T,Q501H</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18397343</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MKB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Megakaryoblastic leukemia</td>
    </tr>
    <tr>
      <th>626</th>
      <td>KCNJ5 (L168R)</td>
      <td>KCNJ5</td>
      <td>MUT</td>
      <td>KCNJ5:L168R</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Na-Ca chanel blocker</td>
      <td>Amiloride</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24506072</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>AA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Amiloride (Na-Ca chanel blocker)</td>
      <td>Adrenal adenoma</td>
    </tr>
    <tr>
      <th>627</th>
      <td>KCNJ5 (L168R)</td>
      <td>KCNJ5</td>
      <td>MUT</td>
      <td>KCNJ5:L168R</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Na-Ca chanel blocker</td>
      <td>Verapamil</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24506072</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>AA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Verapamil (Na-Ca chanel blocker)</td>
      <td>Adrenal adenoma</td>
    </tr>
    <tr>
      <th>628</th>
      <td>KDR (A1065T)</td>
      <td>KDR</td>
      <td>MUT</td>
      <td>KDR:A1065T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[VEGFR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24569783</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>VEGFR inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>629</th>
      <td>KIT mutation in exon 11</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22898035</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>630</th>
      <td>KIT mutation in exon 9 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:788-828,449-514</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21737509</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>631</th>
      <td>KIT wildtype</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16397263</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>632</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592,627-664</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:19671763</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>633</th>
      <td>KIT (D816V)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:D816V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:18559612</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>SM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Systemic mastocytosis</td>
    </tr>
    <tr>
      <th>634</th>
      <td>KIT (D816V)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:D816V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:18986703</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>635</th>
      <td>KIT (D816Y,D816F,D816V)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:D816Y,D816F,D816V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16397263</td>
      <td>CRubio-Perez;RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>636</th>
      <td>KIT (N822K)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:N822K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23149070</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>637</th>
      <td>KIT inframe deletion (416-422),inframe insertion (416-422)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT::consequence::inframe_deletion:416-422,::inframe_insertion:416-422</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:15618474</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>638</th>
      <td>KIT inframe deletion (V560)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT::consequence::inframe_deletion:V560.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:15201427</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>639</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:19223544;PMID:20619739</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>640</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:449-514,550-592,627-664,664-714,788-828</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>641</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592,627-664</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>642</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592,627-664</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>643</th>
      <td>PTEN biallelic inactivation</td>
      <td>PTEN</td>
      <td>BIA</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>Caris molecular intelligence</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>644</th>
      <td>ERCC1 overexpression</td>
      <td>ERCC1</td>
      <td>EXPR</td>
      <td>ERCC1:over</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20846399;PMID:21177407</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>645</th>
      <td>MDM2 amplification</td>
      <td>MDM2</td>
      <td>CNA</td>
      <td>MDM2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27646943</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>MGCT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Male germ cell tumor</td>
    </tr>
    <tr>
      <th>646</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27646943</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>FGCT;MGCT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Female germ cell tumor;Male germ cell tumor</td>
    </tr>
    <tr>
      <th>647</th>
      <td>ALK inframe insertion (1151T)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK::consequence::inframe_insertion:.1151T.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22277784</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>648</th>
      <td>KIT (D820Y)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:D820Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23775962</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>649</th>
      <td>ALK oncogenic mutation</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Clinical trials</td>
      <td>NaN</td>
      <td>PMID:22235099</td>
      <td>EArriola</td>
      <td>09/15</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>650</th>
      <td>ALK amplification</td>
      <td>ALK</td>
      <td>CNA</td>
      <td>ALK:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Clinical trials</td>
      <td>NaN</td>
      <td>PMID:22235099</td>
      <td>EArriola</td>
      <td>09/15</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>651</th>
      <td>KIT (Y553N)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:Y553N</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21969494</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>652</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592,627-664</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22068222;PMID:25695690</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>653</th>
      <td>KIT mutation in exon 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:788-828</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22119758;PMID:21456006</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>654</th>
      <td>KIT (D820Y)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:D820Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25695690</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>655</th>
      <td>KIT (788-828,829-860,550-592)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:788-828,829-860,550-592</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>656</th>
      <td>KIT (A829P,V654A,T670I)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:A829P,V654A,T670I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25239608</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>657</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:449-514,550-592,627-664,664-714,788-828</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-kinase inhibitor</td>
      <td>Regorafenib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Exon 9,11,14,17</td>
      <td>Regorafenib (Pan-kinase inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>658</th>
      <td>KIT inframe deletion (577-579)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT::consequence::inframe_deletion:577-579</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:20970876</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>659</th>
      <td>KIT wildtype</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2011 (abstr 10009)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>660</th>
      <td>KIT mutation in exon 9 or 11</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592,449-514</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22270258</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>661</th>
      <td>KIT (550-592,627-664,788-828,829-860)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592,627-664,788-828,829-860</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:18936790;PMID:20372153</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>662</th>
      <td>KIT mutation in exon 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:788-828</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23840364</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>663</th>
      <td>KIT (D820E)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:D820E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:19461405</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>664</th>
      <td>KIT wildtype</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18955458</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>665</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:449-514,550-592,627-664,664-714,788-828</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>666</th>
      <td>ALK amplification</td>
      <td>ALK</td>
      <td>CNA</td>
      <td>ALK:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22277784</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>667</th>
      <td>KIT mutation in exon 9,11,13,14 or 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592,627-664</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>668</th>
      <td>ALK (C1156Y,L1196M)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:C1156Y,L1196M</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:20979473</td>
      <td>EArriola</td>
      <td>09/15</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>669</th>
      <td>ALK (F1174L)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:F1174L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22072639</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>670</th>
      <td>KIT (H697Y)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:H697Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19861435</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>671</th>
      <td>KIT (H697Y)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:H697Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19861435</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>672</th>
      <td>KIT (Y553N)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:Y553N</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23375402</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>673</th>
      <td>KRAS (12,13,59,61,117,146)</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.12.,.13.,.59.,.61.,.117.,.146.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Resistant</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA guidelines</td>
      <td>CRubio-Perez;RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>674</th>
      <td>KRAS (G12)</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:G12.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24687822</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>675</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>676</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR mAb inhibitor</td>
      <td>Cetuximab</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cetuximab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>677</th>
      <td>ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)</td>
      <td>ALK</td>
      <td>MUT</td>
      <td>ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22277784;PMID:25228534</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>678</th>
      <td>MET (Y1230C,Y1235D)</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:Y1230C,Y1235D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:17483355</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>679</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor]</td>
      <td>[]</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>680</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor;ERBB2 inhibitor</td>
      <td>Trastuzumab;Lapatinib</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 3508);NCT01104571;EBCC10</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>681</th>
      <td>ROS1 (G2032R)</td>
      <td>ROS1</td>
      <td>MUT</td>
      <td>ROS1:G2032R</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23724914;PMID:25688157</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>682</th>
      <td>ROS1 (S1986Y,S1986F)</td>
      <td>ROS1</td>
      <td>MUT</td>
      <td>ROS1:S1986Y,S1986F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27401242</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>683</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23129625;PMID:24045185</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>684</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20609353</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4 inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>685</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2017 (CT046)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitor + MEK inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>686</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK4/6 inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27167191</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CESC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitor + MEK inhibitors</td>
      <td>Cervix squamous cell</td>
    </tr>
    <tr>
      <th>687</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR mAb inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24553387</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor + MEK inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>688</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23614898</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>689</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23358651</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FAK inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>690</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FAS inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>AACR 2016;abstr</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FAS inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>691</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FAS inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>AACR 2016, abstr LB214</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FAS inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>692</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor (in combination)]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23012248;PMID:21907929</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitor (in combination)s</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>693</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK/TBK1/IKKε inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24444711</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK/TBK1/IKKε inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>694</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor;BCL-XL inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23245996</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor + BCL-XL inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>695</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor;IGF1R inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24045180</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor + IGF1R inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>696</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor;PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22392911</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor + PI3K pathway inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>697</th>
      <td>ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:V299L,T315A,F317L,F317V,F317I,F317C</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Resistant</td>
      <td>European LeukemiaNet guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>CRubio-Perez</td>
      <td>12/15</td>
      <td>CML;AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Has to be rechecked</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Chronic myeloid leukemia;Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>698</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L;BT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Lung;Billiary tract</td>
    </tr>
    <tr>
      <th>699</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22507781;PMID:22169769;PMID:19018267</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML;CER;OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Acute myeloid leukemia;Cervix;Ovary</td>
    </tr>
    <tr>
      <th>700</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24296828</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>701</th>
      <td>KRAS (G12)</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:G12.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18701506</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>702</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24296828</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>703</th>
      <td>FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)</td>
      <td>FGFR2</td>
      <td>MUT</td>
      <td>FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FGFR inhibitor</td>
      <td>Dovitinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23908597</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dovitinib (FGFR inhibitor)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>704</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor;BH3 mimetics]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24163374</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitor + BH3 mimeticss</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>705</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[pan-RAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2017 (abstr  CT002)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>pan-RAF inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>706</th>
      <td>AR (F877L)</td>
      <td>AR</td>
      <td>MUT</td>
      <td>AR:F877L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>AR inhibitor</td>
      <td>Enzalutamide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23779130</td>
      <td>RDientsmann;ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>TRUE</td>
      <td>REMAP:F876L to F877L the previous mutation was not found in . transcript to our knowledge.</td>
      <td>Enzalutamide (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>707</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[pan-RAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>pan-RAF inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>708</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21984976;PMID:22662154</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>709</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25516890</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>710</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO2015(abstre19028)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>711</th>
      <td>EGFR (S720)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:S720.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>No Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26773740</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>712</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitor</td>
      <td>Abemaciclib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27217383</td>
      <td>RDientsmann;DTamborero;CRubio-Perez</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Abemaciclib (CDK4/6 inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>713</th>
      <td>IGF1R amplification</td>
      <td>IGF1R</td>
      <td>CNA</td>
      <td>IGF1R:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24458568</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>714</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24535670</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>715</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24535670</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>716</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:20736812</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>717</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:20736812</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>718</th>
      <td>NF2 oncogenic mutation + EGFR oncogenic mutation</td>
      <td>NF2;EGFR</td>
      <td>MUT;MUT</td>
      <td>NF2:.;EGFR:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen;EGFR mAb inhibitor</td>
      <td>Erlotinib;Cetuximab</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24813888</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>In Egfr Mutant Tumors</td>
      <td>Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>719</th>
      <td>NF2 deletion + EGFR oncogenic mutation</td>
      <td>NF2;EGFR</td>
      <td>CNA;MUT</td>
      <td>NF2:del;EGFR:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen;EGFR mAb inhibitor</td>
      <td>Erlotinib;Cetuximab</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24813888</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>In Egfr Mutant Tumors</td>
      <td>Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>720</th>
      <td>MTOR (F2108L)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:F2108L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25295501</td>
      <td>DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Metastatic THCA with superresponse putatively assoiated with TSC2 nonsense mutation developing resistance associated with MTOR mutation after 18months</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>721</th>
      <td>MAP2K1 (F129L,L215P,I103N,P124)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:F129L,L215P,I103N,P124.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23614898</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>722</th>
      <td>MAP2K1 (P124)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:P124.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25370473</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>723</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01365468</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>724</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01365468</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>725</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;VEGFR mAb inhibitor</td>
      <td>Everolimus;Bevacizumab</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 11053)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>726</th>
      <td>MAP2K1 (C121S)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:C121S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[novel MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24448821</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>novel MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>727</th>
      <td>MAP2K1 (K57T)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:K57T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor;MEK inhibitor</td>
      <td>Panitumumab;Trametinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26644315</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab + Trametinib (EGFR mAb inhibitor + MEK inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>728</th>
      <td>MAP2K1 inframe deletion (56-60)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1::consequence::inframe_deletion:56-60</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26324360</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>729</th>
      <td>MAP2K1 (Q56P)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:Q56P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26582713</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>730</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;VEGFR mAb inhibitor</td>
      <td>Everolimus;Bevacizumab</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 11053)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>731</th>
      <td>MAP2K1 (P124S,I111S) + BRAF oncogenic mutation</td>
      <td>MAP2K1;BRAF</td>
      <td>MUT;MUT</td>
      <td>MAP2K1:P124S,I111S;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22588879</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BRAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>732</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;EGFR inhibitor 1st gen</td>
      <td>Everolimus;Erlotinib</td>
      <td>No Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24634382</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>733</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;EGFR inhibitor 1st gen</td>
      <td>Everolimus;Erlotinib</td>
      <td>No Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24634382</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>734</th>
      <td>ESR1 oncogenic mutation</td>
      <td>ESR1</td>
      <td>MUT</td>
      <td>ESR1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Hormonal therapy</td>
      <td>Exemestane</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:27269946</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Exemestane (Hormonal therapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>735</th>
      <td>AR (T878A)</td>
      <td>AR</td>
      <td>MUT</td>
      <td>AR:T878A</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>AR inhibitor</td>
      <td>Flutamide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:2260966</td>
      <td>RDientsmann;ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>PRAD</td>
      <td>TRUE</td>
      <td>REMAP:T877A to T878A the previous mutation was not found in . transcript to our knowledge.</td>
      <td>Flutamide (AR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>736</th>
      <td>ESR1 (Y537S)</td>
      <td>ESR1</td>
      <td>MUT</td>
      <td>ESR1:Y537S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Hormonal therapy</td>
      <td>Fulvestrant</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27986707</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Fulvestrant (Hormonal therapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>737</th>
      <td>MDM2 amplification</td>
      <td>MDM2</td>
      <td>CNA</td>
      <td>MDM2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MDM2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23084521;ASCO 2015 (abstr 10564)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LIP</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MDM2 inhibitors</td>
      <td>Liposarcoma</td>
    </tr>
    <tr>
      <th>738</th>
      <td>EGFR inframe deletion (L747),inframe insertion (P753PS)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR::consequence::inframe_deletion:L747.,::inframe_insertion:P753PS</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>No Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21274259</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>739</th>
      <td>MDM4 amplification</td>
      <td>MDM4</td>
      <td>CNA</td>
      <td>MDM4:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MDM2/MDMX inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24336067</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>S</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MDM2/MDMX inhibitors</td>
      <td>Sarcoma</td>
    </tr>
    <tr>
      <th>740</th>
      <td>EGFR amplification</td>
      <td>EGFR</td>
      <td>CNA</td>
      <td>EGFR:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:21274259;PMID:22261807</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>741</th>
      <td>MET kinase domain mutation</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:1078-1345</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MET inhibitor</td>
      <td>Savolitinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28644771</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Savolitinib (MET inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>742</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BCL2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BCL2 inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>743</th>
      <td>EGFR (V843I)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:V843I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Gefitinib</td>
      <td>No Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21274259</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gefitinib (EGFR inhibitor 1st gen)</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>744</th>
      <td>SLC29A1 oncogenic mutation</td>
      <td>SLC29A1</td>
      <td>MUT</td>
      <td>SLC29A1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Gemcitabine</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21166756</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>SLC29A1 is HENT1 used symbol</td>
      <td>Gemcitabine (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>745</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2015 (abstract A55)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>HC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MET inhibitors</td>
      <td>Hepatic carcinoma</td>
    </tr>
    <tr>
      <th>746</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22729845;PMID:23327903</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MET inhibitors</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>747</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23213094;AACR 2016 (abstr CT2006)</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MET inhibitors</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>748</th>
      <td>BTK (C481)</td>
      <td>BTK</td>
      <td>MUT</td>
      <td>BTK:C481.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BTK inhibitor</td>
      <td>Ibrutinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25082755</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MCL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ibrutinib (BTK inhibitor)</td>
      <td>Mantle cell lymphoma</td>
    </tr>
    <tr>
      <th>749</th>
      <td>MET (H1112R)</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:H1112R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23213094</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP:H1094r changed to H1112R</td>
      <td>MET inhibitors</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>750</th>
      <td>MET (M1268T)</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:M1268T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23610116</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MET inhibitors</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>751</th>
      <td>MET (H1112L)</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:H1112L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MET inhibitor]</td>
      <td>[Crizotinib]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>AACR 2012 (abstr 1786)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MET inhibitors (Crizotinib,etc)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>752</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>Pan-kinase inhibitor;EGFR mAb inhibitor</td>
      <td>Cabozantinib;Panitumumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2015 (abstr A52)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib + Panitumumab (Pan-kinase inhibitor + EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>753</th>
      <td>MET fusion</td>
      <td>MET</td>
      <td>FUS</td>
      <td>MET__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27748748</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>754</th>
      <td>MET mutation in exon 16-19</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:1132-1330</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2016 (abstr CT2006)</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>EXON 16-19</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>755</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02499614;ASCO 2015 (abstr 2595)</td>
      <td>EArriola;CRubio-Perez</td>
      <td>01/16</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>756</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD;ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma;Stomach</td>
    </tr>
    <tr>
      <th>757</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22162573</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>758</th>
      <td>MET (V1110I,H1112R,M1268T,R988C,T1010I)</td>
      <td>MET</td>
      <td>MUT</td>
      <td>MET:V1110I,H1112R,M1268T,R988C,T1010I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:17483355</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP:H1094R changed to H1112R, v1092i changed to v1110i (all mutations annotated in same transcript ENST00000318493; these mutations where from ENST00000397752)</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>759</th>
      <td>BTK (C481S)</td>
      <td>BTK</td>
      <td>MUT</td>
      <td>BTK:C481S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BTK inhibitor</td>
      <td>Ibrutinib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24869598;PMID:27199251</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CLL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ibrutinib (BTK inhibitor)</td>
      <td>Chronic lymphocytic leukemia</td>
    </tr>
    <tr>
      <th>760</th>
      <td>PLCG2 (R665W,L845F)</td>
      <td>PLCG2</td>
      <td>MUT</td>
      <td>PLCG2:R665W,L845F</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BTK inhibitor</td>
      <td>Ibrutinib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24869598</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CLL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ibrutinib (BTK inhibitor)</td>
      <td>Chronic lymphocytic leukemia</td>
    </tr>
    <tr>
      <th>761</th>
      <td>ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>European LeukemiaNet guidelines</td>
      <td>NaN</td>
      <td>PMID:21562040</td>
      <td>CRubio-Perez</td>
      <td>12/15</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>762</th>
      <td>MET amplification + BRAF (V600E)</td>
      <td>MET;BRAF</td>
      <td>CNA;MUT</td>
      <td>MET:amp;BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor;BRAF inhibitor</td>
      <td>Crizotinib;Vemurafenib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27325282</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib + Vemurafenib (ALK inhibitor + BRAF inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>763</th>
      <td>KIT wildtype</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18955458</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>764</th>
      <td>KIT (627-664,664-714,449-514)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:627-664,664-714,449-514</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18955458;PMID:18955451;PMID:16624552</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>765</th>
      <td>MET amplification + ERBB2 amplification</td>
      <td>MET;ERBB2</td>
      <td>CNA;CNA</td>
      <td>MET:amp;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor;ERBB2 mAb inhibitor</td>
      <td>Crizotinib;Trastuzumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26432108</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>766</th>
      <td>MET amplification + ERBB2 amplification</td>
      <td>MET;ERBB2</td>
      <td>CNA;CNA</td>
      <td>MET:amp;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor;ERBB2 mAb inhibitor</td>
      <td>Crizotinib;Trastuzumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26432108</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>767</th>
      <td>KIT mutation in exon 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:788-828</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23840364</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>768</th>
      <td>KIT mutation in exon 17 or 18</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:788-828,829-860</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:21690468;PMID:21642685</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>769</th>
      <td>KIT amplification</td>
      <td>KIT</td>
      <td>CNA</td>
      <td>KIT:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23775962</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>770</th>
      <td>KIT (D816)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:D816.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>GIST;MDS;MDPS;HES;ECL;CML;ALL;SM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal;Myelodisplasic syndrome;Myelodisplasic proliferative syndrome;Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia;Chronic myeloid leukemia;Acute lymphoblastic leukemia;Systemic mastocytosis</td>
    </tr>
    <tr>
      <th>771</th>
      <td>KIT (T670I)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:T670I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:24687822</td>
      <td>RDientsmann;RShadrina</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>772</th>
      <td>MKI67 overexpression</td>
      <td>MKI67</td>
      <td>EXPR</td>
      <td>MKI67:over</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24086736</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>773</th>
      <td>MLL fusion</td>
      <td>MLL</td>
      <td>FUS</td>
      <td>MLL__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21964340</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>774</th>
      <td>MLL fusion</td>
      <td>MLL</td>
      <td>FUS</td>
      <td>MLL__.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>HDAC inhibitor</td>
      <td>Belinostat</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT00351975;NCT00357032;PMID:22015773</td>
      <td>ECampo;RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Belinostat (HDAC inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>775</th>
      <td>MLL fusion</td>
      <td>MLL</td>
      <td>FUS</td>
      <td>MLL__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Daunorubicin</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:22417203</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Daunorubicin (Chemotherapy)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>776</th>
      <td>MLL fusion</td>
      <td>MLL</td>
      <td>FUS</td>
      <td>MLL__.</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>DOTL1 inhibitor</td>
      <td>EPZ-5676</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02141828;NCT01684150;PMID:21741596</td>
      <td>ECampo;RDientsmann</td>
      <td>NaN</td>
      <td>AML;ALL;MDS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EPZ-5676 (DOTL1 inhibitor)</td>
      <td>Acute myeloid leukemia;Acute lymphoblastic leukemia;Myelodisplasic syndrome</td>
    </tr>
    <tr>
      <th>777</th>
      <td>MLL2 oncogenic mutation</td>
      <td>MLL2</td>
      <td>MUT</td>
      <td>MLL2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>AR inhibitor</td>
      <td>Bicalutamide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>LUSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Bicalutamide (AR inhibitor)</td>
      <td>Lung squamous cell</td>
    </tr>
    <tr>
      <th>778</th>
      <td>MPL (W515F)</td>
      <td>MPL</td>
      <td>MUT</td>
      <td>MPL:W515F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16834459</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>779</th>
      <td>MSH3 oncogenic mutation</td>
      <td>MSH3</td>
      <td>MUT</td>
      <td>MSH3:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[DNA-PKc inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24556366</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>DNA-PKc inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>780</th>
      <td>MTOR (F2108L)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:F2108L</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR kinase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25295501</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR kinase inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>781</th>
      <td>MTOR (E2014K,E2419K,N1421D)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:E2014K,E2419K,N1421D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24625776</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>782</th>
      <td>KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23582185;PMID:21689725;PMID:17259998</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>783</th>
      <td>MTOR (I1973F)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:I1973F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 11010);PMID:26859683</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>AS;R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Angiosarcoma;Renal</td>
    </tr>
    <tr>
      <th>784</th>
      <td>MTOR (K1771R)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:K1771R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 11010);PMID:26859683</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST;AG</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Stomach;Anaplastic oligodendroglioma</td>
    </tr>
    <tr>
      <th>785</th>
      <td>MTOR (N1421D)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:N1421D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26859683</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>786</th>
      <td>MTOR (Q2223K)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:Q2223K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24622468</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>787</th>
      <td>MTOR (L1460P,S2215Y,R2505P)</td>
      <td>MTOR</td>
      <td>MUT</td>
      <td>MTOR:L1460P,S2215Y,R2505P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Sirolimus</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24631838</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sirolimus (MTOR inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>788</th>
      <td>MYC amplification</td>
      <td>MYC</td>
      <td>CNA</td>
      <td>MYC:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21889194;PMID:23430699</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MYMA;NB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Myeloma;Neuroblastoma</td>
    </tr>
    <tr>
      <th>789</th>
      <td>MYC amplification</td>
      <td>MYC</td>
      <td>CNA</td>
      <td>MYC:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CDK7 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25416950</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>NB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK7 inhibitors</td>
      <td>Neuroblastoma</td>
    </tr>
    <tr>
      <th>790</th>
      <td>MYC amplification</td>
      <td>MYC</td>
      <td>CNA</td>
      <td>MYC:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FACT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26537256</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>NB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FACT inhibitors</td>
      <td>Neuroblastoma</td>
    </tr>
    <tr>
      <th>791</th>
      <td>MYC amplification</td>
      <td>MYC</td>
      <td>CNA</td>
      <td>MYC:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PIM inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25505253</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PIM inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>792</th>
      <td>MYC amplification</td>
      <td>MYC</td>
      <td>CNA</td>
      <td>MYC:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Temozolomide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Temozolomide (Chemotherapy)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>793</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy;BCL2 inhibitor</td>
      <td>Decitabine;BCL2 inhibitor</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25968887</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>794</th>
      <td>MYD88 (L265P)</td>
      <td>MYD88</td>
      <td>MUT</td>
      <td>MYD88:L265P</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BTK inhibitor</td>
      <td>Ibrutinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:25853747</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>WM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ibrutinib (BTK inhibitor)</td>
      <td>Waldenström macroglobulinemia</td>
    </tr>
    <tr>
      <th>795</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AURK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24373973</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>AURK inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>796</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AURK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24373973</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>AURK inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>797</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRD4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24373973</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>BRD4 inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>798</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BRD4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24373973</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>BRD4 inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>799</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[KIT inhibitor;MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24718867</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>KIT inhibitor + MTOR inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>800</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[KIT inhibitor;MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24718867</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>KIT inhibitor + MTOR inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>801</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23221341</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>802</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22573716;PMID:19727076</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G;LK</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Glioma;Leukemia</td>
    </tr>
    <tr>
      <th>803</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23221341</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>804</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22573716;PMID:19727076</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G;LK</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Glioma;Leukemia</td>
    </tr>
    <tr>
      <th>805</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor;HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21907929</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>MTOR inhibitor + HSP90 inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>806</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor;HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21907929</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>MTOR inhibitor + HSP90 inhibitors</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>807</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G;MPN;LK</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Glioma;Malignant peripheral nerve sheat tumor;Leukemia</td>
    </tr>
    <tr>
      <th>808</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G;MPN;LK</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Glioma;Malignant peripheral nerve sheat tumor;Leukemia</td>
    </tr>
    <tr>
      <th>809</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-RAF inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26351322</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-RAF inhibitor + MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>810</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-RAF inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26351322</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-RAF inhibitor + MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>811</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 105)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>812</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 105)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>, PD1 expression higher in NF1 mutant melanoma (PMID 26960397)</td>
      <td>PD1 Ab inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>813</th>
      <td>PDGFRA wildtype</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:14645423;PMID:18955458</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>814</th>
      <td>PDGFRA (D842V)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:D842V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Late trials,Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22718859;PMID:16638875</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>815</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>VEGFR mAb inhibitor</td>
      <td>Bevacizumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24232489;PMID:2485933</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Bevacizumab (VEGFR mAb inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>816</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>VEGFR mAb inhibitor</td>
      <td>Bevacizumab</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24232489;PMID:2485933</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Bevacizumab (VEGFR mAb inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>817</th>
      <td>PDGFRA (T674I)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:T674I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:12660384</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HES</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Hyper eosinophilic advanced snydrome</td>
    </tr>
    <tr>
      <th>818</th>
      <td>ERBB2 (K753E)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:K753E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27697991</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>819</th>
      <td>MET amplification + ERBB2 amplification</td>
      <td>MET;ERBB2</td>
      <td>CNA;CNA</td>
      <td>MET:amp;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22238368</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>820</th>
      <td>NTRK1 (G595R)</td>
      <td>NTRK1</td>
      <td>MUT</td>
      <td>NTRK1:G595R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>TRK Kinase Inhibitor</td>
      <td>Larotrectinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:28578312</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Larotrectinib (TRK Kinase Inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>821</th>
      <td>NTRK3 (G623R)</td>
      <td>NTRK3</td>
      <td>MUT</td>
      <td>NTRK3:G623R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>TRK Kinase Inhibitor</td>
      <td>Larotrectinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:28578312</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Larotrectinib (TRK Kinase Inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>822</th>
      <td>CRBN oncogenic mutation</td>
      <td>CRBN</td>
      <td>MUT</td>
      <td>CRBN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Immunomodulator</td>
      <td>Lenalidomide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25108355</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>. other mutation disrupting IMID - CRBN or CRBN - ubiqutin complex may confer IMiD resistance</td>
      <td>Lenalidomide (Immunomodulator)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>823</th>
      <td>CRBN (Q100*,R283K)</td>
      <td>CRBN</td>
      <td>MUT</td>
      <td>CRBN:Q100*,R283K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Immunomodulator</td>
      <td>Lenalidomide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23480694</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP:Q99 changed to Q100 (meaning that i change from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C&gt;T chr3:g.3215822G&gt;A)</td>
      <td>Lenalidomide (Immunomodulator)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>824</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26859683;ASCO 2016 (abstr e17557)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>HNC;SG</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Head an neck;Salivary glands</td>
    </tr>
    <tr>
      <th>825</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>NCT01365468</td>
      <td>MMartínez</td>
      <td>09/15</td>
      <td>NF</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>benign</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Neurofibroma</td>
    </tr>
    <tr>
      <th>826</th>
      <td>NF1 (D1644A)</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:D1644A</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 11010);PMID:26859683</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>827</th>
      <td>CRBN undexpression</td>
      <td>CRBN</td>
      <td>EXPR</td>
      <td>CRBN:under</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Immunomodulator</td>
      <td>Lenalidomide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21860026</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression</td>
      <td>Lenalidomide (Immunomodulator)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>828</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26859683;ASCO 2016 (abstr e17557)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>HNC;SG</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Head an neck;Salivary glands</td>
    </tr>
    <tr>
      <th>829</th>
      <td>LRP1B oncogenic mutation</td>
      <td>LRP1B</td>
      <td>MUT</td>
      <td>LRP1B:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Liposomal Doxorubicin</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22896685</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Liposomal Doxorubicin (Chemotherapy)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>830</th>
      <td>LRP1B deletion</td>
      <td>LRP1B</td>
      <td>CNA</td>
      <td>LRP1B:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Liposomal Doxorubicin</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22896685</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Liposomal Doxorubicin (Chemotherapy)</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>831</th>
      <td>STK11 oncogenic mutation + KRAS oncogenic mutation</td>
      <td>STK11;KRAS</td>
      <td>MUT;MUT</td>
      <td>STK11:.;KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor;Chemotherapy</td>
      <td>MEK inhibitor;Docetaxel</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22425996</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>832</th>
      <td>STK11 deletion + KRAS oncogenic mutation</td>
      <td>STK11;KRAS</td>
      <td>CNA;MUT</td>
      <td>STK11:del;KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor;Chemotherapy</td>
      <td>MEK inhibitor;Docetaxel</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22425996</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>833</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;VEGFR inhibitor</td>
      <td>Everolimus;Pazopanib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24931142</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>HC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)</td>
      <td>Hepatic carcinoma</td>
    </tr>
    <tr>
      <th>834</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23099009</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>835</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23099009</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>836</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24173684</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN;MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Plexiform neurofibroma;Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>837</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24173684</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN;MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Plexiform neurofibroma;Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>838</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>PLX3397</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23099891</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>PLX3397 (Pan-TK inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>839</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>PLX3397</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23099891</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>PLX3397 (Pan-TK inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>840</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 10018)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>841</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 10018)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>842</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Sirolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25314964</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Sirolimus (MTOR inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>843</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Sirolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25314964</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Sirolimus (MTOR inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>844</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;EGFR inhibitor 1st gen</td>
      <td>Sirolimus;Erlotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22434731</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline, rampamycin = sirolimus</td>
      <td>Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>845</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;EGFR inhibitor 1st gen</td>
      <td>Sirolimus;Erlotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22434731</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline, rampamycin = sirolimus</td>
      <td>Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>846</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor;MTOR inhibitor</td>
      <td>Sorafenib;Sirolimus</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25810463</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>847</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor;MTOR inhibitor</td>
      <td>Sorafenib;Sirolimus</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25810463</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>848</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Hormonal therapy</td>
      <td>Tamoxifen</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21075781</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Tamoxifen (Hormonal therapy)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>849</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Hormonal therapy</td>
      <td>Tamoxifen</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21075781</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MPN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Tamoxifen (Hormonal therapy)</td>
      <td>Malignant peripheral nerve sheat tumor</td>
    </tr>
    <tr>
      <th>850</th>
      <td>ERBB2 (T798I)</td>
      <td>ERBB2</td>
      <td>MUT</td>
      <td>ERBB2:T798I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Neratinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:28274957</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Neratinib (ERBB2 inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>851</th>
      <td>ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)</td>
      <td>ABL1</td>
      <td>MUT</td>
      <td>ABL1:E255K,E255V,Y253H,F359V,F359C,F359I</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Resistant</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN Guidelines Chronic Myeloid Leukemia 2022;NCCN Guidelines Acute Lymphoblastic Leukemia 2022;PMID:21562040</td>
      <td>CRubio-Perez;RShadrina;SDemajo</td>
      <td>12/15</td>
      <td>CML;ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Chronic myeloid leukemia;Acute Lymphoblastic Leukemia</td>
    </tr>
    <tr>
      <th>852</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26936308</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>853</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24576830;PMID:2524381</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>854</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26936308</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>855</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24576830;PMID:2524381</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>856</th>
      <td>EGFR (C797S)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:C797S</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25939061</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Osimertinib (EGFR inhibitor 3rd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>857</th>
      <td>EGFR (L718)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L718.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2572)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Osimertinib (EGFR inhibitor 3rd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>858</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Vinblastine</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 2019)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Vinblastine (Chemotherapy)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>859</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Vinblastine</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 2019)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Vinblastine (Chemotherapy)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>860</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy;BCR-ABL inhibitor 2nd gen</td>
      <td>Vinblastine;Nilotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 10555)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>861</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy;BCR-ABL inhibitor 2nd gen</td>
      <td>Vinblastine;Nilotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 10555)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>862</th>
      <td>EGFR (L792)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L792.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gen</td>
      <td>Osimertinib</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2572)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Osimertinib (EGFR inhibitor 3rd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>863</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>3rd generation EGFR inhibitor</td>
      <td>Osimertinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27252416</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Osimertinib (3rd generation EGFR inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>864</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>[EGFR inhibitor 3rd gen]</td>
      <td>Osimertinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27252416</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gens (Osimertinib,etc)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>865</th>
      <td>TUBB3 overexpression</td>
      <td>TUBB3</td>
      <td>EXPR</td>
      <td>TUBB3:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Taxane</td>
      <td>Paclitaxel</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23184177</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Paclitaxel (Taxane)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>866</th>
      <td>CCND1 amplification</td>
      <td>CCND1</td>
      <td>CNA</td>
      <td>CCND1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitor</td>
      <td>Palbociclib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9056)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Palbociclib (CDK4/6 inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>867</th>
      <td>CDK4 amplification</td>
      <td>CDK4</td>
      <td>CNA</td>
      <td>CDK4:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitor</td>
      <td>Palbociclib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9056)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Palbociclib (CDK4/6 inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>868</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2012 (abstr 610)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MESO</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FAK inhibitors</td>
      <td>Mesothelioma</td>
    </tr>
    <tr>
      <th>869</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24848258;PMID:24786638</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MESO;OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FAK inhibitors</td>
      <td>Mesothelioma;Ovary</td>
    </tr>
    <tr>
      <th>870</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ENA 2012 (abstr 610)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MESO</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FAK inhibitors</td>
      <td>Mesothelioma</td>
    </tr>
    <tr>
      <th>871</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24848258;PMID:24786638</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MESO;OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FAK inhibitors</td>
      <td>Mesothelioma;Ovary</td>
    </tr>
    <tr>
      <th>872</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23714726</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>HSP90 inhibitors</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>873</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23714726</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>HSP90 inhibitors</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>874</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26359368</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>875</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26359368</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>876</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19451225;PMID:2242646</td>
      <td>RDientsmann</td>
      <td>07/18</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>877</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19451225;PMID:2242646</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>878</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23960073;PMID:25596744</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW;MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>PAK inhibitors</td>
      <td>Schwannoma;Meningioma</td>
    </tr>
    <tr>
      <th>879</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23960073;PMID:25596744</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW;MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>PAK inhibitors</td>
      <td>Schwannoma;Meningioma</td>
    </tr>
    <tr>
      <th>880</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PDK1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19359162</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>PDK1 inhibitors</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>881</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PDK1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19359162</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>PDK1 inhibitors</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>882</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>HDAC inhibitor</td>
      <td>AR42</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21778190</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>AR42 (HDAC inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>883</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>HDAC inhibitor</td>
      <td>AR42</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 2558)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline,minor response</td>
      <td>AR42 (HDAC inhibitor)</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>884</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>HDAC inhibitor</td>
      <td>AR42</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21778190</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>AR42 (HDAC inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>885</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>HDAC inhibitor</td>
      <td>AR42</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 2558)</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline,minor response</td>
      <td>AR42 (HDAC inhibitor)</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>886</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>VEGFR mAb inhibitor</td>
      <td>Bevacizumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19587327;PMID:22805104;PMID:26022982</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Bevacizumab (VEGFR mAb inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>887</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>VEGFR mAb inhibitor</td>
      <td>Bevacizumab</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:19587327;PMID:22805104;PMID:26022982</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Bevacizumab (VEGFR mAb inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>888</th>
      <td>BRAF (V600E)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:20619739;PMID:21163703;PMID:23325582</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>889</th>
      <td>EGFR (G465R)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:G465R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26059438</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>890</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24311643;2556735</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline, minor responsiv</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>891</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24311643;2556735</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline, minor responsiv</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>892</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;Somatostatin analog</td>
      <td>Everolimus;Octreotide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26015296</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>893</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;Somatostatin analog</td>
      <td>Everolimus;Octreotide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26015296</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)</td>
      <td>Meningioma</td>
    </tr>
    <tr>
      <th>894</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19509233;PMID:2290085</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>895</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19509233;PMID:2290085</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>SCHW</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Schwannoma</td>
    </tr>
    <tr>
      <th>896</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22844108;NCT00973739</td>
      <td>RDientsmann;MMartínez</td>
      <td>07/16</td>
      <td>SCHW;NF</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Schwannoma;Neurofibroma</td>
    </tr>
    <tr>
      <th>897</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22844108;NCT00973739</td>
      <td>RDientsmann;MMartínez</td>
      <td>07/16</td>
      <td>SCHW;NF</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Schwannoma;Neurofibroma</td>
    </tr>
    <tr>
      <th>898</th>
      <td>NF2 oncogenic mutation</td>
      <td>NF2</td>
      <td>MUT</td>
      <td>NF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;Chemotherapy</td>
      <td>Tensirolimus;Chemotherapy</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25878190</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>899</th>
      <td>NF2 deletion</td>
      <td>NF2</td>
      <td>CNA</td>
      <td>NF2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;Chemotherapy</td>
      <td>Tensirolimus;Chemotherapy</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25878190</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>900</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy;MEK inhibitor</td>
      <td>Gemcitabine;MEK inhibitor</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23583440</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>901</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT00890825</td>
      <td>EArriola</td>
      <td>09/15</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>902</th>
      <td>NOTCH1 activating mutation in Cterm-PEST domain</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor;CDK4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19318552</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitor + CDK4 inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>903</th>
      <td>NOTCH1 activating mutation in Cterm-PEST domain</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor;MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19246562</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitor + MTOR inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>904</th>
      <td>NOTCH1 fusion</td>
      <td>NOTCH1</td>
      <td>FUS</td>
      <td>NOTCH1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16688224;PMID:23033986</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>905</th>
      <td>NOTCH1 fusion</td>
      <td>NOTCH1</td>
      <td>FUS</td>
      <td>NOTCH1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22101766</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>906</th>
      <td>NOTCH1 activating mutation in Cterm-PEST domain</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2006 (abstr 6585)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>907</th>
      <td>NOTCH1 activating mutation in Cterm-PEST domain</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors</td>
      <td>Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>908</th>
      <td>NOTCH1 activating mutation in Cterm-PEST domain</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25564152</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>909</th>
      <td>NOTCH1 oncogenic mutation</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22210878</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MCL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors</td>
      <td>Mantle cell lymphoma</td>
    </tr>
    <tr>
      <th>910</th>
      <td>NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[NOTCH1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27870570</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>ADCC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>NOTCH1 inhibitors</td>
      <td>Adenoid cystic carcinoma</td>
    </tr>
    <tr>
      <th>911</th>
      <td>NOTCH1 activating mutation in Cterm-PEST domain</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[Ro4929097,Pf-03084014,Mk-0752]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01703572;NCT01778439; NCT01098344; NCT01981551</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors (Ro4929097,Pf-03084014,Mk-0752,etc)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>912</th>
      <td>NOTCH1 activating mutation in Cterm-PEST domain</td>
      <td>NOTCH1</td>
      <td>MUT</td>
      <td>NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>NOTCH1 inhibitor</td>
      <td>OMP-52M51</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01703572;NCT01778439</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>OMP-52M51 (NOTCH1 inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>913</th>
      <td>NOTCH2 fusion</td>
      <td>NOTCH2</td>
      <td>FUS</td>
      <td>NOTCH2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Gamma secretase inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22101766</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gamma secretase inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>914</th>
      <td>NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)</td>
      <td>NOTCH2</td>
      <td>MUT</td>
      <td>NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>Gamma secretase inhibitor</td>
      <td>Mk-0752</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25564152</td>
      <td>KKarube;RDientsmann</td>
      <td>NaN</td>
      <td>BRCA;AML;ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Mk-0752 (Gamma secretase inhibitor)</td>
      <td>Breast adenocarcinoma;Acute myeloid leukemia;Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>915</th>
      <td>NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)</td>
      <td>NOTCH2</td>
      <td>MUT</td>
      <td>NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420</td>
      <td>Direct</td>
      <td>Clinical Trials</td>
      <td>NOTCH2 inhibitor</td>
      <td>OMP-59R5</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01859741;NCT01277146</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>SOLID</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>OMP-59R5 (NOTCH2 inhibitor)</td>
      <td>Solid tumors</td>
    </tr>
    <tr>
      <th>916</th>
      <td>NPM1 oncogenic mutation</td>
      <td>NPM1</td>
      <td>MUT</td>
      <td>NPM1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[DOT1L inhibitors;MLL1 inhibitors]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27535106</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>DOT1L inhibitors + MLL1 inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>917</th>
      <td>NPM1 oncogenic mutation</td>
      <td>NPM1</td>
      <td>MUT</td>
      <td>NPM1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Daunorubicin</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:22417203</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Daunorubicin (Chemotherapy)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>918</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Resistant</td>
      <td>NCCN/CAP guidelines</td>
      <td>NaN</td>
      <td>NCCN</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2 inhibitor&amp;EGFR inhibitor 2nd gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>919</th>
      <td>PTEN biallelic inactivation</td>
      <td>PTEN</td>
      <td>BIA</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR mAb inhibitor</td>
      <td>Panitumumab</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>Caris molecular intelligence</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Panitumumab (EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>920</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>[CDK4/6 inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)</td>
      <td>DTamborero;CRubio-Perez;RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CDK4/6 inhibitor + MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>921</th>
      <td>NRAS (G12C)</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:G12C</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23614898</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>922</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ERK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 2508)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ERK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>923</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23538902</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>924</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor +/- PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23274911;PMID:22392911</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitor +/- PI3K pathway inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>925</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22507781;PMID:23515407;PMID:18701506</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML;LUAD;ALL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia</td>
    </tr>
    <tr>
      <th>926</th>
      <td>NRAS (Q61)</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:Q61.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:23414587,ASCO 2016 (abstr 9500)</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>927</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-RAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ESMO 2015 (abstract 300);AACR 2017 (abstr CT002)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-RAF inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>928</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22985491</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>929</th>
      <td>CRBN oncogenic mutation</td>
      <td>CRBN</td>
      <td>MUT</td>
      <td>CRBN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Immunomodulator</td>
      <td>Pomalidomide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25108355</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>IMiD-compound pocket in TBD of the CRBN is formed by three tryptophan residues, Trp380, Trp386 and Trp400</td>
      <td>Pomalidomide (Immunomodulator)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>930</th>
      <td>CRBN (Q100*,R283K)</td>
      <td>CRBN</td>
      <td>MUT</td>
      <td>CRBN:Q100*,R283K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Immunomodulator</td>
      <td>Pomalidomide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23480694</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP:Q99 changed to Q100 (meaning that i changed from ENSTENST00000432408 to ENST00000231948) (chr3:g.3195747C&gt;T chr3:g.3215822G&gt;A)</td>
      <td>Pomalidomide (Immunomodulator)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>931</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor;MEK inhibitor</td>
      <td>Sorafenib;MEK inhibitor</td>
      <td>Responsive</td>
      <td>Early Trials,Case Report</td>
      <td>NaN</td>
      <td>PMID:25294897</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>HC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)</td>
      <td>Hepatic carcinoma</td>
    </tr>
    <tr>
      <th>932</th>
      <td>CRBN undexpression</td>
      <td>CRBN</td>
      <td>EXPR</td>
      <td>CRBN:under</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Immunomodulator</td>
      <td>Pomalidomide</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21860026</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>MYMA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>several manuscripts reporting that the IMiD resistant patients exhibit lower CRBN expression</td>
      <td>Pomalidomide (Immunomodulator)</td>
      <td>Myeloma</td>
    </tr>
    <tr>
      <th>933</th>
      <td>NRG1 fusion</td>
      <td>NRG1</td>
      <td>FUS</td>
      <td>NRG1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2&amp;EGFR inhibitor 2nd gen</td>
      <td>Afatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>AACR 2016 (abstr 2631)</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Afatinib (ERBB2&amp;EGFR inhibitor 2nd gen)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>934</th>
      <td>NRG1 fusion</td>
      <td>NRG1</td>
      <td>FUS</td>
      <td>NRG1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 inhibitor</td>
      <td>Lapatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24727320</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lapatinib (ERBB2 inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>935</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-TK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24162815</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-TK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>936</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-TKR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28183697;ASCO 2017 (LBA2501)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-TKR inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>937</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Pan-TK inhibitor]</td>
      <td>[Entrectinib]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26546295</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-TK inhibitors (Entrectinib,etc)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>938</th>
      <td>NTRK1 fusion</td>
      <td>NTRK1</td>
      <td>FUS</td>
      <td>NTRK1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr 8023)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>939</th>
      <td>NTRK3 fusion</td>
      <td>NTRK3</td>
      <td>FUS</td>
      <td>NTRK3__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[IGF1R inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21148487;PMID:23131561</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>IGF1R inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>940</th>
      <td>NTRK3 fusion</td>
      <td>NTRK3</td>
      <td>FUS</td>
      <td>NTRK3__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21148487;PMID:23131561</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>941</th>
      <td>NTRK3 fusion</td>
      <td>NTRK3</td>
      <td>FUS</td>
      <td>NTRK3__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Midostaurin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21148487;PMID:23131561</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Midostaurin (Pan-TK inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>942</th>
      <td>PAK1 amplification</td>
      <td>PAK1</td>
      <td>CNA</td>
      <td>PAK1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23535073</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PAK inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>943</th>
      <td>PALB2 oncogenic mutation</td>
      <td>PALB2</td>
      <td>MUT</td>
      <td>PALB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2015 (abstr CT322);PMID:26510020</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>944</th>
      <td>PALB2 oncogenic mutation</td>
      <td>PALB2</td>
      <td>MUT</td>
      <td>PALB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25263539;NCT01585805</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>945</th>
      <td>PALB2 deletion</td>
      <td>PALB2</td>
      <td>CNA</td>
      <td>PALB2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2015 (abstr CT322);PMID:26510020</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>946</th>
      <td>PALB2 deletion</td>
      <td>PALB2</td>
      <td>CNA</td>
      <td>PALB2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25263539;NCT01585805</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>947</th>
      <td>PALB2 oncogenic mutation</td>
      <td>PALB2</td>
      <td>MUT</td>
      <td>PALB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Mytomycin C</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21135251</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Mytomycin C (Chemotherapy)</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>948</th>
      <td>PALB2 deletion</td>
      <td>PALB2</td>
      <td>CNA</td>
      <td>PALB2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Mytomycin C</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21135251</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Mytomycin C (Chemotherapy)</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>949</th>
      <td>PALB2 oncogenic mutation</td>
      <td>PALB2</td>
      <td>MUT</td>
      <td>PALB2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Platinum Agent</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25719666</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Platinum Agent (Chemotherapy)</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>950</th>
      <td>PALB2 deletion</td>
      <td>PALB2</td>
      <td>CNA</td>
      <td>PALB2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Platinum Agent</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25719666</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Platinum Agent (Chemotherapy)</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>951</th>
      <td>PBRM1 oncogenic mutation</td>
      <td>PBRM1</td>
      <td>MUT</td>
      <td>PBRM1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26552009</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>952</th>
      <td>PBRM1 deletion</td>
      <td>PBRM1</td>
      <td>CNA</td>
      <td>PBRM1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26552009</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>953</th>
      <td>PBRM1 undexpression</td>
      <td>PBRM1</td>
      <td>EXPR</td>
      <td>PBRM1:under</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:25997916</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>954</th>
      <td>PDGFRA (D842V)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:D842V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18794084</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>955</th>
      <td>FLT3 (D835,Y842)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:D835.,Y842.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23430109</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>956</th>
      <td>PDGFRA (D842V)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:D842V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FLT3 inhibitor</td>
      <td>Crenolanib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2016 (abstr 11010)</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crenolanib (FLT3 inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>957</th>
      <td>PDGFRA (V658A,P577S,R841K,H845Y,G853D)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:V658A,P577S,R841K,H845Y,G853D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>FLT3 inhibitor</td>
      <td>Crenolanib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24132921</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crenolanib (FLT3 inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>958</th>
      <td>PDGFRA wildtype</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16397263</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>959</th>
      <td>PDGFRA (D842V)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:D842V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Dasatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18794084</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Dasatinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>960</th>
      <td>PDGFRA fusion</td>
      <td>PDGFRA</td>
      <td>FUS</td>
      <td>PDGFRA__.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>EMA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>MDS;MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Myelodisplasic syndrome;Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>961</th>
      <td>PDGFRA-FIP1L1 fusion</td>
      <td>PDGFRA</td>
      <td>FUS</td>
      <td>PDGFRA__FIP1L1</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>EMA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>HES;ECL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia</td>
    </tr>
    <tr>
      <th>962</th>
      <td>PDGFRA inframe deletion (I843)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA::consequence::inframe_deletion:I843.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>963</th>
      <td>RET (I788N)</td>
      <td>RET</td>
      <td>MUT</td>
      <td>RET:I788N</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Ponatinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:28615362</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Ponatinib (BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>964</th>
      <td>PDGFRA (552-596,631-668,814-854)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:552-596,631-668,814-854</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>965</th>
      <td>FLT3 (F691,D835,N676,Y842)</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3:F691.,D835.,N676.,Y842.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Quizartinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22504184;PMID:23878140</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Quizartinib (Pan-TK inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>966</th>
      <td>PDGFRA (P577S,R841K,H845Y,G853D)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:P577S,R841K,H845Y,G853D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24132921</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>967</th>
      <td>EGFR (T790M)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:T790M</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor 1st gen</td>
      <td>Erlotinib</td>
      <td>Resistant</td>
      <td>NCCN/CAP guidelines</td>
      <td>NaN</td>
      <td>NCCN</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Erlotinib (EGFR inhibitor 1st gen)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>968</th>
      <td>PDGFRA (552-596,631-668,814-854)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:552-596,631-668,814-854</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-kinase inhibitor</td>
      <td>Regorafenib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Mutation exon 12,14,18</td>
      <td>Regorafenib (Pan-kinase inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>969</th>
      <td>PDGFRA wildtype</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2011 (abstr 10009)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>970</th>
      <td>PDGFRA wildtype</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18955458</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>971</th>
      <td>PDGFRA (552-596,631-668,814-854)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:552-596,631-668,814-854</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>NCCN guidelines</td>
      <td>NaN</td>
      <td>NCCN guidelines</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Mutation exon 12,14,18</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>972</th>
      <td>EGFR (L798I)</td>
      <td>EGFR</td>
      <td>MUT</td>
      <td>EGFR:L798I</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>EGFR inhibitor</td>
      <td>Rociletinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27283993</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Rociletinib (EGFR inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>973</th>
      <td>PDGFRA overexpression</td>
      <td>PDGFRA</td>
      <td>EXPR</td>
      <td>PDGFRA:over</td>
      <td>Direct</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24086736</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>974</th>
      <td>PDGFB-COL1A1 fusion</td>
      <td>PDGFB</td>
      <td>FUS</td>
      <td>PDGFB__COL1A1</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Imatinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>DFS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000406/WC500022207.pdf</td>
      <td>Imatinib (BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Dermatofibrosarcoma</td>
    </tr>
    <tr>
      <th>975</th>
      <td>PDPK1 amplification</td>
      <td>PDPK1</td>
      <td>CNA</td>
      <td>PDPK1:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19602588</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>976</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 2500)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AKT inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>977</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>3rd generation EGFR inhibitor</td>
      <td>Rociletinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27252416</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Rociletinib (3rd generation EGFR inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>978</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor (alone or in combination)]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23136191;PMID:23475782;PMID:22392911</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L;COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor (alone or in combination)s</td>
      <td>Lung;Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>979</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BLCA;HNC;L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Bladder;Head an neck;Lung</td>
    </tr>
    <tr>
      <th>980</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA;OV;CESC;ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium</td>
    </tr>
    <tr>
      <th>981</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26787751;PMID:26763254</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>982</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19671762;PMID:21289267</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G;THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Glioma;Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>983</th>
      <td>MET amplification</td>
      <td>MET</td>
      <td>CNA</td>
      <td>MET:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EGFR inhibitor 3rd gen]</td>
      <td>Rociletinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27252416</td>
      <td>EArriola</td>
      <td>06/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EGFR inhibitor 3rd gens (Rociletinib,etc)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>984</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor;MEK inhibitor</td>
      <td>Sorafenib;MEK inhibitor</td>
      <td>Responsive</td>
      <td>Early Trials,Case Report</td>
      <td>NaN</td>
      <td>PMID:25294897</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>HC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)</td>
      <td>Hepatic carcinoma</td>
    </tr>
    <tr>
      <th>985</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PIK3CA inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28331003</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PIK3CA inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>986</th>
      <td>PIK3CA oncogenic mutation</td>
      <td>PIK3CA</td>
      <td>MUT</td>
      <td>PIK3CA:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PIK3CA inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 2501)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PIK3CA inhibitors</td>
      <td>Stomach</td>
    </tr>
    <tr>
      <th>987</th>
      <td>NF1 oncogenic mutation + BRAF oncogenic mutation</td>
      <td>NF1;BRAF</td>
      <td>MUT;MUT</td>
      <td>NF1:.;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23444215</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>988</th>
      <td>PIK3CA oncogenic mutation + ERBB2 amplification</td>
      <td>PIK3CA;ERBB2</td>
      <td>MUT;CNA</td>
      <td>PIK3CA:.;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy</td>
      <td>Everolimus;Trastuzumab;Chemotherapy</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:27091708</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>989</th>
      <td>PIK3CB oncogenic mutation</td>
      <td>PIK3CB</td>
      <td>MUT</td>
      <td>PIK3CB:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23619167</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AKT inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>990</th>
      <td>PIK3CB (D1067Y)</td>
      <td>PIK3CB</td>
      <td>MUT</td>
      <td>PIK3CB:D1067Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26759240</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AKT inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>991</th>
      <td>PIK3CB oncogenic mutation</td>
      <td>PIK3CB</td>
      <td>MUT</td>
      <td>PIK3CB:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTORC1/2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23619167</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTORC1/2 inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>992</th>
      <td>PIK3CB (D1067Y)</td>
      <td>PIK3CB</td>
      <td>MUT</td>
      <td>PIK3CB:D1067Y</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTORC1/2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26759240</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTORC1/2 inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>993</th>
      <td>PIK3CB oncogenic mutation</td>
      <td>PIK3CB</td>
      <td>MUT</td>
      <td>PIK3CB:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23619167</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HNSC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Head an neck squamous</td>
    </tr>
    <tr>
      <th>994</th>
      <td>NF1 deletion + BRAF oncogenic mutation</td>
      <td>NF1;BRAF</td>
      <td>CNA;MUT</td>
      <td>NF1:del;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Selumetinib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23444215</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Selumetinib (MEK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>995</th>
      <td>PIK3R1 oncogenic mutation</td>
      <td>PIK3R1</td>
      <td>MUT</td>
      <td>PIK3R1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23166678</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AKT inhibitors</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>996</th>
      <td>PIK3R1 oncogenic mutation</td>
      <td>PIK3R1</td>
      <td>MUT</td>
      <td>PIK3R1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 11075)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>997</th>
      <td>PIK3R2 (A171V,N561D)</td>
      <td>PIK3R2</td>
      <td>MUT</td>
      <td>PIK3R2:A171V,N561D</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21984976;PMID:19962665</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>998</th>
      <td>PML-RARA fusion</td>
      <td>PML</td>
      <td>FUS</td>
      <td>PML__RARA</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Retinoid</td>
      <td>Tretinoin</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>APML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tretinoin (Retinoid)</td>
      <td>Acute promyelocytic leukemia</td>
    </tr>
    <tr>
      <th>999</th>
      <td>PML-RARA fusion</td>
      <td>PML</td>
      <td>FUS</td>
      <td>PML__RARA</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Retinoid;Chemotherapy</td>
      <td>Tretinoin;Arsenic Trioxide</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tretinoin + Arsenic Trioxide (Retinoid + Chemotherapy)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>1000</th>
      <td>PML-RARA fusion</td>
      <td>PML</td>
      <td>FUS</td>
      <td>PML__RARA</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>PLK1 inhibitor</td>
      <td>Volasertib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT02198482;NCT01662505</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Volasertib (PLK1 inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>1001</th>
      <td>POLE (268-471)</td>
      <td>POLE</td>
      <td>MUT</td>
      <td>POLE:268-471</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27001570;PMID:27683556;PMID:27159395</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>G;ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Mutations in exonuclease domain. Domain coordinates from (PMID:23528559)</td>
      <td>PD1 Ab inhibitors</td>
      <td>Glioma;Endometrium</td>
    </tr>
    <tr>
      <th>1002</th>
      <td>POLE oncogenic mutation</td>
      <td>POLE</td>
      <td>MUT</td>
      <td>POLE:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:28188185</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>1003</th>
      <td>PRKCH amplification + ABL1-BCR fusion</td>
      <td>PRKCH;ABL1</td>
      <td>CNA;FUS</td>
      <td>PRKCH:amp;ABL1__BCR</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor;BCR-ABL inhibitor 1st gen&amp;KIT inhibitor</td>
      <td>Trametinib;Imatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25186176</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trametinib + Imatinib (MEK inhibitor + BCR-ABL inhibitor 1st gen&amp;KIT inhibitor)</td>
      <td>Chronic myeloid leukemia</td>
    </tr>
    <tr>
      <th>1004</th>
      <td>PTCH1 oncogenic mutation</td>
      <td>PTCH1</td>
      <td>MUT</td>
      <td>PTCH1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>[SMO inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24651015</td>
      <td>DTamborero;RDientsmann</td>
      <td>10/16</td>
      <td>MB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SMO inhibitors</td>
      <td>Medulloblastoma</td>
    </tr>
    <tr>
      <th>1005</th>
      <td>PTCH1 oncogenic mutation</td>
      <td>PTCH1</td>
      <td>MUT</td>
      <td>PTCH1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MET inhibitor</td>
      <td>Foretinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25391241</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>MB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Foretinib (MET inhibitor)</td>
      <td>Medulloblastoma</td>
    </tr>
    <tr>
      <th>1006</th>
      <td>PTCH1 oncogenic mutation</td>
      <td>PTCH1</td>
      <td>MUT</td>
      <td>PTCH1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>SHH inhibitor</td>
      <td>Vismodegib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:19726763;PMID:19726761</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BCC;MB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vismodegib (SHH inhibitor)</td>
      <td>Basal cell carcinoma;Medulloblastoma</td>
    </tr>
    <tr>
      <th>1007</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22025163</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AKT inhibitors</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>1008</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[AKT inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:22025163</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AKT inhibitors</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>1009</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[ATM inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>ATM inhibitors</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1010</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21468130;PMID:20944090</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>(low estrogen)</td>
      <td>PARP inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>1011</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21468130;PMID:20944090</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>(low estrogen)</td>
      <td>PARP inhibitors</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>1012</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26645196</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1013</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PD1 Ab inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26645196</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PD1 Ab inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1014</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;AR antagonist]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21575859</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + AR antagonists</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1015</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;AR antagonist]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21575859</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + AR antagonists</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1016</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21632463</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>1017</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor;MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21632463</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitor + MEK inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>1018</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH;G;L;OV;BRCA;CANCER;ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium</td>
    </tr>
    <tr>
      <th>1019</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PI3K pathway inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH;G;L;OV;BRCA;CANCER;ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PI3K pathway inhibitors</td>
      <td>Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium</td>
    </tr>
    <tr>
      <th>1020</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PIK3CB inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 2514)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PIK3CB inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1021</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PIK3CB inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2014 (abstr 2514)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PIK3CB inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1022</th>
      <td>KIT mutation in exon 11</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:550-592</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Resistant</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:18955458</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>1023</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23582881</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1024</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23582881</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1025</th>
      <td>KIT mutation in exon 17</td>
      <td>KIT</td>
      <td>MUT</td>
      <td>KIT:788-828</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23840364</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>1026</th>
      <td>PTEN oncogenic mutation</td>
      <td>PTEN</td>
      <td>MUT</td>
      <td>PTEN:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Sirolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr 2532)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sirolimus (MTOR inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1027</th>
      <td>PTEN deletion</td>
      <td>PTEN</td>
      <td>CNA</td>
      <td>PTEN:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Sirolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2013 (abstr 2532)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sirolimus (MTOR inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1028</th>
      <td>KIT amplification</td>
      <td>KIT</td>
      <td>CNA</td>
      <td>KIT:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22261812</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1029</th>
      <td>PDGFRA (D842V)</td>
      <td>PDGFRA</td>
      <td>MUT</td>
      <td>PDGFRA:D842V</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Resistant</td>
      <td>Late trials,Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22718859;PMID:16638875</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>GIST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Gastrointestinal stromal</td>
    </tr>
    <tr>
      <th>1030</th>
      <td>ESR1 (E380Q,537,538,L536,P535H)</td>
      <td>ESR1</td>
      <td>MUT</td>
      <td>ESR1:E380Q,.537.,.538.,L536.,P535H</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Hormonal therapy</td>
      <td>Tamoxifen</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24185512;PMID:24185510;PMID:24398047</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tamoxifen (Hormonal therapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1031</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Farnesyltransferase inhibitor</td>
      <td>Tipifarnib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24500418</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Tipifarnib (Farnesyltransferase inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>1032</th>
      <td>PTEN oncogenic mutation + ERBB2 amplification</td>
      <td>PTEN;ERBB2</td>
      <td>MUT;CNA</td>
      <td>PTEN:.;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy</td>
      <td>Everolimus;Trastuzumab;Chemotherapy</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:27091708</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1033</th>
      <td>PTPRD oncogenic mutation</td>
      <td>PTPRD</td>
      <td>MUT</td>
      <td>PTPRD:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[IGF1R inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23800680</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>S</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>IGF1R inhibitors</td>
      <td>Sarcoma</td>
    </tr>
    <tr>
      <th>1034</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Farnesyltransferase inhibitor</td>
      <td>Tipifarnib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24500418</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>PLEN</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>germline</td>
      <td>Tipifarnib (Farnesyltransferase inhibitor)</td>
      <td>Plexiform neurofibroma</td>
    </tr>
    <tr>
      <th>1035</th>
      <td>NF1 oncogenic mutation</td>
      <td>NF1</td>
      <td>MUT</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>No Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26325560</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>OS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Osteosarcoma</td>
    </tr>
    <tr>
      <th>1036</th>
      <td>RAD50 (L1237F) + ATM deletion</td>
      <td>RAD50;ATM</td>
      <td>MUT;CNA</td>
      <td>RAD50:L1237F;ATM:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>TOPO1 inhibitor;CHK1/2 inhibitor</td>
      <td>Irinotecan;CHK1/2 inhibitor</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24934408</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Irinotecan + CHK1/2 inhibitor (TOPO1 inhibitor + CHK1/2 inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1037</th>
      <td>RAD51C oncogenic mutation</td>
      <td>RAD51C</td>
      <td>MUT</td>
      <td>RAD51C:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 5508)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>1038</th>
      <td>RAD51C oncogenic mutation</td>
      <td>RAD51C</td>
      <td>MUT</td>
      <td>RAD51C:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ASCO 2015 (abstr 5508)</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>1039</th>
      <td>RAF1 fusion</td>
      <td>RAF1</td>
      <td>FUS</td>
      <td>RAF1__.</td>
      <td>Direct</td>
      <td>Pre-clinical</td>
      <td>[Pan-RAF inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:20526349</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pan-RAF inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1040</th>
      <td>RAF1 fusion</td>
      <td>RAF1</td>
      <td>FUS</td>
      <td>RAF1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20526349</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1041</th>
      <td>RAF1 overexpression</td>
      <td>RAF1</td>
      <td>EXPR</td>
      <td>RAF1:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:24375110</td>
      <td>CdeTorres</td>
      <td>10/16</td>
      <td>OS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Osteosarcoma</td>
    </tr>
    <tr>
      <th>1042</th>
      <td>RAF1 fusion</td>
      <td>RAF1</td>
      <td>FUS</td>
      <td>RAF1__.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>MEK inhibitor</td>
      <td>U0126</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Cell line</td>
      <td>PMID:20526349</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>U0126 (MEK inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1043</th>
      <td>NF1 deletion</td>
      <td>NF1</td>
      <td>CNA</td>
      <td>NF1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor</td>
      <td>Trametinib</td>
      <td>No Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26325560</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>OS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trametinib (MEK inhibitor)</td>
      <td>Osteosarcoma</td>
    </tr>
    <tr>
      <th>1044</th>
      <td>RB1 oncogenic mutation</td>
      <td>RB1</td>
      <td>MUT</td>
      <td>RB1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HDAC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18483379</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>RB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HDAC inhibitors</td>
      <td>Retinoblastoma</td>
    </tr>
    <tr>
      <th>1045</th>
      <td>RB1 deletion</td>
      <td>RB1</td>
      <td>CNA</td>
      <td>RB1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HDAC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:18483379</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>RB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HDAC inhibitors</td>
      <td>Retinoblastoma</td>
    </tr>
    <tr>
      <th>1046</th>
      <td>RB1 oncogenic mutation</td>
      <td>RB1</td>
      <td>MUT</td>
      <td>RB1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MDM2/MDMX inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:17080083;PMID:21515735</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>RB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MDM2/MDMX inhibitors</td>
      <td>Retinoblastoma</td>
    </tr>
    <tr>
      <th>1047</th>
      <td>RB1 deletion</td>
      <td>RB1</td>
      <td>CNA</td>
      <td>RB1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MDM2/MDMX inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:17080083;PMID:21515735</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>RB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MDM2/MDMX inhibitors</td>
      <td>Retinoblastoma</td>
    </tr>
    <tr>
      <th>1048</th>
      <td>RB1 oncogenic mutation</td>
      <td>RB1</td>
      <td>MUT</td>
      <td>RB1:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26238431</td>
      <td>ARodriguez-Vida;RDientsmann</td>
      <td>NaN</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>1049</th>
      <td>RB1 deletion</td>
      <td>RB1</td>
      <td>CNA</td>
      <td>RB1:del</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26238431</td>
      <td>ARodriguez-Vida;RDientsmann</td>
      <td>NaN</td>
      <td>BLCA</td>
      <td>BLCA</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>1050</th>
      <td>RB1 overexpression</td>
      <td>RB1</td>
      <td>EXPR</td>
      <td>RB1:over</td>
      <td>Indirect</td>
      <td>Pre-clinical</td>
      <td>CDK4/6 inhibitor</td>
      <td>Palbociclib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Xenograft</td>
      <td>PMID:23708653</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Palbociclib (CDK4/6 inhibitor)</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1051</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[RET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:22327624;PMID:22327622</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>RET inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1052</th>
      <td>RET-TPCN1 fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__TPCN1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[RET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23056499</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>RET inhibitors</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>1053</th>
      <td>RET (C634W,M918T)</td>
      <td>RET</td>
      <td>MUT</td>
      <td>RET:C634W,M918T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[RET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23056499</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>RET inhibitors</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>1054</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28447912</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib (Pan-kinase inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1055</th>
      <td>RET-TPCN1 fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__TPCN1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21470995</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib (Pan-kinase inhibitor)</td>
      <td>Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>1056</th>
      <td>RET (C634W,M918T)</td>
      <td>RET</td>
      <td>MUT</td>
      <td>RET:C634W,M918T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21470995</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib (Pan-kinase inhibitor)</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>1057</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Nintedanib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26787234</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nintedanib (Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1058</th>
      <td>ARID1A oncogenic mutation + ANXA1 overexpression</td>
      <td>ARID1A;ANXA1</td>
      <td>MUT;EXPR</td>
      <td>ARID1A:.;ANXA1:over</td>
      <td>NaN</td>
      <td>FDA approved</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27172896</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Anaxa 1 high</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1059</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28447912</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1060</th>
      <td>RET-TPCN1 fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__TPCN1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21470995</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>1061</th>
      <td>RET (C634W,M918T)</td>
      <td>RET</td>
      <td>MUT</td>
      <td>RET:C634W,M918T</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sunitinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21470995</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>TH</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sunitinib (Pan-TK inhibitor)</td>
      <td>Thyroid</td>
    </tr>
    <tr>
      <th>1062</th>
      <td>RET fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Vandetanib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:28447912</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vandetanib (Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1063</th>
      <td>RET-TPCN1 fusion</td>
      <td>RET</td>
      <td>FUS</td>
      <td>RET__TPCN1</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Vandetanib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21470995</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vandetanib (Pan-TK inhibitor)</td>
      <td>Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>1064</th>
      <td>RET (618,620,634,768,791,891,918,C634W,M918T)</td>
      <td>RET</td>
      <td>MUT</td>
      <td>RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Pan-TK inhibitor</td>
      <td>Vandetanib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>PMID:20065189;PMID:22025146</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vandetanib (Pan-TK inhibitor)</td>
      <td>Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>1065</th>
      <td>RICTOR amplification</td>
      <td>RICTOR</td>
      <td>CNA</td>
      <td>RICTOR:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTORC1/2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26370156</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTORC1/2 inhibitors</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>1066</th>
      <td>RNF43 oncogenic mutation</td>
      <td>RNF43</td>
      <td>MUT</td>
      <td>RNF43:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Porcupine inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2015 (abstr C45)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Porcupine inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>1067</th>
      <td>ROS1 fusion</td>
      <td>ROS1</td>
      <td>FUS</td>
      <td>ROS1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23533265</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1068</th>
      <td>ROS1 fusion</td>
      <td>ROS1</td>
      <td>FUS</td>
      <td>ROS1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27370605</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib (Pan-kinase inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1069</th>
      <td>ROS1 (G2032R)</td>
      <td>ROS1</td>
      <td>MUT</td>
      <td>ROS1:G2032R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-kinase inhibitor</td>
      <td>Cabozantinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25351743</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cabozantinib (Pan-kinase inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1070</th>
      <td>ARID1A amplification + ANXA1 overexpression</td>
      <td>ARID1A;ANXA1</td>
      <td>CNA;EXPR</td>
      <td>ARID1A:amp;ANXA1:over</td>
      <td>NaN</td>
      <td>FDA approved</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27172896</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Anaxa 1 high</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1071</th>
      <td>ROS1 fusion</td>
      <td>ROS1</td>
      <td>FUS</td>
      <td>ROS1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24875859</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>IM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Inflammatory myofibroblastic</td>
    </tr>
    <tr>
      <th>1072</th>
      <td>ROS1 fusion</td>
      <td>ROS1</td>
      <td>FUS</td>
      <td>ROS1__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:25264305</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1073</th>
      <td>ROS1 fusion</td>
      <td>ROS1</td>
      <td>FUS</td>
      <td>ROS1__.</td>
      <td>NaN</td>
      <td>Clinical trials</td>
      <td>ALK inhibitor</td>
      <td>Crizotinib</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>CRubio-Perez;EArriola</td>
      <td>NaN</td>
      <td>NSCLC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Crizotinib (ALK inhibitor)</td>
      <td>Non-small cell lung</td>
    </tr>
    <tr>
      <th>1074</th>
      <td>ERBB2 amplification</td>
      <td>ERBB2</td>
      <td>CNA</td>
      <td>ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26099744;PMID:19840887</td>
      <td>DTamborero;RDientsmann</td>
      <td>NaN</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>1075</th>
      <td>HGF amplification + ERBB2 amplification</td>
      <td>HGF;ERBB2</td>
      <td>CNA;CNA</td>
      <td>HGF:amp;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22850551</td>
      <td>RDientsmann;CRubio-Perez</td>
      <td>NaN</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1076</th>
      <td>ROS1 (S1986Y,S1986F)</td>
      <td>ROS1</td>
      <td>MUT</td>
      <td>ROS1:S1986Y,S1986F</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ALK&amp;ROS1 inhibitor</td>
      <td>Lorlatinib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27401242</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Lorlatinib (ALK&amp;ROS1 inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1077</th>
      <td>SERPINB3 oncogenic mutation</td>
      <td>SERPINB3</td>
      <td>MUT</td>
      <td>SERPINB3:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[CTLA4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27668655</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>CTLA4 inhibitors</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1078</th>
      <td>SETD2 oncogenic mutation</td>
      <td>SETD2</td>
      <td>MUT</td>
      <td>SETD2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[WEE1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 211)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>WEE1 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1079</th>
      <td>SETD2 deletion</td>
      <td>SETD2</td>
      <td>CNA</td>
      <td>SETD2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[WEE1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 211)</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>WEE1 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1080</th>
      <td>SF3B1 (K700E,K666N)</td>
      <td>SF3B1</td>
      <td>MUT</td>
      <td>SF3B1:K700E,K666N</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Spliceosome inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Spliceosome inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1081</th>
      <td>SH2B3 oncogenic mutation</td>
      <td>SH2B3</td>
      <td>MUT</td>
      <td>SH2B3:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20404132</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>1082</th>
      <td>SH2B3 deletion</td>
      <td>SH2B3</td>
      <td>CNA</td>
      <td>SH2B3:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[JAK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20404132</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>JAK inhibitors</td>
      <td>Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>1083</th>
      <td>MET amplification + ERBB2 amplification</td>
      <td>MET;ERBB2</td>
      <td>CNA;CNA</td>
      <td>MET:amp;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22850551</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1084</th>
      <td>SLC44A4 overexpression</td>
      <td>SLC44A4</td>
      <td>EXPR</td>
      <td>SLC44A4:over</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SLC44A4 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27550944</td>
      <td>CRubio-Perez</td>
      <td>02/17</td>
      <td>PRAD;PAAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SLC44A4 inhibitors</td>
      <td>Prostate adenocarcinoma;Pancreas adenocarcinoma</td>
    </tr>
    <tr>
      <th>1085</th>
      <td>SMARCA1 oncogenic mutation</td>
      <td>SMARCA1</td>
      <td>MUT</td>
      <td>SMARCA1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26552009</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1086</th>
      <td>SMARCA4 oncogenic mutation</td>
      <td>SMARCA4</td>
      <td>MUT</td>
      <td>SMARCA4:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ESMO 2015 (abstract 302)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>1087</th>
      <td>SMARCA4 deletion</td>
      <td>SMARCA4</td>
      <td>CNA</td>
      <td>SMARCA4:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ESMO 2015 (abstract 302)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>1088</th>
      <td>SMARCB1 oncogenic mutation</td>
      <td>SMARCB1</td>
      <td>MUT</td>
      <td>SMARCB1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>MRT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>INI1 gene symbol: SMARCB1</td>
      <td>EZH2 inhibitors</td>
      <td>Malignant rhabdoid tumor</td>
    </tr>
    <tr>
      <th>1089</th>
      <td>SMARCB1 deletion</td>
      <td>SMARCB1</td>
      <td>CNA</td>
      <td>SMARCB1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>MRT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>INI1 gene symbol: SMARCB1</td>
      <td>EZH2 inhibitors</td>
      <td>Malignant rhabdoid tumor</td>
    </tr>
    <tr>
      <th>1090</th>
      <td>SMARCB1 deletion</td>
      <td>SMARCB1</td>
      <td>CNA</td>
      <td>SMARCB1:del</td>
      <td>NaN</td>
      <td>Clinical Trials</td>
      <td>[EZH2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>ESMO 2015 (abstract 302)</td>
      <td>RDientsmann</td>
      <td>11/15</td>
      <td>MRT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>EZH2 inhibitors</td>
      <td>Malignant rhabdoid tumor</td>
    </tr>
    <tr>
      <th>1091</th>
      <td>SMARCB1 oncogenic mutation</td>
      <td>SMARCB1</td>
      <td>MUT</td>
      <td>SMARCB1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HDAC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26920892</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>MRT</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HDAC inhibitors</td>
      <td>Malignant rhabdoid tumor</td>
    </tr>
    <tr>
      <th>1092</th>
      <td>MET amplification + ERBB2 amplification</td>
      <td>MET;ERBB2</td>
      <td>CNA;CNA</td>
      <td>MET:amp;ERBB2:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>ERBB2 mAb inhibitor</td>
      <td>Trastuzumab</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22850551; PMID:26432108</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA;ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trastuzumab (ERBB2 mAb inhibitor)</td>
      <td>Breast adenocarcinoma;Stomach</td>
    </tr>
    <tr>
      <th>1093</th>
      <td>KRAS oncogenic mutation</td>
      <td>KRAS</td>
      <td>MUT</td>
      <td>KRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MEK inhibitor;BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor</td>
      <td>Trametinib;Ponatinib</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27338794</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&amp;Pan-TK inhibitor)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1094</th>
      <td>SMO (P641A)</td>
      <td>SMO</td>
      <td>MUT</td>
      <td>SMO:P641A</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>SHH inhibitor</td>
      <td>Vismodegib</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>ASCO 2017 (abstr 9062)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>L</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vismodegib (SHH inhibitor)</td>
      <td>Lung</td>
    </tr>
    <tr>
      <th>1095</th>
      <td>SRSF2 oncogenic mutation</td>
      <td>SRSF2</td>
      <td>MUT</td>
      <td>SRSF2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Spliceosome inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27135740</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Spliceosome inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>1096</th>
      <td>STAG2 oncogenic mutation</td>
      <td>STAG2</td>
      <td>MUT</td>
      <td>STAG2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24356817</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>G</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Glioma</td>
    </tr>
    <tr>
      <th>1097</th>
      <td>BRAF inframe deletion (L485),inframe deletion (P490)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26732095</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1098</th>
      <td>STK11 oncogenic mutation</td>
      <td>STK11</td>
      <td>MUT</td>
      <td>STK11:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19165201</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1099</th>
      <td>STK11 deletion</td>
      <td>STK11</td>
      <td>CNA</td>
      <td>STK11:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19165201</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MEK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1100</th>
      <td>STK11 oncogenic mutation</td>
      <td>STK11</td>
      <td>MUT</td>
      <td>STK11:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19541609</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1101</th>
      <td>STK11 deletion</td>
      <td>STK11</td>
      <td>CNA</td>
      <td>STK11:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:19541609</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1102</th>
      <td>STK11 oncogenic mutation</td>
      <td>STK11</td>
      <td>MUT</td>
      <td>STK11:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SRC inhibitor;PI3K/MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20541700</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SRC inhibitor + PI3K/MEK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1103</th>
      <td>STK11 deletion</td>
      <td>STK11</td>
      <td>CNA</td>
      <td>STK11:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SRC inhibitor;PI3K/MEK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20541700</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SRC inhibitor + PI3K/MEK inhibitors</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1104</th>
      <td>STK11 (D194E)</td>
      <td>STK11</td>
      <td>MUT</td>
      <td>STK11:D194E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:21189378</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Pancreas</td>
    </tr>
    <tr>
      <th>1105</th>
      <td>STK11 oncogenic mutation</td>
      <td>STK11</td>
      <td>MUT</td>
      <td>STK11:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Anti-diabetic</td>
      <td>Phenformin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23352126</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Phenformin (Anti-diabetic)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1106</th>
      <td>STK11 deletion</td>
      <td>STK11</td>
      <td>CNA</td>
      <td>STK11:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Anti-diabetic</td>
      <td>Phenformin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23352126</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>LUAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Phenformin (Anti-diabetic)</td>
      <td>Lung adenocarcinoma</td>
    </tr>
    <tr>
      <th>1107</th>
      <td>BRAF (V600)</td>
      <td>BRAF</td>
      <td>MUT</td>
      <td>BRAF:V600.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>No Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:26287849</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>1108</th>
      <td>MAP2K1 (E203K,Q56P,K57E)</td>
      <td>MAP2K1</td>
      <td>MUT</td>
      <td>MAP2K1:E203K,Q56P,K57E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23569304</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1109</th>
      <td>NF1 biallelic inactivation</td>
      <td>NF1</td>
      <td>BIA</td>
      <td>NF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:23171796</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1110</th>
      <td>SUZ12 oncogenic mutation</td>
      <td>SUZ12</td>
      <td>MUT</td>
      <td>SUZ12:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25119042</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1111</th>
      <td>SUZ12 deletion</td>
      <td>SUZ12</td>
      <td>CNA</td>
      <td>SUZ12:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[BET inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25119042</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>BET inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1112</th>
      <td>SYK amplification</td>
      <td>SYK</td>
      <td>CNA</td>
      <td>SYK:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SYK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:16409295;PMID:19549911</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MCL;CLL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SYK inhibitors</td>
      <td>Mantle cell lymphoma;Chronic lymphocytic leukemia</td>
    </tr>
    <tr>
      <th>1113</th>
      <td>TERT promoters core</td>
      <td>TERT</td>
      <td>MUT</td>
      <td>TERT::consequence::promoters_core:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Macrocyclic analog</td>
      <td>Eribulin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&amp;legid=neuonc;18/suppl_4/iv50-b</td>
      <td>CRubio-Perez</td>
      <td>02/17</td>
      <td>GBM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Eribulin (Macrocyclic analog)</td>
      <td>Glioblastoma multiforme</td>
    </tr>
    <tr>
      <th>1114</th>
      <td>TMPRSS2 fusion</td>
      <td>TMPRSS2</td>
      <td>FUS</td>
      <td>TMPRSS2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[DNA-PKc inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21575865</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>DNA-PKc inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1115</th>
      <td>TMPRSS2 fusion</td>
      <td>TMPRSS2</td>
      <td>FUS</td>
      <td>TMPRSS2__.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[PARP inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:21575865</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>PRAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>PARP inhibitors</td>
      <td>Prostate adenocarcinoma</td>
    </tr>
    <tr>
      <th>1116</th>
      <td>TOP2A amplification</td>
      <td>TOP2A</td>
      <td>CNA</td>
      <td>TOP2A:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Anthracyclines</td>
      <td>Responsive</td>
      <td>Late trials</td>
      <td>NaN</td>
      <td>PMID:22864769</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BRCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Anthracyclines (Chemotherapy)</td>
      <td>Breast adenocarcinoma</td>
    </tr>
    <tr>
      <th>1117</th>
      <td>TP53 wildtype</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53::wildtype:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HDM2 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>AACR 2017 (abstr CT152)</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HDM2 inhibitors</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>1118</th>
      <td>TP53 (R248Q,R175H)</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:R248Q,R175H</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26009011</td>
      <td>RDientsmann</td>
      <td>04/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>HSP90 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1119</th>
      <td>TP53 (R248Q,R175H)</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:R248Q,R175H</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[HSP90 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26009011</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>REMAP:R172H changed to R175H it was not the human mutation</td>
      <td>HSP90 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1120</th>
      <td>NF1 oncogenic mutation + BRAF oncogenic mutation</td>
      <td>NF1;BRAF</td>
      <td>MUT;MUT</td>
      <td>NF1:.;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23288408;PMID:231718</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1121</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[WEE1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25125259</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>HNC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>WEE1 inhibitors</td>
      <td>Head an neck</td>
    </tr>
    <tr>
      <th>1122</th>
      <td>NF1 deletion + BRAF oncogenic mutation</td>
      <td>NF1;BRAF</td>
      <td>CNA;MUT</td>
      <td>NF1:del;BRAF:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:23288408;PMID:231718</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1123</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>ATR inhibitor</td>
      <td>AZD6738</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>BCL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AZD6738 (ATR inhibitor)</td>
      <td>B cell lymphoma</td>
    </tr>
    <tr>
      <th>1124</th>
      <td>TP53 deletion</td>
      <td>TP53</td>
      <td>CNA</td>
      <td>TP53:del</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>ATR inhibitor</td>
      <td>AZD6738</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html</td>
      <td>ECampo</td>
      <td>NaN</td>
      <td>BCL</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>AZD6738 (ATR inhibitor)</td>
      <td>B cell lymphoma</td>
    </tr>
    <tr>
      <th>1125</th>
      <td>NRAS oncogenic mutation</td>
      <td>NRAS</td>
      <td>MUT</td>
      <td>NRAS:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor</td>
      <td>Vemurafenib</td>
      <td>Resistant</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:20179705</td>
      <td>DTamborero</td>
      <td>NaN</td>
      <td>CM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>there is also some report in real patients with resistance, but not clear association</td>
      <td>Vemurafenib (BRAF inhibitor)</td>
      <td>Cutaneous melanoma</td>
    </tr>
    <tr>
      <th>1126</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Decitabine</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27959731</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>AML;MDPS</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Decitabine (Chemotherapy)</td>
      <td>Acute myeloid leukemia;Myelodisplasic proliferative syndrome</td>
    </tr>
    <tr>
      <th>1127</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Anthracycline antitumor antibiotic</td>
      <td>Doxorubicin</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Doxorubicin (Anthracycline antitumor antibiotic)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>1128</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Gemcitabine</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Gemcitabine (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>1129</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Chemotherapy</td>
      <td>Mitomycin C</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Mitomycin C (Chemotherapy)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>1130</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>Indirect</td>
      <td>Clinical Trials</td>
      <td>[WEE1 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27998224</td>
      <td>KKarube;RDientsmann;DTamborero</td>
      <td>NaN</td>
      <td>OV</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>WEE1 inhibitors</td>
      <td>Ovary</td>
    </tr>
    <tr>
      <th>1131</th>
      <td>TP53 oncogenic mutation</td>
      <td>TP53</td>
      <td>MUT</td>
      <td>TP53:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Amylin analogue</td>
      <td>Pramlintide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25409149</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pramlintide (Amylin analogue)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>1132</th>
      <td>TP53 deletion</td>
      <td>TP53</td>
      <td>CNA</td>
      <td>TP53:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Amylin analogue</td>
      <td>Pramlintide</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:25409149</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>THYM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pramlintide (Amylin analogue)</td>
      <td>Thymic</td>
    </tr>
    <tr>
      <th>1133</th>
      <td>TPMT splice acceptor variant</td>
      <td>TPMT</td>
      <td>MUT</td>
      <td>TPMT::consequence::splice_acceptor_variant:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Increased Toxicity (Ototoxicity)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1134</th>
      <td>TPMT biallelic inactivation</td>
      <td>TPMT</td>
      <td>BIA</td>
      <td>TPMT:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Increased Toxicity (Ototoxicity)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1135</th>
      <td>TPMT (A80P,Y240C,A154T,A167G)</td>
      <td>TPMT</td>
      <td>MUT</td>
      <td>TPMT:A80P,Y240C,A154T,A167G</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Chemotherapy</td>
      <td>Cisplatin</td>
      <td>Increased Toxicity (Ototoxicity)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Cisplatin (Chemotherapy)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1136</th>
      <td>TPMT splice acceptor variant</td>
      <td>TPMT</td>
      <td>MUT</td>
      <td>TPMT::consequence::splice_acceptor_variant:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Purine analog</td>
      <td>Mercaptopurine</td>
      <td>Increased Toxicity (Myelosupression)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Mercaptopurine (Purine analog)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1137</th>
      <td>TPMT biallelic inactivation</td>
      <td>TPMT</td>
      <td>BIA</td>
      <td>TPMT:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Purine analog</td>
      <td>Mercaptopurine</td>
      <td>Increased Toxicity (Myelosupression)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Mercaptopurine (Purine analog)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1138</th>
      <td>TPMT (A80P,Y240C,A154T,A167G)</td>
      <td>TPMT</td>
      <td>MUT</td>
      <td>TPMT:A80P,Y240C,A154T,A167G</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Purine analog</td>
      <td>Mercaptopurine</td>
      <td>Increased Toxicity (Myelosupression)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Mercaptopurine (Purine analog)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1139</th>
      <td>TPMT splice acceptor variant</td>
      <td>TPMT</td>
      <td>MUT</td>
      <td>TPMT::consequence::splice_acceptor_variant:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Guanine analog</td>
      <td>Thioguanine</td>
      <td>Increased Toxicity (Myelosupression)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Thioguanine (Guanine analog)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1140</th>
      <td>TPMT biallelic inactivation</td>
      <td>TPMT</td>
      <td>BIA</td>
      <td>TPMT:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Guanine analog</td>
      <td>Thioguanine</td>
      <td>Increased Toxicity (Myelosupression)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Thioguanine (Guanine analog)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1141</th>
      <td>TPMT (A80P,Y240C,A154T,A167G)</td>
      <td>TPMT</td>
      <td>MUT</td>
      <td>TPMT:A80P,Y240C,A154T,A167G</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>Guanine analog</td>
      <td>Thioguanine</td>
      <td>Increased Toxicity (Myelosupression)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Thioguanine (Guanine analog)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1142</th>
      <td>MET amplification + BRAF (V600E)</td>
      <td>MET;BRAF</td>
      <td>CNA;MUT</td>
      <td>MET:amp;BRAF:V600E</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BRAF inhibitor;EGFR mAb inhibitor</td>
      <td>Vemurafenib;Panitumumab</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27325282</td>
      <td>RDientsmann</td>
      <td>12/16</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vemurafenib + Panitumumab (BRAF inhibitor + EGFR mAb inhibitor)</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
    <tr>
      <th>1143</th>
      <td>NTRK3 (G623R)</td>
      <td>NTRK3</td>
      <td>MUT</td>
      <td>NTRK3:G623R</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[novel TRK inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:28578312</td>
      <td>RDientsmann</td>
      <td>07/17</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>novel TRK inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1144</th>
      <td>FLT3-ITD</td>
      <td>FLT3</td>
      <td>MUT</td>
      <td>FLT3::consequence::inframe_variant:572-630</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>BCL2 inhibitor</td>
      <td>Venetoclax</td>
      <td>Resistant</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:27520294</td>
      <td>DTamborero;CRubio-Perez;SDemajo;RShadrina</td>
      <td>10/16</td>
      <td>AML</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>ITD (codified as inframe) in Juxtamembrane domain</td>
      <td>Venetoclax (BCL2 inhibitor)</td>
      <td>Acute myeloid leukemia</td>
    </tr>
    <tr>
      <th>1145</th>
      <td>TSC1 oncogenic mutation</td>
      <td>TSC1</td>
      <td>MUT</td>
      <td>TSC1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23312829;PMID:21525172;PMID:20048174</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>RA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Renal angiomyolipoma</td>
    </tr>
    <tr>
      <th>1146</th>
      <td>TSC1 oncogenic mutation</td>
      <td>TSC1</td>
      <td>MUT</td>
      <td>TSC1:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22923433</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>TSC1 or TSC2 mutated</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>1147</th>
      <td>TSC1 oncogenic mutation</td>
      <td>TSC1</td>
      <td>MUT</td>
      <td>TSC1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>1148</th>
      <td>TSC1 oncogenic mutation</td>
      <td>TSC1</td>
      <td>MUT</td>
      <td>TSC1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero</td>
      <td>04/16</td>
      <td>GCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Tuberous sclerosis complex in 80% of cases = mutations in TSC1 or TSC2</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Giant cell astrocytoma</td>
    </tr>
    <tr>
      <th>1149</th>
      <td>TSC1 oncogenic mutation</td>
      <td>TSC1</td>
      <td>MUT</td>
      <td>TSC1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:26859683</td>
      <td>RDientsmann</td>
      <td>06/16</td>
      <td>S;ST</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Sarcoma;Stomach</td>
    </tr>
    <tr>
      <th>1150</th>
      <td>TSC1 oncogenic mutation</td>
      <td>TSC1</td>
      <td>MUT</td>
      <td>TSC1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>RA</td>
      <td>RA</td>
      <td>TRUE</td>
      <td>TSC positive.Renal angilypoma is benign tumor</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Renal angiomyolipoma</td>
    </tr>
    <tr>
      <th>1151</th>
      <td>TSC1 deletion</td>
      <td>TSC1</td>
      <td>CNA</td>
      <td>TSC1:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>1152</th>
      <td>TSC2 oncogenic mutation</td>
      <td>TSC2</td>
      <td>MUT</td>
      <td>TSC2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[MTOR inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:23312829;PMID:21525172;PMID:20048174</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>RA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>MTOR inhibitors</td>
      <td>Renal angiomyolipoma</td>
    </tr>
    <tr>
      <th>1153</th>
      <td>TSC2 oncogenic mutation</td>
      <td>TSC2</td>
      <td>MUT</td>
      <td>TSC2:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SRC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24691995</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LAM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>SRC inhibitors</td>
      <td>Lymphangioleiomyomatosis</td>
    </tr>
    <tr>
      <th>1154</th>
      <td>TSC2 deletion</td>
      <td>TSC2</td>
      <td>CNA</td>
      <td>TSC2:del</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[SRC inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:24691995</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>LAM</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>Lymphangioleiomyomatosis (LAM) is a rare, progressive, systemic disease that typically results in cystic lung destruction</td>
      <td>SRC inhibitors</td>
      <td>Lymphangioleiomyomatosis</td>
    </tr>
    <tr>
      <th>1155</th>
      <td>TSC2 oncogenic mutation</td>
      <td>TSC2</td>
      <td>MUT</td>
      <td>TSC2:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:22923433</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>BLCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>TSC1 or TSC2 mutated</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Bladder</td>
    </tr>
    <tr>
      <th>1156</th>
      <td>TSC2 oncogenic mutation</td>
      <td>TSC2</td>
      <td>MUT</td>
      <td>TSC2:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>ARodriguez-Vida;DTamborero</td>
      <td>04/16</td>
      <td>RA;GCA</td>
      <td>RA</td>
      <td>TRUE</td>
      <td>TSC positive.Renal angilypoma is benign tumor</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Renal angiomyolipoma;Giant cell astrocytoma</td>
    </tr>
    <tr>
      <th>1157</th>
      <td>TSC2 (Q1178*)</td>
      <td>TSC2</td>
      <td>MUT</td>
      <td>TSC2:Q1178*</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>MTOR inhibitor</td>
      <td>Everolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25295501</td>
      <td>CRubio-Perez;RDientsmann</td>
      <td>01/16</td>
      <td>THCA</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Everolimus (MTOR inhibitor)</td>
      <td>Thyroid carcinoma</td>
    </tr>
    <tr>
      <th>1158</th>
      <td>TSC2 (E66K)</td>
      <td>TSC2</td>
      <td>MUT</td>
      <td>TSC2:E66K</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>MTOR inhibitor</td>
      <td>Tensirolimus</td>
      <td>Responsive</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:27016228</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>ED</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Tensirolimus (MTOR inhibitor)</td>
      <td>Endometrium</td>
    </tr>
    <tr>
      <th>1159</th>
      <td>SMO (D473H)</td>
      <td>SMO</td>
      <td>MUT</td>
      <td>SMO:D473H</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>SHH inhibitor</td>
      <td>Vismodegib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:19726788;PMID:25759019</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>MB</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vismodegib (SHH inhibitor)</td>
      <td>Medulloblastoma</td>
    </tr>
    <tr>
      <th>1160</th>
      <td>U2AF1 oncogenic mutation</td>
      <td>U2AF1</td>
      <td>MUT</td>
      <td>U2AF1:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[FLT3 inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:27397505</td>
      <td>RDientsmann</td>
      <td>07/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>FLT3 inhibitors</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1161</th>
      <td>UGT1A1 biallelic inactivation</td>
      <td>UGT1A1</td>
      <td>BIA</td>
      <td>UGT1A1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>TOPO1 inhibitor</td>
      <td>Irinotecan</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Irinotecan (TOPO1 inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1162</th>
      <td>UGT1A1 (G71R,P229Q)</td>
      <td>UGT1A1</td>
      <td>MUT</td>
      <td>UGT1A1:G71R,P229Q</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>TOPO1 inhibitor</td>
      <td>Irinotecan</td>
      <td>Increased Toxicity</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Irinotecan (TOPO1 inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1163</th>
      <td>UGT1A1 biallelic inactivation</td>
      <td>UGT1A1</td>
      <td>BIA</td>
      <td>UGT1A1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Increased Toxicity (Hyperbilirubinemia)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1164</th>
      <td>UGT1A1 (G71R,P229Q)</td>
      <td>UGT1A1</td>
      <td>MUT</td>
      <td>UGT1A1:G71R,P229Q</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>BCR-ABL inhibitor 2nd gen</td>
      <td>Nilotinib</td>
      <td>Increased Toxicity (Hyperbilirubinemia)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Nilotinib (BCR-ABL inhibitor 2nd gen)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1165</th>
      <td>UGT1A1 biallelic inactivation</td>
      <td>UGT1A1</td>
      <td>BIA</td>
      <td>UGT1A1:.</td>
      <td>NaN</td>
      <td>Approved</td>
      <td>VEGFR inhibitor</td>
      <td>Pazopanib</td>
      <td>Increased Toxicity (Hyperbilirubinemia)</td>
      <td>FDA guidelines</td>
      <td>NaN</td>
      <td>FDA</td>
      <td>DTamborero;CRubio-Perez</td>
      <td>01/16</td>
      <td>CANCER</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Pazopanib (VEGFR inhibitor)</td>
      <td>Any cancer type</td>
    </tr>
    <tr>
      <th>1166</th>
      <td>VEGFA amplification</td>
      <td>VEGFA</td>
      <td>CNA</td>
      <td>VEGFA:amp</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>Pan-TK inhibitor</td>
      <td>Sorafenib</td>
      <td>Responsive</td>
      <td>Early trials</td>
      <td>NaN</td>
      <td>PMID:24687604</td>
      <td>RDientsmann</td>
      <td>01/16</td>
      <td>HC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Sorafenib (Pan-TK inhibitor)</td>
      <td>Hepatic carcinoma</td>
    </tr>
    <tr>
      <th>1167</th>
      <td>VHL oncogenic mutation</td>
      <td>VHL</td>
      <td>MUT</td>
      <td>VHL:.</td>
      <td>Indirect</td>
      <td>Approved</td>
      <td>[VEGFR inhibitor]</td>
      <td>[Sorafenib,Sunitinib,Bevacizumab,Axitinib]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>Retrospective analysis</td>
      <td>PMID:18635227</td>
      <td>ARodriguez-Vida</td>
      <td>09/15</td>
      <td>R</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>VEGFR inhibitors (Sorafenib,Sunitinib,Bevacizumab,Axitinib,etc)</td>
      <td>Renal</td>
    </tr>
    <tr>
      <th>1168</th>
      <td>SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)</td>
      <td>SMO</td>
      <td>MUT</td>
      <td>SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>SHH inhibitor</td>
      <td>Vismodegib</td>
      <td>Resistant</td>
      <td>Case report</td>
      <td>NaN</td>
      <td>PMID:25759020;PMID:25306392</td>
      <td>DTamborero;RDientsmann</td>
      <td>04/16</td>
      <td>BCC</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Vismodegib (SHH inhibitor)</td>
      <td>Basal cell carcinoma</td>
    </tr>
    <tr>
      <th>1169</th>
      <td>ZNRF3 oncogenic mutation</td>
      <td>ZNRF3</td>
      <td>MUT</td>
      <td>ZNRF3:.</td>
      <td>NaN</td>
      <td>NaN</td>
      <td>[Porcupine inhibitor]</td>
      <td>[]</td>
      <td>Responsive</td>
      <td>Pre-clinical</td>
      <td>NaN</td>
      <td>PMID:26023187</td>
      <td>RDientsmann</td>
      <td>NaN</td>
      <td>COREAD</td>
      <td>NaN</td>
      <td>TRUE</td>
      <td>NaN</td>
      <td>Porcupine inhibitors</td>
      <td>Colorectal adenocarcinoma</td>
    </tr>
  </tbody>
</table>